CISNET: Publications by Topic

Publications by Research Topic

On this page:

Characterization and Efficiency of Community Screening Practices and Processes
Costs / Cost Effectiveness
Cross Model Comparisons
Evaluation of New and Existing Prevention, Screening, and Treatment Strategies and Technologies
Health Disparities
Individualized Prevention, Screening and Treatment Strategies
International Cancer Control Planning
Model Descriptions
Modeling Methods
National Cancer Control Planning
Screening Guidelines
State and Local Cancer Control Planning
Trial Design and Interpretation of Trial Results
Understanding National Trends in Cancer Incidence and Mortality

Characterization and Efficiency of Community Screening Practices and Processes

2023

Nascimento de Lima P, van den Puttelaar R, Hahn AI, Harlass M, Collier N, Ozik J, Zauber AG, Lansdorp-Vogelaar I, Rutter CM. Projected long-term effects of colorectal cancer screening disruptions following the COVID-19 pandemic. Elife 2023 May 2;12. [Abstract]

van den Puttelaar R, Lansdorp-Vogelaar I, Hahn AI, Rutter CM, Levin TR, Zauber AG, Meester RGS. Impact and Recovery from COVID-19-Related Disruptions in Colorectal Cancer Screening and Care in the US: A Scenario Analysis. Cancer Epidemiol Biomarkers Prev 2023 Jan 9;32(1):22-29. [Abstract]

2022

Burger EA, de Kok IMCM, O'Mahony JF, Rebolj M, Jansen EEL, de Bondt DD, Killen J, Hanley SJ, Castanon A, Kim JJ, Canfell K, Smith MA, Regan MC. Health impacts of COVID-19 disruptions to primary cervical screening by time since last screen: A model-based analysis for current and future disruptions. medRxiv 2022 Jul 25. [Abstract]

2021

Alagoz O, Lowry KP, Kurian AW, Mandelblatt JS, Ergun MA, Huang H, Lee SJ, Schechter CB, Tosteson ANA, Miglioretti DL, Trentham-Dietz A, Nyante SJ, Kerlikowske K, Sprague BL, Stout NK, from the CISNET Breast Working Group. Impact of the COVID-19 Pandemic on Breast Cancer Mortality in the US: Estimates From Collaborative Simulation Modeling. J Natl Cancer Inst 2021 Nov 2;113(11):1484-1494. [Abstract]

Burger EA, Jansen EE, Killen J, Kok IM, Smith MA, Sy S, Dunnewind N, G Campos N, Haas JS, Kobrin S, Kamineni A, Canfell K, Kim JJ. Impact of COVID-19-related care disruptions on cervical cancer screening in the United States. J Med Screen 2021 Jun;28(2):213-216. Epub 2021 Mar 17. [Abstract]

Ozanne EM, Silver ER, Saini SD, Rubenstein JH, Lansdorp-Vogelaar I, Bowers N, Tan SX, Inadomi JM, Hur C. Surveillance Cessation for Barrett's Esophagus: A Survey of Gastroenterologists. Am J Gastroenterol 2021 Aug 1;116(8):1730-1733. [Abstract]

2019

Hur C, Zhan T, Thrift AP, Vaughan TL, Feuer EJ. Lorenz Curves and Gini Coefficient Analyses Indicate Inefficiencies in Esophageal Adenocarcinoma Screening. Clin Gastroenterol Hepatol 2019 Feb;17(3):560-562.e2. Epub 2018 May 9. [Abstract]

2018

Han SS, Ten Haaf K, Hazelton WD, Jeon J, Meza R, Kong CY, Feuer EJ, de Koning HJ, Plevritis SK. Re: Think before you leap. Int J Cancer 2018 Apr 1;142(7):1507-1509. Epub 2017 Dec 28. [Abstract]

Kinsella N, Helleman J, Bruinsma S, Carlsson S, Cahill D, Brown C, Van Hemelrijck M. Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. Transl Androl Urol 2018 Feb;7(1):83-97. [Abstract]

Rutter CM, Kim JJ, Meester RGS, Sprague BL, Burger EA, Zauber AG, Ergun MA, Campos NG, Doubeni CA, Trentham-Dietz A, Sy S, Alagoz O, Stout N, Lansdorp-Vogelaar I, Corley DA, Tosteson ANA. Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. Cancer Epidemiol Biomarkers Prev 2018 Feb;27(2):158-164. Epub 2017 Nov 17. [Abstract]

Tavakkoli A, Appelman HD, Beer DG, Madiyal C, Khodadost M, Nofz K, Metko V, Elta G, Wang T, Rubenstein JH. Use of Appropriate Surveillance for Patients With Nondysplastic Barrett's Esophagus. Clin Gastroenterol Hepatol 2018 Jun;16(6):862-869.e3. Epub 2018 Feb 9. [Abstract]

2016

Etzioni R, Gulati R. Recent Trends in PSA Testing and Prostate Cancer Incidence: A Look at Context. JAMA Oncol 2016 Jul 1;2(7):955-6. [Abstract]

Joseph DA, Meester RG, Zauber AG, Manninen DL, Winges L, Dong FB, Peaker B, van Ballegooijen M. Colorectal cancer screening: Estimated future colonoscopy need and current volume and capacity. Cancer 2016 Aug 15;122(16):2479-86. Epub 2016 May 20. [Abstract]

Meester RG, Zauber AG, Doubeni CA, Jensen CD, Quinn VP, Helfand M, Dominitz JA, Levin TR, Corley DA, Lansdorp-Vogelaar I. Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test. Clin Gastroenterol Hepatol 2016 Oct;14(10):1445-1451.e8. Epub 2016 May 19. [Abstract]

2014

Etzioni R, Gulati R. Oversimplifying overdiagnosis. J Gen Intern Med 2014 Sep;29(9):1218-20. [Abstract]

Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R. Overdiagnosis and overtreatment of prostate cancer. Eur Urol 2014 Jun;65(6):1046-55. Epub 2014 Jan 9. [Abstract]

Weedon-Fekjær H, Romundstad PR, Vatten LJ. Modern mammography screening and breast cancer mortality: population study. BMJ 2014 Jun 17;348:g3701. [Abstract]

2013

van Luijt PA, Fracheboud J, Heijnsdijk EA, den Heeten GJ, de Koning HJ, National Evaluation Team for Breast Cancer Screening in Netherlands Study Group (NETB). Nation-wide data on screening performance during the transition to digital mammography: observations in 6 million screens. Eur J Cancer 2013 Nov;49(16):3517-25. Epub 2013 Jul 17. [Abstract]

2012

Rutter CM, Johnson E, Miglioretti DL, Mandelson MT, Inadomi J, Buist DS. Adverse events after screening and follow-up colonoscopy. Cancer Causes Control 2012 Feb;23(2):289-96. Epub 2011 Nov 22. [Abstract]

2011

Sprague BL, Trentham-Dietz A, Hampton JM, Egan KM, Titus-Ernstof L, Remington PL, Newcomb PA. Variation in breast cancer risk factors by mode of detection. Am J Epidemiol 2011 Jun 1;173(11 Suppl):S251, Abstract 1002.

2010

van Ballegooijen M, Boer R, Zauber AG. Simulation of colorectal cancer screening: what we do and do not know and does it matter. Best Pract Res Clin Gastroenterol 2010 Aug;24(4):427-37. [Abstract]

2008

Miglioretti DL, Rutter CM, Bradford SC, Zauber AG, Kessler LG, Feuer EJ, Grossman DC. Improvement in the diagnostic evaluation of a positive fecal occult blood test in an integrated health care organization. Med Care 2008 Sep;46(9 Suppl 1):S91-6. [Abstract]

2006

Hanin LG, Pavlova LV. Chapter 11. Optimal Regimens of Cancer Screening. In: Edler L, Kitsos CP, editors. Recent Advances in Quantitative Methods in Cancer and Human Health Risk Assessment. New York: Wiley; 2006 Mar 17. p. 177-91. (Wiley Series in Probability and Statistics) [Link]

Stout NK, Rosenberg MA, Trentham-Dietz A, Smith MA, Robinson SM, Fryback DG. Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst 2006 Jun 7;98(11):774-82. [Abstract]

2003

Yabroff KR, Washington KS, Leader A, Neilson E, Mandelblatt J. Is the promise of cancer-screening programs being compromised? Quality of follow-up care after abnormal screening results. Med Care Res Rev 2003 Sep;60(3):294-331. [Abstract]

2001

Hanin LG, Tsodikov AD, Yakovlev AY. Optimal schedules of cancer surveillance and tumor size at detection. Math Comp Model 2001 Jun;33(12-13):1419-1430. [Link]

Yabroff KR, O'Malley A, Mangan P, Mandelblatt J. Inreach and outreach interventions to improve mammography use. J Am Med Womens Assoc (1972) 2001 Fall;56(4):166-73, 188. [Abstract]

Costs / Cost Effectiveness

2023

Alarid-Escudero F, Krijkamp E, Enns EA, Yang A, Hunink MGM, Pechlivanoglou P, Jalal H. An Introductory Tutorial on Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example. Med Decis Making 2023 Jan;43(1):3-20. Epub 2022 Jun 30. [Abstract]

Alarid-Escudero F, Krijkamp E, Enns EA, Yang A, Hunink MGM, Pechlivanoglou P, Jalal H. A Tutorial on Time-Dependent Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example. Med Decis Making 2023 Jan;43(1):21-41. Epub 2022 Sep 16. [Abstract]

Jansen JP, Incerti D, Trikalinos TA. Multi-state network meta-analysis of progression and survival data. Stat Med 2023 Aug 30;42(19):3371-3391. Epub 2023 Jun 10. [Abstract]

Toumazis I, Cao P, de Nijs K, Bastani M, Munshi V, Hemmati M, Ten Haaf K, Jeon J, Tammemägi M, Gazelle GS, Feuer EJ, Kong CY, Meza R, de Koning HJ, Plevritis SK, Han SS. Risk Model-Based Lung Cancer Screening : A Cost-Effectiveness Analysis. Ann Intern Med 2023 Mar;176(3):320-332. Epub 2023 Feb 7. [Abstract]

van den Puttelaar R, Meester RGS, Peterse EFP, Zauber AG, Zheng J, Hayes RB, Su YR, Lee JK, Thomas M, Sakoda LC, Li Y, Corley DA, Peters U, Hsu L, Lansdorp-Vogelaar I. Risk-Stratified Screening for Colorectal Cancer Using Genetic and Environmental Risk Factors: A Cost-Effectiveness Analysis Based on Real-World Data. Clin Gastroenterol Hepatol 2023 Mar 9. Epub 2023 Mar 9. [Abstract]

Zauber AG, Winawer SJ, O'Brien MJ, Mills GM, Allen JI, Feld AD, Jordan PA, Fleisher M, Orlow I, Meester RGS, Lansdorp-Vogelaar I, Rutter CM, Knudsen AB, Mandelson M, Shaukat A, Mendelsohn RB, Hahn AI, Lobaugh SM, Soto Palmer B, Serrano V, Kumar JR, Fischer SE, Chen JC, Bayuga-Miller S, Kuk D, O'Connell K, Church TR. Randomized Trial of Facilitated Adherence to Screening Colonoscopy vs Sequential Fecal-Based Blood Test. Gastroenterology 2023 Jul;165(1):252-266. Epub 2023 Mar 21. [Abstract]

2022

Alarid-Escudero F, Knudsen AB, Ozik J, Collier N, Kuntz KM. Characterization and Valuation of the Uncertainty of Calibrated Parameters in Microsimulation Decision Models. Front Physiol 2022 May 9;13:780917. doi: 10.3389/fphys.2022.780917. eCollection 2022. [Abstract]

Alarid-Escudero F, Schrag D, Kuntz KM. CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis. Value Health 2022 Mar;25(3):409-418. Epub 2021 Nov 2. [Abstract]

Cao P, Smith L, Mandelblatt JS, Jeon J, Taylor KL, Zhao A, Levy DT, Williams RM, Meza R, Jayasekera J. Cost-Effectiveness of a Telephone-Based Smoking Cessation Randomized Trial in the Lung Cancer Screening Setting. JNCI Cancer Spectr 2022 Jul 1;6. (4). [Abstract]

Cenin D, Li P, Wang J, de Jonge L, Yan B, Tao S, Lansdorp-Vogelaar I. Optimising colorectal cancer screening in Shanghai, China: a modelling study. BMJ Open 2022 May 16;12(5):e048156. [Abstract]

de Jonge L, van de Schootbrugge-Vandermeer HJ, Breekveldt ECH, Spaander MCW, van Vuuren HJ, van Kemenade FJ, Dekker E, Nagtegaal ID, van Leerdam ME, Lansdorp-Vogelaar I. Modelling optimal use of temporarily restricted colonoscopy capacity in a FIT-based CRC screening program: Application during the COVID-19 pandemic. PLoS One 2022 Jun 24;17(6):e0270223. doi: 10.1371/journal.pone.0270223. eCollection 2022. [Abstract]

Eluri S, Paterson A, Lauren BN, O'Donovan M, Bhandari P, di Pietro M, Lee M, Haidry R, Lovat L, Ragunath K, Hur C, Fitzgerald RC, Shaheen NJ. Utility and Cost-Effectiveness of a Nonendoscopic Approach to Barrett's Esophagus Surveillance After Endoscopic Therapy. Clin Gastroenterol Hepatol 2022 Feb;20(2):e51-e63. Epub 2021 Feb 10. [Abstract]

Heijnsdijk EAM, de Koning HJ. Improved Harm/Benefit Ratio and Cost-effectiveness of Prostate Cancer Screening Using New Technologies. Eur Urol 2022 Jul;82(1):20-21. Epub 2022 Feb 4. [Abstract]

Jansen JP, Trikalinos TA, Phillips KA. Assessments of the Value of New Interventions Should Include Health Equity Impact. Pharmacoeconomics 2022 May;40(5):489-495. Epub 2022 Mar 3. [Abstract]

Keeney E, Sanghera S, Martin RM, Gulati R, Wiklund F, Walsh EI, Donovan JL, Hamdy F, Neal DE, Lane JA, Turner EL, Thom H, Clements MS. Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial. Pharmacoeconomics 2022 Dec;40(12):1207-1220. Epub 2022 Oct 6. [Abstract]

Kregting LM, Sankatsing VDV, Heijnsdijk EAM, de Koning HJ, van Ravesteyn NT. Finding the optimal mammography screening strategy: A cost-effectiveness analysis of 920 modelled strategies. Int J Cancer 2022 Jul 15;151(2):287-296. Epub 2022 Mar 21. [Abstract]

McFerran E, O'Mahony JF, Naber S, Sharp L, Zauber AG, Lansdorp-Vogelaar I, Kee F. Colorectal Cancer Screening within Colonoscopy Capacity Constraints: Can FIT-Based Programs Save More Lives by Trading off More Sensitive Test Cutoffs against Longer Screening Intervals? MDM Policy Pract 2022 May 7;7(1):23814683221097064. doi: 10.1177/23814683221097064. eCollection 2022 Jan-Jun. [Abstract]

Rubenstein JH, Omidvari AH, Lauren BN, Hazelton WD, Lim F, Tan SX, Kong CY, Lee M, Ali A, Hur C, Inadomi JM, Luebeck G, Lansdorp-Vogelaar I. Endoscopic Screening Program for Control of Esophageal Adenocarcinoma in Varied Populations: A Comparative Cost-Effectiveness Analysis. Gastroenterology 2022 Jul;163(1):163-173. Epub 2022 Mar 29. [Abstract]

van der Poort EKJ, van Ravesteyn NT, van den Broek JJ, de Koning HJ. The Early Detection of Breast Cancer Using Liquid Biopsies: Model Estimates of the Benefits, Harms, and Costs. Cancers (Basel) 2022 Jun 15;14. (12). [Abstract]

Wang J, de Jonge L, Cenin DR, Li P, Tao S, Yang C, Yan B, Lansdorp-Vogelaar I. Cost-effectiveness analysis of colorectal cancer screening in Shanghai, China: A modelling study. Prev Med Rep 2022 Jul 4;29:101891. doi: 10.1016/j.pmedr.2022.101891. eCollection 2022 Oct. [Abstract]

Wolff HB, Qendri V, Kunst N, Alarid-Escudero F, Coupé VMH. Methods for Communicating the Impact of Parameter Uncertainty in a Multiple-Strategies Cost-Effectiveness Comparison. Med Decis Making 2022 Oct;42(7):956-968. Epub 2022 May 19. [Abstract]

2021

Alblas M, Peterse EFP, Du M, Zauber AG, Steyerberg EW, van Leeuwen N, Lansdorp-Vogelaar I. Cost-effectiveness of prophylactic hysterectomy in first-degree female relatives with Lynch syndrome of patients diagnosed with colorectal cancer in the United States: a microsimulation study. Cancer Med 2021 Oct;10(19):6835-6844. Epub 2021 Sep 12. [Abstract]

Cadham CJ, Cao P, Jayasekera J, Taylor KL, Levy DT, Jeon J, Elkin EB, Foley KL, Joseph A, Kong CY, Minnix JA, Rigotti NA, Toll BA, Zeliadt SB, Meza R, Mandelblatt J, CISNET-SCALE Collaboration. Cost-Effectiveness of Smoking Cessation Interventions in the Lung Cancer Screening Setting: A Simulation Study. J Natl Cancer Inst 2021 Aug 2;113(8):1065-1073. [Abstract]

Chootipongchaivat S, Wong XY, Ten Haaf K, Hartman M, Tan KB, van Ravesteyn NT, Wee HL. Cost-effectiveness Analysis of Breast Cancer Screening Using Mammography in Singapore: A Modeling Study. Cancer Epidemiol Biomarkers Prev 2021 Apr;30(4):653-660. Epub 2021 Feb 2. [Abstract]

Curtius K, Dewanji A, Hazelton WD, Rubenstein JH, Luebeck GE. Optimal Timing for Cancer Screening and Adaptive Surveillance Using Mathematical Modeling. Cancer Res 2021 Feb 15;81(4):1123-1134. Epub 2020 Dec 8. [Abstract]

Hendrix N, Gulati R, Jiao B, Kader AK, Ryan ST, Etzioni R. Clarifying the Trade-Offs of Risk-Stratified Screening for Prostate Cancer: A Cost-Effectiveness Study. Am J Epidemiol 2021 Oct 1;190(10):2064-2074. [Abstract]

Jiao B, Gulati R, Hendrix N, Gore JL, Rais-Bahrami S, Morgan TM, Etzioni R. Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States. Value Health 2021 Aug;24(8):1111-1117. Epub 2021 Apr 22. [Abstract]

Kim JJ, Simms KT, Killen J, Smith MA, Burger EA, Sy S, Regan C, Canfell K. Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis. PLoS Med 2021 Mar 11;18(3):e1003534. doi: 10.1371/journal.pmed.1003534. eCollection 2021 Mar. [Abstract]

Omidvari AH, Hazelton WD, Lauren BN, Naber SK, Lee M, Ali A, Seguin C, Kong CY, Richmond E, Rubenstein JH, Luebeck GE, Inadomi JM, Hur C, Lansdorp-Vogelaar I. The Optimal Age to Stop Endoscopic Surveillance of Patients With Barrett's Esophagus Based on Sex and Comorbidity: A Comparative Cost-Effectiveness Analysis. Gastroenterology 2021 Aug;161(2):487-494.e4. Epub 2021 May 8. [Abstract]

Omidvari AH, Lansdorp-Vogelaar I, de Koning HJ, Meester RGS. Impact of assumptions on future costs, disutility and mortality in cost-effectiveness analysis; a model exploration. PLoS One 2021 Jul 12;16(7):e0253893. doi: 10.1371/journal.pone.0253893. eCollection 2021. [Abstract]

Omidvari AH, Roumans CAM, Naber SK, Kroep S, Wijnhoven BPL, van der Gaast A, de Jonge PJ, Spaander MCW, Lansdorp-Vogelaar I. Correction to: The Impact of the Policy-Practice Gap on Costs and Benefits of Barrett's Esophagus Management. Am J Gastroenterol 2021 Feb 1;116(2):435-439. [Abstract]

Peterse EFP, Osoro CB, Bardou M, Lansdorp-Vogelaar I. Comparative benefit and cost-effectiveness of mailed-out faecal immunochemical tests vs collection at the general practitioner. Aliment Pharmacol Ther 2021 May;53(10):1118-1125. Epub 2021 Mar 8. [Abstract]

Rubenstein JH, Inadomi JM. Cost-Effectiveness of Screening, Surveillance, and Endoscopic Eradication Therapies for Managing the Burden of Esophageal Adenocarcinoma. Gastrointest Endosc Clin N Am 2021 Jan;31(1):77-90. Epub 2020 Oct 26. [Abstract]

Sami SS, Moriarty JP, Rosedahl JK, Borah BJ, Katzka DA, Wang KK, Kisiel JB, Ragunath K, Rubenstein JH, Iyer PG. Comparative Cost Effectiveness of Reflux-Based and Reflux-Independent Strategies for Barrett's Esophagus Screening. Am J Gastroenterol 2021 Aug 1;116(8):1620-1631. [Abstract]

Toumazis I, de Nijs K, Cao P, Bastani M, Munshi V, Ten Haaf K, Jeon J, Gazelle GS, Feuer EJ, de Koning HJ, Meza R, Kong CY, Han SS, Plevritis SK. Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening. JAMA Oncol 2021 Dec 1;7(12):1833-1842. [Abstract]

2020

Alarid-Escudero F, Kuntz KM. Potential Bias Associated with Modeling the Effectiveness of Healthcare Interventions in Reducing Mortality Using an Overall Hazard Ratio. Pharmacoeconomics 2020 Mar;38(3):285-296. [Abstract]

Blom EF, Haaf KT, de Koning HJ. Systematic Review and Meta-Analysis of Community- and Choice-Based Health State Utility Values for Lung Cancer. Pharmacoeconomics 2020 Nov;38(11):1187-1200. [Abstract]

Cenin DR, Naber SK, de Weerdt AC, Jenkins MA, Preen DB, Ee HC, O'Leary PC, Lansdorp-Vogelaar I. Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History. Cancer Epidemiol Biomarkers Prev 2020 Jan;29(1):10-21. Epub 2019 Nov 20. [Abstract]

Chen Y, Criss SD, Watson TR, Eckel A, Palazzo L, Tramontano AC, Wang Y, Mercaldo ND, Kong CY. Cost and Utilization of Lung Cancer End-of-Life Care Among Racial-Ethnic Minority Groups in the United States. Oncologist 2020 Jan;25(1):e120-e129. Epub 2019 Sep 9. [Abstract]

Criss SD, Palazzo L, Watson TR, Paquette AM, Sigel K, Wisnivesky J, Kong CY. Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden. PLoS One 2020 Jan 29;15(1):e0228288. doi: 10.1371/journal.pone.0228288. eCollection 2020. [Abstract]

Getaneh AM, Heijnsdijk EAM, Roobol MJ, de Koning HJ. Assessment of harms, benefits, and cost-effectiveness of prostate cancer screening: A micro-simulation study of 230 scenarios. Cancer Med 2020 Oct;9(20):7742-7750. Epub 2020 Aug 19. [Abstract]

Hammer MM, Palazzo LL, Paquette A, Eckel AL, Jacobson FL, Barbosa EM Jr, Kong CY. Cost-Effectiveness of Follow-Up for Subsolid Pulmonary Nodules in High-Risk Patients. J Thorac Oncol 2020 Aug;15(8):1298-1305. Epub 2020 Apr 6. [Abstract]

Jayasekera J, Mandelblatt JS. Systematic Review of the Cost Effectiveness of Breast Cancer Prevention, Screening, and Treatment Interventions. J Clin Oncol 2020 Feb 1;38(4):332-350. Epub 2019 Dec 5. [Abstract]

Lowry KP, Trentham-Dietz A, Schechter CB, Alagoz O, Barlow WE, Burnside ES, Conant EF, Hampton JM, Huang H, Kerlikowske K, Lee SJ, Miglioretti DL, Sprague BL, Tosteson ANA, Yaffe MJ, Stout NK. Long-Term Outcomes and Cost-Effectiveness of Breast Cancer Screening With Digital Breast Tomosynthesis in the United States. J Natl Cancer Inst 2020 Jun 1;112(6):582-589. [Abstract]

Mariotto A, Jayasekerea J, Petkov V, Schechter CB, Enewold L, Helzlsouer KJ, Feuer EJ, Mandelblatt JS. Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial. J Natl Cancer Inst 2020 Feb 1;112(2):154-160. [Abstract]

Omidvari AH, Ali A, Hazelton WD, Kroep S, Lee M, Naber SK, Lauren BN, Ostvar S, Richmond E, Kong CY, Rubenstein JH, Lansdorp-Vogelaar I, Luebeck G, Hur C, Inadomi J. Optimizing Management of Patients With Barrett's Esophagus and Low-Grade or No Dysplasia Based on Comparative Modeling. Clin Gastroenterol Hepatol 2020 Aug;18(9):1961-1969. Epub 2019 Dec 6. [Abstract]

Peterse EFP, Naber SK, Daly C, Pollett A, Paszat LF, Spaander MCW, Aronson M, Gryfe R, Rabeneck L, Lansdorp-Vogelaar I, Baxter NN. Cost-effectiveness of Active Identification and Subsequent Colonoscopy Surveillance of Lynch Syndrome Cases. Clin Gastroenterol Hepatol 2020 Nov;18(12):2760-2767.e12. Epub 2019 Oct 17. [Abstract]

Rubenstein JH, Noureldin M, Tavakkoli A, Hur C, Omidvari AH, Waljee AK. Utilization of Surveillance Endoscopy for Barrett's Esophagus in Medicare Enrollees. Gastroenterology 2020 Feb;158(3):773-775.e1. Epub 2019 Oct 31. [Abstract]

Sankatsing VDV, Juraniec K, Grimm SE, Joore MA, Pijnappel RM, de Koning HJ, van Ravesteyn NT. Cost-effectiveness of Digital Breast Tomosynthesis in Population-based Breast Cancer Screening: A Probabilistic Sensitivity Analysis. Radiology 2020 Oct;297(1):40-48. Epub 2020 Aug 4. [Abstract]

Sankatsing VDV, van Ravesteyn NT, Heijnsdijk EAM, Broeders MJM, de Koning HJ. Risk stratification in breast cancer screening: Cost-effectiveness and harm-benefit ratios for low-risk and high-risk women. Int J Cancer 2020 Dec 1;147(11):3059-3067. Epub 2020 Jun 30. [Abstract]

Yeh JM, Lowry KP, Schechter CB, Diller LR, Alagoz O, Armstrong GT, Hampton JM, Leisenring W, Liu Q, Mandelblatt JS, Miglioretti DL, Moskowitz CS, Oeffinger KC, Trentham-Dietz A, Stout NK. Clinical Benefits, Harms, and Cost-Effectiveness of Breast Cancer Screening for Survivors of Childhood Cancer Treated With Chest Radiation : A Comparative Modeling Study. Ann Intern Med 2020 Sep 1;173(5):331-341. Epub 2020 Jul 7. [Abstract]

2019

Alarid-Escudero F, Enns EA, Kuntz KM, Michaud TL, Jalal H. "Time Traveling Is Just Too Dangerous" but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier. Value Health 2019 May;22(5):611-618. [Abstract]

Alarid-Escudero F, Krijkamp EM, Pechlivanoglou P, Jalal H, Kao SZ, Yang A, Enns EA. A Need for Change! A Coding Framework for Improving Transparency in Decision Modeling. Pharmacoeconomics 2019 Nov;37(11):1329-1339. [Abstract]

Criss SD, Cao P, Bastani M, Ten Haaf K, Chen Y, Sheehan DF, Blom EF, Toumazis I, Jeon J, de Koning HJ, Plevritis SK, Meza R, Kong CY. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study. Ann Intern Med 2019 Dec 3;171(11):796-804. Epub 2019 Nov 5. [Abstract]

Criss SD, Mooradian MJ, Sheehan DF, Zubiri L, Lumish MA, Gainor JF, Reynolds KL, Kong CY. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System. JAMA Oncol 2019 Mar 1;5(3):358-365. [Abstract]

Gini A, Meester RGS, Keshavarz H, Oeffinger KC, Ahmed S, Hodgson DC, Lansdorp-Vogelaar I. Cost-Effectiveness of Colonoscopy-Based Colorectal Cancer Screening in Childhood Cancer Survivors. J Natl Cancer Inst 2019 Nov 1;111(11):1161-1169. [Abstract]

Meester RGS, Lansdorp-Vogelaar I, Winawer SJ, Zauber AG, Knudsen AB, Ladabaum U. High-Intensity Versus Low-Intensity Surveillance for Patients With Colorectal Adenomas: A Cost-Effectiveness Analysis. Ann Intern Med 2019 Nov 5;171(9):612-622. Epub 2019 Sep 24. [Abstract]

Naber SK, Knudsen AB, Zauber AG, Rutter CM, Fischer SE, Pabiniak CJ, Soto B, Kuntz KM, Lansdorp-Vogelaar I. Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries. PLoS One 2019 Sep 4;14(9):e0220234. doi: 10.1371/journal.pone.0220234. eCollection 2019. [Abstract]

Naber SK, Kundu S, Kuntz KM, Dotson WD, Williams MS, Zauber AG, Calonge N, Zallen DT, Ganiats TG, Webber EM, Goddard KAB, Henrikson NB, van Ballegooijen M, Janssens ACJW, Lansdorp-Vogelaar I. Cost-Effectiveness of Risk-Stratified Colorectal Cancer Screening Based on Polygenic Risk: Current Status and Future Potential. JNCI Cancer Spectr 2019 Oct 14;4(1):pkz086. doi: 10.1093/jncics/pkz086. eCollection 2020 Feb. [Abstract]

Toumazis I, Tsai EB, Erdogan SA, Han SS, Wan W, Leung A, Plevritis SK. Cost-Effectiveness Analysis of Lung Cancer Screening Accounting for the Effect of Indeterminate Findings. JNCI Cancer Spectr 2019 May 23;3(3):pkz035. doi: 10.1093/jncics/pkz035. eCollection 2019 Sep. [Abstract]

Tramontano AC, Chen Y, Watson TR, Eckel A, Hur C, Kong CY. Esophageal cancer treatment costs by phase of care and treatment modality, 2000-2013. Cancer Med 2019 Sep;8(11):5158-5172. Epub 2019 Jul 26. [Abstract]

2018

Campos NG, Lince-Deroche N, Chibwesha CJ, Firnhaber C, Smith JS, Michelow P, Meyer-Rath G, Jamieson L, Jordaan S, Sharma M, Regan C, Sy S, Liu G, Tsu V, Jeronimo J, Kim JJ. Cost-Effectiveness of Cervical Cancer Screening in Women Living With HIV in South Africa: A Mathematical Modeling Study. J Acquir Immune Defic Syndr 2018 Oct 1;79(2):195-205. [Abstract]

Chandler Y, Schechter CB, Jayasekera J, Near A, O'Neill SC, Isaacs C, Phelps CE, Ray GT, Lieu TA, Ramsey S, Mandelblatt JS. Cost Effectiveness of Gene Expression Profile Testing in Community Practice. J Clin Oncol 2018 Feb 20;36(6):554-562. Epub 2018 Jan 8. [Abstract]

Chu JN, Choi J, Tramontano A, Morse C, Forcione D, Nishioka NS, Abrams JA, Rubenstein JH, Kong CY, Inadomi JM, Hur C. Surgical vs Endoscopic Management of T1 Esophageal Adenocarcinoma: A Modeling Decision Analysis. Clin Gastroenterol Hepatol 2018 Mar;16(3):392-400.e7. Epub 2017 Nov 24. [Abstract]

de Carvalho TM, Heijnsdijk EAM, de Koning HJ. Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance. Cancer 2018 Feb 1;124(3):507-513. Epub 2017 Dec 12. [Abstract]

Gini A, Zauber AG, Cenin DR, Omidvari AH, Hempstead SE, Fink AK, Lowenfels AB, Lansdorp-Vogelaar I. Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer. Gastroenterology 2018 Feb;154(3):556-567.e18. Epub 2017 Nov 2. [Abstract]

Krijkamp EM, Alarid-Escudero F, Enns EA, Jalal HJ, Hunink MGM, Pechlivanoglou P. Microsimulation Modeling for Health Decision Sciences Using R: A Tutorial. Med Decis Making 2018 Apr;38(3):400-422. [Abstract]

Lansdorp-Vogelaar I, Goede SL, Bosch LJW, Melotte V, Carvalho B, van Engeland M, Meijer GA, de Koning HJ, van Ballegooijen M. Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening. Clin Gastroenterol Hepatol 2018 Apr;16(4):504-512.e11. Epub 2017 Jul 18. [Abstract]

Naber SK, Kuntz KM, Henrikson NB, Williams MS, Calonge N, Goddard KAB, Zallen DT, Ganiats TG, Webber EM, Janssens ACJW, van Ballegooijen M, Zauber AG, Lansdorp-Vogelaar I. Cost Effectiveness of Age-Specific Screening Intervals for People With Family Histories of Colorectal Cancer. Gastroenterology 2018 Jan;154(1):105-116.e20. Epub 2017 Sep 28. [Abstract]

van der Meulen MP, Lansdorp-Vogelaar I, Goede SL, Kuipers EJ, Dekker E, Stoker J, van Ballegooijen M. Colorectal Cancer: Cost-effectiveness of Colonoscopy versus CT Colonography Screening with Participation Rates and Costs. Radiology 2018 Jun;287(3):901-911. Epub 2018 Feb 27. [Abstract]

2017

de Carvalho TM, Heijnsdijk EAM, de Koning HJ. When should active surveillance for prostate cancer stop if no progression is detected? Prostate 2017 Jun;77(9):962-969. Epub 2017 Apr 17. [Abstract]

Goede SL, Rabeneck L, van Ballegooijen M, Zauber AG, Paszat LF, Hoch JS, Yong JH, Kroep S, Tinmouth J, Lansdorp-Vogelaar I. Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening. PLoS One 2017 Mar 15;12(3):e0172864. doi: 10.1371/journal.pone.0172864. eCollection 2017. [Abstract]

Heberle CR, Omidvari AH, Ali A, Kroep S, Kong CY, Inadomi JM, Rubenstein JH, Tramontano AC, Dowling EC, Hazelton WD, Luebeck EG, Lansdorp-Vogelaar I, Hur C. Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device. Clin Gastroenterol Hepatol 2017 Sep;15(9):1397-1404.e7. Epub 2017 Feb 24. [Abstract]

Kroep S, Heberle CR, Curtius K, Kong CY, Lansdorp-Vogelaar I, Ali A, Wolf WA, Shaheen NJ, Spechler SJ, Rubenstein JH, Nishioka NS, Meltzer SJ, Hazelton WD, van Ballegooijen M, Tramontano AC, Gazelle GS, Luebeck EG, Inadomi JM, Hur C. Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis. Clin Gastroenterol Hepatol 2017 Sep;15(9):1471-1474. Epub 2017 Jan 12. [Abstract]

Mandelblatt JS, Ramsey SD, Lieu TA, Phelps CE. Evaluating Frameworks That Provide Value Measures for Health Care Interventions. Value Health 2017 Feb;20(2):185-192. [Abstract]

Meulen MPV, Kapidzic A, Leerdam MEV, van der Steen A, Kuipers EJ, Spaander MCW, de Koning HJ, Hol L, Lansdorp-Vogelaar I. Do Men and Women Need to Be Screened Differently with Fecal Immunochemical Testing? A Cost-Effectiveness Analysis. Cancer Epidemiol Biomarkers Prev 2017 Aug;26(8):1328-1336. Epub 2017 May 17. [Abstract]

Peterse EFP, Meester RGS, Gini A, Doubeni CA, Anderson DS, Berger FG, Zauber AG, Lansdorp-Vogelaar I. Value Of Waiving Coinsurance For Colorectal Cancer Screening In Medicare Beneficiaries. Health Aff (Millwood) 2017 Dec;36(12):2151-2159. [Abstract]

Sheehan DF, Criss SD, Gazelle GS, Pandharipande PV, Kong CY. Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach. PLoS One 2017 Mar 8;12(3):e0173119. doi: 10.1371/journal.pone.0173119. eCollection 2017. [Abstract]

Ten Haaf K, Tammemägi MC, Bondy SJ, van der Aalst CM, Gu S, McGregor SE, Nicholas G, de Koning HJ, Paszat LF. Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada. PLoS Med 2017 Feb 7;14(2):e1002225. doi: 10.1371/journal.pmed.1002225. eCollection 2017 Feb. [Abstract]

Tramontano AC, Sheehan DF, Yeh JM, Kong CY, Dowling EC, Rubenstein JH, Abrams JA, Inadomi JM, Schrag D, Hur C. The Impact of a Prior Diagnosis of Barrett's Esophagus on Esophageal Adenocarcinoma Survival. Am J Gastroenterol 2017 Aug;112(8):1256-1264. Epub 2017 Apr 4. [Abstract]

2016

Chang Y, Near AM, Butler KM, Hoeffken A, Edwards SL, Stroup AM, Kohlmann W, Gammon A, Buys SS, Schwartz MD, Peshkin BN, Kinney AY, Mandelblatt JS, Chang Y, Near AM, Butler KM, Hoeffken A, Edwards SL, Stroup AM, Kohlmann W, Gammon A, Buys SS, Schwartz MD, Peshkin BN, Kinney AY, Mandelblatt JS. Economic Evaluation Alongside a Clinical Trial of Telephone Versus In-Person Genetic Counseling for BRCA1/2 Mutations in Geographically Underserved Areas. J Oncol Pract 2016 Jan;12(1):59, e1-13. [Abstract]

Kong CY, Sheehan DF, McMahon PM, Gazelle GS, Pandharipande P. Combined Biomarker and Computed Tomography Screening Strategies for Lung Cancer: Projections of Health and Economic Tradeoffs in the US Population. MDM Policy Pract 2016 Jul-Dec;1. (1). Epub 2016 Jul 7. [Abstract]

Roth JA, Gulati R, Gore JL, Cooperberg MR, Etzioni R. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies. JAMA Oncol 2016 Jul 1;2(7):890-8. [Abstract]

Tavakkoli A, Prabhu A, Rubenstein JH. Predicting Lymph Node Metastases in Superficial Esophageal Adenocarcinoma. Gastroenterology 2016 Jun;150(7):1680-1682. Epub 2016 Apr 29. [Abstract]

ten Haaf K, de Koning HJ. Clarifying Assumptions and Outcomes in Cost-effectiveness Analyses. JAMA Oncol 2016 Feb;2(2):277-8. [Abstract]

Trentham-Dietz A, Kerlikowske K, Stout NK, Miglioretti DL, Schechter CB, Ergun MA, van den Broek JJ, Alagoz O, Sprague BL, van Ravesteyn NT, Near AM, Gangnon RE, Hampton JM, Chandler Y, de Koning HJ, Mandelblatt JS, Tosteson AN, Breast Cancer Surveillance Consortium and the Cancer Intervention and Surveillance Modeling Network. Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes. Ann Intern Med 2016 Nov 15;165(10):700-712. Epub 2016 Aug 23. [Abstract]

2015

Goede SL, Kuntz KM, van Ballegooijen M, Knudsen AB, Lansdorp-Vogelaar I, Tangka FK, Howard DH, Chin J, Zauber AG, Seeff LC. Cost-Savings to Medicare From Pre-Medicare Colorectal Cancer Screening. Med Care 2015 Jul;53(7):630-8. [Abstract]

Hur C, Choi SE, Kong CY, Wang GQ, Xu H, Polydorides AD, Xue LY, Perzan KE, Tramontano AC, Richards-Kortum RR, Anandasabapathy S. High-resolution microendoscopy for esophageal cancer screening in China: A cost-effectiveness analysis. World J Gastroenterol 2015 May 14;21(18):5513-23. [Abstract]

Inadomi JM. Cost considerations in implementing a screening and surveillance strategy for Barrett's oesophagus. Best Pract Res Clin Gastroenterol 2015 Feb;29(1):51-63. Epub 2014 Dec 18. [Abstract]

Lee CI, Cevik M, Alagoz O, Sprague BL, Tosteson AN, Miglioretti DL, Kerlikowske K, Stout NK, Jarvik JG, Ramsey SD, Lehman CD. Comparative effectiveness of combined digital mammography and tomosynthesis screening for women with dense breasts. Radiology 2015 Mar;274(3):772-80. Epub 2014 Oct 28. [Abstract]

Meester RG, Doubeni CA, Lansdorp-Vogelaar I, Jensen CD, van der Meulen MP, Levin TR, Quinn VP, Schottinger JE, Zauber AG, Corley DA, van Ballegooijen M. Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening: A Microsimulation Model. JAMA 2015 Jun 16;313(23):2349-58. [Abstract]

Ten Haaf K, van Rosmalen J, de Koning HJ. Lung cancer detectability by test, histology, stage, and gender: estimates from the NLST and the PLCO trials. Cancer Epidemiol Biomarkers Prev 2015 Jan;24(1):154-61. Epub 2014 Oct 13. [Abstract]

Tramontano AC, Schrag DL, Malin JK, Miller MC, Weeks JC, Swan JS, McMahon PM. Catalog and comparison of societal preferences (utilities) for lung cancer health states: results from the Cancer Care Outcomes Research and Surveillance (CanCORS) study. Med Decis Making 2015 Apr;35(3):371-87. Epub 2015 Feb 10. [Abstract]

van der Steen A, Knudsen AB, van Hees F, Walter GP, Berger FG, Daguise VG, Kuntz KM, Zauber AG, van Ballegooijen M, Lansdorp-Vogelaar I. Optimal colorectal cancer screening in states' low-income, uninsured populations—the case of South Carolina. Health Serv Res 2015 Jun;50(3):768-89. Epub 2014 Oct 16. [Abstract]

van Hees F, Saini SD, Lansdorp-Vogelaar I, Vijan S, Meester RG, de Koning HJ, Zauber AG, van Ballegooijen M. Personalizing colonoscopy screening for elderly individuals based on screening history, cancer risk, and comorbidity status could increase cost effectiveness. Gastroenterology 2015 Nov;149(6):1425-37. Epub 2015 Aug 4. [Abstract]

van Ravesteyn NT, van Lier L, Schechter CB, Ekwueme DU, Royalty J, Miller JW, Near AM, Cronin KA, Heijnsdijk EA, Mandelblatt JS, de Koning HJ. Transition from film to digital mammography: impact for breast cancer screening through the national breast and cervical cancer early detection program. Am J Prev Med 2015 May;48(5):535-42. [Abstract]

2014

Choi SE, Perzan KE, Tramontano AC, Kong CY, Hur C. Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis. Cancer Prev Res (Phila) 2014 Mar;7(3):341-50. Epub 2013 Dec 31. [Abstract]

Heijnsdijk EA, de Carvalho TM, Auvinen A, Zappa M, Nelen V, Kwiatkowski M, Villers A, Páez A, Moss SM, Tammela TL, Recker F, Denis L, Carlsson SV, Wever EM, Bangma CH, Schröder FH, Roobol MJ, Hugosson J, de Koning HJ. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data. J Natl Cancer Inst 2014 Dec 13;107(1):366. Print 2015 Jan. [Abstract]

van Hees F, Habbema JD, Meester RG, Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG. Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis. Ann Intern Med 2014 Jun 3;160(11):750-9. [Abstract]

van Hees F, Zauber AG, Klabunde CN, Goede SL, Lansdorp-Vogelaar I, van Ballegooijen M. The appropriateness of more intensive colonoscopy screening than recommended in Medicare beneficiaries: a modeling study. JAMA Intern Med 2014 Oct;174(10):1568-76. [Abstract]

2013

Goede SL, van Roon AH, Reijerink JC, van Vuuren AJ, Lansdorp-Vogelaar I, Habbema JD, Kuipers EJ, van Leerdam ME, van Ballegooijen M. Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening. Gut 2013 May;62(5):727-34. Epub 2012 Apr 5. [Abstract]

2011

Bradley CJ, Lansdorp-Vogelaar I, Yabroff KR, Dahman B, Mariotto A, Feuer EJ, Brown ML. Productivity savings from colorectal cancer prevention and control strategies. Am J Prev Med 2011 Aug;41(2):e5-e14. [Abstract]

Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Cost-effectiveness of colorectal cancer screening. Epidemiol Rev 2011;33(1):88-100. Epub 2011 Jun 1. [Abstract]

McMahon PM, Kong CY, Bouzan C, Weinstein MC, Cipriano LE, Tramontano AC, Johnson BE, Weeks JC, Gazelle GS. Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol 2011 Nov;6(11):1841-8. [Abstract]

Vanness DJ, Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Gareen IF, Herman BA, Kuntz KM, Zauber AG, van Ballegooijen M, Feuer EJ, Chen MH, Johnson CD. Comparative economic evaluation of data from the ACRIN National CT Colonography Trial with three cancer intervention and surveillance modeling network microsimulations. Radiology 2011 Nov;261(2):487-98. Epub 2011 Aug 3. [Abstract]

Wilschut JA, Hol L, Dekker E, Jansen JB, Van Leerdam ME, Lansdorp-Vogelaar I, Kuipers EJ, Habbema JD, Van Ballegooijen M. Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. Gastroenterology 2011 Nov;141(5):1648-55.e1. Epub 2011 Jul 22. [Abstract]

Wilschut JA, Steyerberg EW, van Leerdam ME, Lansdorp-Vogelaar I, Habbema JD, van Ballegooijen M. How much colonoscopy screening should be recommended to individuals with various degrees of family history of colorectal cancer? Cancer 2011 Sep 15;117(18):4166-74. Epub 2011 Mar 8. [Abstract]

2010

Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Cost-effectiveness of colorectal cancer screening - an overview. Best Pract Res Clin Gastroenterol 2010 Aug;24(4):439-49. [Abstract]

2009

Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Boer R, Wilschut J, Habbema JD. At what costs will screening with CT colonography be competitive? A cost-effectiveness approach. Int J Cancer 2009 Mar 1;124(5):1161-8. [Abstract]

Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Habbema JD, Kuipers EJ. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst 2009 Oct 21;101(20):1412-22. Epub 2009 Sep 24. [Abstract]

Zauber AG, Knudsen AB, Rutter CM, Lansdorp-Vogelaar I, Savarino JE, van Ballegooijen M, Kuntz KM. Cost-Effectiveness of CT Colonography to Screen for Colorectal Cancer. 2009 Jan 22. Available at https://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id58TA.pdf. [Link]

2008

Tosteson AN, Stout NK, Fryback DG, Acharyya S, Herman BA, Hannah LG, Pisano ED, DMIST Investigators. Cost-effectiveness of digital mammography breast cancer screening. Ann Intern Med 2008 Jan 1;148(1):1-10. [Abstract]

2007

Zeliadt SB, Etzioni R, Ramsey SD, Penson DF, Potosky AL. Trends in treatment costs for localized prostate cancer: the healthy screenee effect. Med Care 2007 Feb;45(2):154-9. [Abstract]

2005

Pignone M, Saha S, Hoerger T, Lohr KN, Teutsch S, Mandelblatt J. Challenges in systematic reviews of economic analyses. Ann Intern Med 2005 Jun 21;142(12 Pt 2):1073-9. [Abstract]

2003

Polsky D, Mandelblatt JS, Weeks JC, Venditti L, Hwang YT, Glick HA, Hadley J, Schulman KA. Economic evaluation of breast cancer treatment: considering the value of patient choice. J Clin Oncol 2003 Mar 15;21(6):1139-46. [Abstract]

Cross Model Comparisons

2023

2021

Meza R, Jeon J, Toumazis I, Ten Haaf K, Cao P, Bastani M, Han SS, Blom EF, Jonas DE, Feuer EJ, Plevritis SK, de Koning HJ, Kong CY. Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force. JAMA 2021 Mar 9;325(10):988-997. [Abstract]

Nyame YA, Gulati R, Heijnsdijk EAM, Tsodikov A, Mariotto AB, Gore JL, Etzioni R. The Impact of Intensifying Prostate Cancer Screening in Black Men: A Model-Based Analysis. J Natl Cancer Inst 2021 Oct 1;113(10):1336-1342. [Abstract]

van Ravesteyn NT, Schechter CB, Hampton JM, Alagoz O, van den Broek JJ, Kerlikowske K, Mandelblatt JS, Miglioretti DL, Sprague BL, Stout NK, de Koning HJ, Trentham-Dietz A, Tosteson ANA, Breast Cancer Surveillance Consortium and the Cancer Intervention and Surveillance Modeling Network. Trade-Offs Between Harms and Benefits of Different Breast Cancer Screening Intervals Among Low-Risk Women. J Natl Cancer Inst 2021 Aug 2;113(8):1017-1026. [Abstract]

2020

Burger EA, de Kok IMCM, Groene E, Killen J, Canfell K, Kulasingam S, Kuntz KM, Matthijsse S, Regan C, Simms KT, Smith MA, Sy S, Alarid-Escudero F, Vaidyanathan V, van Ballegooijen M, Kim JJ. Estimating the Natural History of Cervical Carcinogenesis Using Simulation Models: A CISNET Comparative Analysis. J Natl Cancer Inst 2020 Sep 1;112(9):955-963. [Abstract]

Burger EA, Smith MA, Killen J, Sy S, Simms KT, Canfell K, Kim JJ. Projected time to elimination of cervical cancer in the USA: a comparative modelling study. Lancet Public Health 2020 Apr;5(4):e213-e222. Epub 2020 Feb 10. [Abstract]

Chootipongchaivat S, van Ravesteyn NT, Li X, Huang H, Weedon-Fekjær H, Ryser MD, Weaver DL, Burnside ES, Heckman-Stoddard BM, de Koning HJ, Lee SJ. Modeling the natural history of ductal carcinoma in situ based on population data. Breast Cancer Res 2020 May 27;22(1):53. [Abstract]

de Kok IMCM, Burger EA, Naber SK, Canfell K, Killen J, Simms K, Kulasingam S, Groene E, Sy S, Kim JJ, van Ballegooijen M. The Impact of Different Screening Model Structures on Cervical Cancer Incidence and Mortality Predictions: The Maximum Clinical Incidence Reduction (MCLIR) Methodology. Med Decis Making 2020 May;40(4):474-482. Epub 2020 Jun 3. [Abstract]

2018

Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Collaborators. Breast Cancer Simulation Modeling. Med Decis Making 2018 Apr;38(1 Suppl):3S-150S.

de Koning HJ, Gulati R, Moss SM, Hugosson J, Pinsky PF, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, de Carvalho TM, Feuer EJ, Tsodikov A, Mariotto AB, Heijnsdijk EAM, Etzioni R. The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials. Cancer 2018 Mar 15;124(6):1197-1206. Epub 2017 Dec 6. [Abstract]

Han SS, Ten Haaf K, Hazelton WD, Jeon J, Meza R, Kong CY, Feuer EJ, de Koning HJ, Plevritis SK. Re: Think before you leap. Int J Cancer 2018 Apr 1;142(7):1507-1509. Epub 2017 Dec 28. [Abstract]

van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Cevik M, Schechter CB, Lee SJ, Huang H, Li Y, Munoz DF, Plevritis SK, de Koning HJ, Stout NK, van Ballegooijen M. Comparing CISNET Breast Cancer Models Using the Maximum Clinical Incidence Reduction Methodology. Med Decis Making 2018 Apr;38(1_suppl):112S-125S. [Abstract]

van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Huang H, Ergun MA, Burnside ES, Xu C, Li Y, Alagoz O, Lee SJ, Stout NK, Song J, Trentham-Dietz A, Plevritis SK, Moss SM, de Koning HJ. Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49. Med Decis Making 2018 Apr;38(1_suppl):140S-150S. [Abstract]

van Ravesteyn NT, van den Broek JJ, Li X, Weedon-Fekjær H, Schechter CB, Alagoz O, Huang X, Weaver DL, Burnside ES, Punglia RS, de Koning HJ, Lee SJ. Modeling Ductal Carcinoma In Situ (DCIS): An Overview of CISNET Model Approaches. Med Decis Making 2018 Apr;38(1_suppl):126S-139S. [Abstract]

2017

Han SS, Ten Haaf K, Hazelton WD, Munshi VN, Jeon J, Erdogan SA, Johanson C, McMahon PM, Meza R, Kong CY, Feuer EJ, de Koning HJ, Plevritis SK. The impact of overdiagnosis on the selection of efficient lung cancer screening strategies. Int J Cancer 2017 Jun 1;140(11):2436-2443. [Abstract]

Tsodikov A, Gulati R, de Carvalho TM, Heijnsdijk EAM, Hunter-Merrill RA, Mariotto AB, de Koning HJ, Etzioni R. Is prostate cancer different in black men? Answers from 3 natural history models. Cancer 2017 Jun 15;123(12):2312-2319. Epub 2017 Apr 24. [Abstract]

Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, de Carvalho TM, Hugosson J, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, Feuer EJ, de Koning HJ, Mariotto AB, Etzioni R. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Ann Intern Med 2017 Oct 3;167(7):449-455. Epub 2017 Sep 5. [Abstract]

2016

Knudsen AB, Zauber AG, Rutter CM, Naber SK, Doria-Rose VP, Pabiniak C, Johanson C, Fischer SE, Lansdorp-Vogelaar I, Kuntz KM. Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force. JAMA 2016 Jun 21;315(23):2595-609. [Abstract]

Mandelblatt JS, Stout NK, Schechter CB, van den Broek JJ, Miglioretti DL, Krapcho M, Trentham-Dietz A, Munoz D, Lee SJ, Berry DA, van Ravesteyn NT, Alagoz O, Kerlikowske K, Tosteson AN, Near AM, Hoeffken A, Chang Y, Heijnsdijk EA, Chisholm G, Huang X, Huang H, Ergun MA, Gangnon R, Sprague BL, Plevritis S, Feuer E, de Koning HJ, Cronin KA. Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies. Ann Intern Med 2016 Feb 16;164(4):215-25. Epub 2016 Jan 12. [Abstract]

2015

Kroep S, Lansdorp-Vogelaar I, van der Steen A, Inadomi JM, van Ballegooijen M. The Impact of Uncertainty in Barrett's Esophagus Progression Rates on Hypothetical Screening and Treatment Decisions. Med Decis Making 2015 Aug;35(6):726-33. Epub 2014 Oct 2. [Abstract]

2014

Kong CY, Kroep S, Curtius K, Hazelton WD, Jeon J, Meza R, Heberle CR, Miller MC, Choi SE, Lansdorp-Vogelaar I, van Ballegooijen M, Feuer EJ, Inadomi JM, Hur C, Luebeck EG. Exploring the recent trend in esophageal adenocarcinoma incidence and mortality using comparative simulation modeling. Cancer Epidemiol Biomarkers Prev 2014 Jun;23(6):997-1006. Epub 2014 Apr 1. [Abstract]

McMahon PM, Meza R, Plevritis SK, Black WC, Tammemagi CM, Erdogan A, ten Haaf K, Hazelton W, Holford TR, Jeon J, Clarke L, Kong CY, Choi SE, Munshi VN, Han SS, van Rosmalen J, Pinsky PF, Moolgavkar S, de Koning HJ, Feuer EJ. Comparing benefits from many possible computed tomography lung cancer screening programs: extrapolating from the National Lung Screening Trial using comparative modeling. PLoS One 2014 Jun 30;9(6):e99978. doi: 10.1371/journal.pone.0099978. eCollection 2014. [Abstract]

Meza R, ten Haaf K, Kong CY, Erdogan A, Black WC, Tammemagi MC, Choi SE, Jeon J, Han SS, Munshi V, van Rosmalen J, Pinsky P, McMahon PM, de Koning HJ, Feuer EJ, Hazelton WD, Plevritis SK. Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. Cancer 2014 Jun 1;120(11):1713-24. Epub 2014 Feb 27. [Abstract]

2012

Holford TR, Levy DT. Chapter 14: Comparing the adequacy of carcinogenesis models in estimating U.S. population rates for lung cancer mortality. Risk Anal 2012 Jul;32 Suppl 1(Suppl 1):S179-89. [Abstract]

McMahon PM, Hazelton WD, Kimmel M, Clarke LD. Chapter 13: CISNET lung models: comparison of model assumptions and model structures. Risk Anal 2012 Jul;32 Suppl 1(Suppl 1):S166-78. [Abstract]

2011

Gulati R, Wever EM, Tsodikov A, Penson DF, Inoue LY, Katcher J, Lee SY, Heijnsdijk EA, Draisma G, de Koning HJ, Etzioni R. What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev 2011 May;20(5):740-50. [Abstract]

Kuntz KM, Lansdorp-Vogelaar I, Rutter CM, Knudsen AB, van Ballegooijen M, Savarino JE, Feuer EJ, Zauber AG. A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. Med Decis Making 2011 Jul-Aug;31(4):530-9. Epub 2011 Jun 14. [Abstract]

Rutter CM, Knudsen AB, Pandharipande PV. Computer disease simulation models: integrating evidence for health policy. Acad Radiol 2011 Sep;18(9):1077-86. Epub 2011 Mar 23. [Abstract]

Rutter CM, Zaslavsky AM, Feuer EJ. Dynamic microsimulation models for health outcomes: a review. Med Decis Making 2011 Jan-Feb;31(1):10-8. Epub 2010 May 18. [Abstract]

van Ballegooijen M, Rutter CM, Knudsen AB, Zauber AG, Savarino JE, Lansdorp-Vogelaar I, Boer R, Feuer EJ, Habbema JD, Kuntz KM. Clarifying differences in natural history between models of screening: the case of colorectal cancer. Med Decis Making 2011 Jul-Aug;31(4):540-9. Epub 2011 Jun 14. [Abstract]

2006

Clarke LD, Plevritis SK, Boer R, Cronin KA, Feuer EJ. A comparative review of CISNET breast models used to analyze U.S. breast cancer incidence and mortality trends. J Natl Cancer Inst Monogr 2006;(36):96-105. [Abstract]

2004

Boer R, Plevritis S, Clarke L. Diversity of model approaches for breast cancer screening: a review of model assumptions by the Cancer Intervention and Surveillance Network (CISNET) Breast Cancer Groups. Stat Methods Med Res 2004 Dec;13(6):525-38. [Abstract]

Evaluation of New and Existing Prevention, Screening, and Treatment Strategies and Technologies

2023

Holford TR, McKay L, Jeon J, Tam J, Cao P, Fleischer NL, Levy DT, Meza R. Smoking Histories by State in the U.S. Am J Prev Med 2023 Apr;64(4 Suppl 1):S42-S52. Epub 2023 Jan 16. [Abstract]

Jayasekera J, Zhao A, Schechter C, Lowry K, Yeh JM, Schwartz MD, O'Neill S, Wernli KJ, Stout N, Mandelblatt J, Kurian AW, Isaacs C. Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor-Positive Breast Cancer. J Clin Oncol 2023 Feb 1;41(4):859-870. Epub 2022 Dec 1. [Abstract]

Jeon J, Cao P, Fleischer NL, Levy DT, Holford TR, Meza R, Tam J. Birth Cohort‒Specific Smoking Patterns by Family Income in the U.S. Am J Prev Med 2023 Apr;64(4 Suppl 1):S32-S41. Epub 2023 Jan 16. [Abstract]

Jeon J, Inoue-Choi M, Mok Y, McNeel TS, Tam J, Freedman ND, Meza R. Mortality Relative Risks by Smoking, Race/Ethnicity, and Education. Am J Prev Med 2023 Apr;64(4 Suppl 1):S53-S62. Epub 2023 Feb 11. [Abstract]

Kregting LM, van Ravesteyn NT, Chootipongchaivat S, Heijnsdijk EAM, Otten JDM, Broeders MJM, de Koning HJ. Cumulative risks of false positive recall and screen-detected breast cancer after multiple screening examinations. Int J Cancer 2023 Jul 15;153(2):312-319. Epub 2023 Apr 10. [Abstract]

Lu Y, Hajjar A, Cryns VL, Trentham-Dietz A, Gangnon RE, Heckman-Stoddard BM, Alagoz O. Breast cancer risk for women with diabetes and the impact of metformin: A meta-analysis. Cancer Med 2023 May;12(10):11703-11718. Epub 2022 Dec 19. [Abstract]

Meza R, Cao P, Jeon J, Fleischer NL, Holford TR, Levy DT, Tam J. Patterns of Birth Cohort‒Specific Smoking Histories by Race and Ethnicity in the U.S. Am J Prev Med 2023 Apr;64(4 Suppl 1):S11-S21. Epub 2023 Jan 16. [Abstract]

Sprague BL, Ichikawa L, Eavey J, Lowry KP, Rauscher G, O'Meara ES, Miglioretti DL, Chen S, Lee JM, Stout NK, Mandelblatt JS, Alsheik N, Herschorn SD, Perry H, Weaver DL, Kerlikowske K. Breast cancer risk characteristics of women undergoing whole-breast ultrasound screening versus mammography alone. Cancer 2023 Aug 15;129(16):2456-2468. Epub 2023 Jun 12. [Abstract]

Tam J, Jaffri MA, Mok Y, Jeon J, Szklo AS, Souza MC, Holford TR, Levy DT, Cao P, Sánchez-Romero LM, Meza R. Patterns of Birth Cohort‒Specific Smoking Histories in Brazil. Am J Prev Med 2023 Apr;64(4 Suppl 1):S63-S71. Epub 2023 Feb 10. [Abstract]

van den Berg DMN, Nascimento de Lima P, Knudsen AB, Rutter CM, Weinberg D, Lansdorp-Vogelaar I, Cisnet-Colon Group. NordICC Trial Results in Line With Expected Colorectal Cancer Mortality Reduction After Colonoscopy: A Modeling Study. Gastroenterology 2023 Jul 15. Epub 2023 Jul 15. [Abstract]

Xi Q, Meza R, Leventhal A, Tam J. Modeling cigarette smoking disparities between people with and without serious psychological distress in the US, 1997-2100. Prev Med 2023 Jan;166:107385. Epub 2022 Dec 7. [Abstract]

2022

Aredo JV, Choi E, Ding VY, Tammemägi MC, Ten Haaf K, Luo SJ, Freedman ND, Wilkens LR, Le Marchand L, Wakelee HA, Meza R, Park SL, Cheng I, Han SS. Racial and Ethnic Disparities in Lung Cancer Screening by the 2021 USPSTF Guidelines Versus Risk-Based Criteria: The Multiethnic Cohort Study. JNCI Cancer Spectr 2022 May 2;6. (3). [Abstract]

Basourakos SP, Gulati R, Vince RA Jr, Spratt DE, Lewicki PJ, Hill A, Nyame YA, Cullen J, Markt SC, Barbieri CE, Hu JC, Trapl E, Shoag JE. Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men. NEJM Evid 2022 Jun;1. (6). Epub 2022 May 15. [Abstract]

Cao P, Jeon J, Meza R. Evaluation of benefits and harms of adaptive screening schedules for lung cancer: A microsimulation study. J Med Screen 2022 Dec;29(4):260-267. Epub 2022 Aug 22. [Abstract]

Cenin D, Li P, Wang J, de Jonge L, Yan B, Tao S, Lansdorp-Vogelaar I. Optimising colorectal cancer screening in Shanghai, China: a modelling study. BMJ Open 2022 May 16;12(5):e048156. [Abstract]

Chandler Y, Schechter C, Jayasekera J, Isaacs C, Kurian AW, Cadham C, Mandelblatt J. Simulation modeling of breast cancer endocrine therapy duration by patient and tumor characteristics. Cancer Med 2022 Jan;11(2):297-307. Epub 2021 Dec 16. [Abstract]

Hammer MM, Byrne SC, Kong CY. Factors Influencing the False Positive Rate in CT Lung Cancer Screening. Acad Radiol 2022 Feb;29 Suppl 2(Suppl 2):S18-S22. Epub 2020 Sep 3. [Abstract]

Heijnsdijk EAM, de Koning HJ. Improved Harm/Benefit Ratio and Cost-effectiveness of Prostate Cancer Screening Using New Technologies. Eur Urol 2022 Jul;82(1):20-21. Epub 2022 Feb 4. [Abstract]

Heijnsdijk EAM, Gulati R, Lange JM, Tsodikov A, Roberts R, Etzioni R. Evaluation of Prostate Cancer Screening Strategies in a Low-Resource, High-risk Population in the Bahamas. JAMA Health Forum 2022 May 20;3(5):e221116. doi: 10.1001/jamahealthforum.2022.1116. eCollection 2022 May. [Abstract]

Lowry KP, Geuzinge HA, Stout NK, Alagoz O, Hampton J, Kerlikowske K, de Koning HJ, Miglioretti DL, van Ravesteyn NT, Schechter C, Sprague BL, Tosteson ANA, Trentham-Dietz A, Weaver D, Yaffe MJ, Yeh JM, Couch FJ, Hu C, Kraft P, Polley EC, Mandelblatt JS, Kurian AW, Robson ME, Breast Working Group of the Cancer Intervention and Surveillance Modeling Network (CISNET) in collaboration with the Breast Cancer Surveillance Consortium (BCSC) and the Cancer Risk Estimates Related to Susceptibility (CARRIERS) Consortium. Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis. JAMA Oncol 2022 Apr 1;8(4):587-596. [Abstract]

Meza R, Cao P, Jeon J, Taylor KL, Mandelblatt JS, Feuer EJ, Lowy DR. Impact of Joint Lung Cancer Screening and Cessation Interventions Under the New Recommendations of the U.S. Preventive Services Task Force. J Thorac Oncol 2022 Jan;17(1):160-166. Epub 2021 Oct 12. [Abstract]

Popp J, Weinberg DS, Enns E, Nyman JA, Beck JR, Kuntz KM. Reevaluating the Evidence for Intensive Postoperative Extracolonic Surveillance for Nonmetastatic Colorectal Cancer. Value Health 2022 Jan;25(1):36-46. Epub 2021 Oct 13. [Abstract]

Rao DW, Bayer CJ, Liu G, Chikandiwa A, Sharma M, Hathaway CL, Tan N, Mugo N, Barnabas RV. Modelling cervical cancer elimination using single-visit screening and treatment strategies in the context of high HIV prevalence: estimates for KwaZulu-Natal, South Africa. J Int AIDS Soc 2022 Oct;25(10):e26021. [Abstract]

Rubenstein JH, Evans RR, Burns JA, Arasim ME, Zhu J, Waljee AK, Harnessing Opportunities to Screen for Esophageal Adenocarcinoma Group. Patients With Adenocarcinoma of the Esophagus or Esophagogastric Junction Frequently Have Potential Screening Opportunities. Gastroenterology 2022 Apr;162(4):1349-1351.e5. Epub 2021 Dec 20. [Abstract]

Rutter CM, Inadomi JM, Maerzluft CE. The impact of cumulative colorectal cancer screening delays: A simulation study. J Med Screen 2022 Jun;29(2):92-98. Epub 2021 Dec 13. [Abstract]

Rutter CM, Nascimento de Lima P, Lee JK, Ozik J. Too Good to Be True? Evaluation of Colonoscopy Sensitivity Assumptions Used in Policy Models. Cancer Epidemiol Biomarkers Prev 2022 Apr 1;31(4):775-782. [Abstract]

Taylor KL, Williams RM, Li T, Luta G, Smith L, Davis KM, Stanton CA, Niaura R, Abrams D, Lobo T, Mandelblatt J, Jayasekera J, Meza R, Jeon J, Cao P, Anderson ED, Georgetown Lung Screening Tobacco and Health Trial. A Randomized Trial of Telephone-Based Smoking Cessation Treatment in the Lung Cancer Screening Setting. J Natl Cancer Inst 2022 Oct 6;114(10):1410-1419. [Abstract]

van Duuren LA, Ozik J, Spliet R, Collier NT, Lansdorp-Vogelaar I, Meester RGS. An Evolutionary Algorithm to Personalize Stool-Based Colorectal Cancer Screening. Front Physiol 2022 Jan 26;12:718276. doi: 10.3389/fphys.2021.718276. eCollection 2021. [Abstract]

2021

Bastani M, Toumazis I, Hedou' J, Leung A, Plevritis SK. Evaluation of Alternative Diagnostic Follow-up Intervals for Lung Reporting and Data System Criteria on the Effectiveness of Lung Cancer Screening. J Am Coll Radiol 2021 Dec;18(12):1614-1623. Epub 2021 Aug 19. [Abstract]

Chang JT, Meza R, Levy DT, Arenberg D, Jeon J. Prediction of COPD risk accounting for time-varying smoking exposures. PLoS One 2021 Mar 10;16(3):e0248535. doi: 10.1371/journal.pone.0248535. eCollection 2021. [Abstract]

Chapman CH, Schechter CB, Cadham CJ, Trentham-Dietz A, Gangnon RE, Jagsi R, Mandelblatt JS. Identifying Equitable Screening Mammography Strategies for Black Women in the United States Using Simulation Modeling. Ann Intern Med 2021 Dec;174(12):1637-1646. Epub 2021 Oct 19. [Abstract]

Getaneh AM, Heijnsdijk EAM, de Koning HJ. The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study. Sci Rep 2021 Jan 19;11(1):1801. [Abstract]

Gulati R, Carlsson SV, Etzioni R. When to Discuss Prostate Cancer Screening With Average-Risk Men. Am J Prev Med 2021 Aug;61(2):294-298. Epub 2021 May 6. [Abstract]

Lange J, Remmers S, Gulati R, Bill-Axelson A, Johansson JE, Kwiatkowski M, Auvinen A, Hugosson J, Hu JC, Roobol MJ, Carlsson SV, Etzioni R. Impact of cancer screening on metastasis: A prostate cancer case study. J Med Screen 2021 Dec;28(4):480-487. Epub 2021 Feb 9. [Abstract]

Levy DT, Cummings KM, Heckman BW, Li Y, Yuan Z, Smith TT, Meza R. The Public Health Gains Had Cigarette Companies Chosen to Sell Very Low Nicotine Cigarettes. Nicotine Tob Res 2021 Feb 16;23(3):438-446. [Abstract]

Mungovan SF, Carlsson SV, Gass GC, Graham PL, Sandhu JS, Akin O, Scardino PT, Eastham JA, Patel MI. Preoperative exercise interventions to optimize continence outcomes following radical prostatectomy. Nat Rev Urol 2021 May;18(5):259-281. Epub 2021 Apr 8. [Abstract]

Nyberg M, Sjoberg DD, Carlsson SV, Wilderäng U, Carlsson S, Stranne J, Wiklund P, Steineck G, Haglind E, Hugosson J, Bjartell A. Surgeon heterogeneity significantly affects functional and oncological outcomes after radical prostatectomy in the Swedish LAPPRO trial. BJU Int 2021 Mar;127(3):361-368. Epub 2020 Sep 29. [Abstract]

Reddy CA, Tavakkoli A, Chen VL, Korsnes S, Bedi AO, Carrott PW, Chang AC, Lagisetty KH, Kwon RS, Elmunzer BJ, Orringer MB, Piraka C, Prabhu A, Reddy RM, Wamsteker E, Rubenstein JH. Long-Term Quality of Life Following Endoscopic Therapy Compared to Esophagectomy for Neoplastic Barrett's Esophagus. Dig Dis Sci 2021 May;66(5):1580-1587. Epub 2020 Jun 9. [Abstract]

Shill DK, Roobol MJ, Ehdaie B, Vickers AJ, Carlsson SV. Active surveillance for prostate cancer. Transl Androl Urol 2021 Jun;10(6):2809-2819. [Abstract]

Sánchez-Romero LM, Cadham CJ, Hirschtick JL, Mattingly DT, Cho B, Fleischer NL, Brouwer A, Mistry R, Land SR, Jeon J, Meza R, Levy DT. A comparison of tobacco product prevalence by different frequency of use thresholds across three US surveys. BMC Public Health 2021 Jun 24;21(1):1203. [Abstract]

Taksler GB, Peterse EFP, Willems I, Ten Haaf K, Jansen EEL, de Kok IMCM, van Ravesteyn NT, de Koning HJ, Lansdorp-Vogelaar I. Modeling Strategies to Optimize Cancer Screening in USPSTF Guideline-Noncompliant Women. JAMA Oncol 2021 Jun 1;7(6):885-894. [Abstract]

Tam J, Warner KE, Zivin K, Taylor GMJ, Meza R. The Potential Impact of Widespread Cessation Treatment for Smokers With Depression. Am J Prev Med 2021 Nov;61(5):674-682. Epub 2021 Jul 7. [Abstract]

Trentham-Dietz A, Alagoz O, Chapman C, Huang X, Jayasekera J, van Ravesteyn NT, Lee SJ, Schechter CB, Yeh JM, Plevritis SK, Mandelblatt JS, Breast Working Group of the Cancer Intervention and Surveillance Modeling Network (CISNET). Reflecting on 20 years of breast cancer modeling in CISNET: Recommendations for future cancer systems modeling efforts. PLoS Comput Biol 2021 Jun 17;17(6):e1009020. doi: 10.1371/journal.pcbi.1009020. eCollection 2021 Jun. [Abstract]

van den Broek JJ, Schechter CB, van Ravesteyn NT, Janssens ACJW, Wolfson MC, Trentham-Dietz A, Simard J, Easton DF, Mandelblatt JS, Kraft P, de Koning HJ. Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History. J Natl Cancer Inst 2021 Apr 6;113(4):434-442. [Abstract]

2020

Blom EF, Ten Haaf K, Arenberg DA, de Koning HJ. Uptake of minimally invasive surgery and stereotactic body radiation therapy for early stage non-small cell lung cancer in the USA: an ecological study of secular trends using the National Cancer Database. BMJ Open Respir Res 2020 May;7. (1). [Abstract]

Blom EF, Ten Haaf K, de Koning HJ. Trends in lung cancer risk and screening eligibility affect overdiagnosis estimates. Lung Cancer 2020 Jan;139:200-206. Epub 2019 Nov 28. [Abstract]

Cao P, Jeon J, Levy DT, Jayasekera JC, Cadham CJ, Mandelblatt JS, Taylor KL, Meza R. Potential Impact of Cessation Interventions at the Point of Lung Cancer Screening on Lung Cancer and Overall Mortality in the United States. J Thorac Oncol 2020 Jul;15(7):1160-1169. Epub 2020 Mar 8. [Abstract]

Curtius K, Rubenstein JH, Chak A, Inadomi JM. Computational modelling suggests that Barrett's oesophagus may be the precursor of all oesophageal adenocarcinomas. Gut 2020 Nov 24;70(8):1435-40. Epub 2020 Nov 24. [Abstract]

Gulati R, Morgan TM, A'mar T, Psutka SP, Tosoian JJ, Etzioni R. Overdiagnosis and Lives Saved by Reflex Testing Men With Intermediate Prostate-Specific Antigen Levels. J Natl Cancer Inst 2020 Apr 1;112(4):384-390. [Abstract]

Heijnsdijk EAM, Gulati R, Tsodikov A, Lange JM, Mariotto AB, Vickers AJ, Carlsson SV, Etzioni R. Lifetime Benefits and Harms of Prostate-Specific Antigen-Based Risk-Stratified Screening for Prostate Cancer. J Natl Cancer Inst 2020 Oct 1;112(10):1013-1020. [Abstract]

Kovac E, Carlsson SV, Lilja H, Hugosson J, Kattan MW, Holmberg E, Stephenson AJ. Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. JAMA Netw Open 2020 Jan 3;3(1):e1919284. [Abstract]

Kunst N, Alarid-Escudero F, Aas E, Coupé VMH, Schrag D, Kuntz KM. Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States. Cancer Epidemiol Biomarkers Prev 2020 Dec;29(12):2710-2718. Epub 2020 Sep 30. [Abstract]

Kurlander JE, Rubenstein JH. Editorial: moving towards the appropriate use of proton pump inhibitors. Aliment Pharmacol Ther 2020 Jan;51(1):175-176. [Abstract]

Lange JM, Laviana AA, Penson DF, Lin DW, Bill-Axelson A, Carlsson SV, Newcomb LF, Trock BJ, Carter HB, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Etzioni RB. Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts. Cancer 2020 Feb 1;126(3):583-592. Epub 2019 Oct 22. [Abstract]

Nyberg M, Akre O, Bock D, Carlsson SV, Carlsson S, Hugosson J, Lantz A, Steineck G, Stranne J, Tyritzis S, Wiklund P, Haglind E, Bjartell A. Risk of Recurrent Disease 6 Years After Open or Robotic-assisted Radical Prostatectomy in the Prospective Controlled Trial LAPPRO. Eur Urol Open Sci 2020 Aug 19;20:54-61. doi: 10.1016/j.euros.2020.06.005. eCollection 2020 Jul. [Abstract]

Panattoni L, Phelps CE, Lieu TA, Alexeeff S, O'Neill S, Mandelblatt JS, Ramsey SD. Feasibility of Measuring Preferences for Chemotherapy Among Early-Stage Breast Cancer Survivors Using a Direct Rank Ordering Multicriteria Decision Analysis Versus a Time Trade-Off. Patient 2020 Oct;13(5):557-566. [Abstract]

Shoag JE, Nyame YA, Gulati R, Etzioni R, Hu JC. Reconsidering the Trade-offs of Prostate Cancer Screening. N Engl J Med 2020 Jun 18;382(25):2465-2468. [Abstract]

Simms KT, Yuill S, Killen J, Smith MA, Kulasingam S, de Kok IMCM, van Ballegooijen M, Burger EA, Regan C, Kim JJ, Canfell K. Historical and projected hysterectomy rates in the USA: Implications for future observed cervical cancer rates and evaluating prevention interventions. Gynecol Oncol 2020 Sep;158(3):710-718. Epub 2020 Jul 26. [Abstract]

Yu M, Hazelton WD, Luebeck GE, Grady WM. Epigenetic Aging: More Than Just a Clock When It Comes to Cancer. Cancer Res 2020 Feb 1;80(3):367-374. Epub 2019 Nov 6. [Abstract]

2019

Cadham CJ, Jayasekera JC, Advani SM, Fallon SJ, Stephens JL, Braithwaite D, Jeon J, Cao P, Levy DT, Meza R, Taylor KL, Mandelblatt JS, CISNET-SCALE Collaboration. Smoking cessation interventions for potential use in the lung cancer screening setting: A systematic review and meta-analysis. Lung Cancer 2019 Sep;135:205-216. Epub 2019 Jul 6. [Abstract]

Hammer MM, Palazzo LL, Eckel AL, Barbosa EM Jr, Kong CY. A Decision Analysis of Follow-up and Treatment Algorithms for Nonsolid Pulmonary Nodules. Radiology 2019 Feb;290(2):506-513. Epub 2018 Nov 20. [Abstract]

Hammer MM, Palazzo LL, Kong CY, Hunsaker AR. Cancer Risk in Subsolid Nodules in the National Lung Screening Trial. Radiology 2019 Nov;293(2):441-448. Epub 2019 Sep 17. [Abstract]

Jayasekera J, Sparano JA, Gray R, Isaacs C, Kurian A, O'Neill S, Schechter CB, Mandelblatt J. Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer. JNCI Cancer Spectr 2019 Aug 10;3(4):pkz062. doi: 10.1093/jncics/pkz062. eCollection 2019 Dec. [Abstract]

Kohestani K, Wallström J, Dehlfors N, Sponga OM, Månsson M, Josefsson A, Carlsson S, Hellström M, Hugosson J. Performance and inter-observer variability of prostate MRI (PI-RADS version 2) outside high-volume centres. Scand J Urol 2019 Oct;53(5):304-311. Epub 2019 Oct 29. [Abstract]

Lin EC, Holub J, Lieberman D, Hur C. Low Prevalence of Suspected Barrett's Esophagus in Patients With Gastroesophageal Reflux Disease Without Alarm Symptoms. Clin Gastroenterol Hepatol 2019 Apr;17(5):857-863. Epub 2018 Sep 7. [Abstract]

Luebeck GE, Hazelton WD, Curtius K, Maden SK, Yu M, Carter KT, Burke W, Lampe PD, Li CI, Ulrich CM, Newcomb PA, Westerhoff M, Kaz AM, Luo Y, Inadomi JM, Grady WM. Implications of Epigenetic Drift in Colorectal Neoplasia. Cancer Res 2019 Feb 1;79(3):495-504. Epub 2018 Oct 5. [Abstract]

Panattoni L, Lieu TA, Jayasekera J, O'Neill S, Mandelblatt JS, Etzioni R, Phelps CE, Ramsey SD. The impact of gene expression profile testing on confidence in chemotherapy decisions and prognostic expectations. Breast Cancer Res Treat 2019 Jan;173(2):417-427. Epub 2018 Oct 10. [Abstract]

Ryser MD, Weaver DL, Zhao F, Worni M, Grimm LJ, Gulati R, Etzioni R, Hyslop T, Lee SJ, Hwang ES. Cancer Outcomes in DCIS Patients Without Locoregional Treatment. J Natl Cancer Inst 2019 Sep 1;111(9):952-960. [Abstract]

Titus AR, Kalousova L, Meza R, Levy DT, Thrasher JF, Elliott MR, Lantz PM, Fleischer NL. Smoke-Free Policies and Smoking Cessation in the United States, 2003-2015. Int J Environ Res Public Health 2019 Sep 2;16. (17). [Abstract]

2018

Brouwer AF, Eisenberg MC, Meza R. Case Studies of Gastric, Lung, and Oral Cancer Connect Etiologic Agent Prevalence to Cancer Incidence. Cancer Res 2018 Jun 15;78(12):3386-3396. [Abstract]

Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Collaborators. Breast Cancer Simulation Modeling. Med Decis Making 2018 Apr;38(1 Suppl):3S-150S.

Caverly TJ, Cao P, Hayward RA, Meza R. Identifying Patients for Whom Lung Cancer Screening Is Preference-Sensitive: A Microsimulation Study. Ann Intern Med 2018 Jul 3;169(1):1-9. Epub 2018 May 29. [Abstract]

Criss SD, Sheehan DF, Palazzo L, Kong CY. Population impact of lung cancer screening in the United States: Projections from a microsimulation model. PLoS Med 2018 Feb 7;15(2):e1002506. doi: 10.1371/journal.pmed.1002506. eCollection 2018 Feb. [Abstract]

Ehdaie B, Carlsson S. Reply to 'Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting'. Prostate Cancer Prostatic Dis 2018 Sep;21(3):446-447. Epub 2018 Jun 1. [Abstract]

Gangnon RE, Stout NK, Alagoz O, Hampton JM, Sprague BL, Trentham-Dietz A. Contribution of Breast Cancer to Overall Mortality for US Women. Med Decis Making 2018 Apr;38(1_suppl):24S-31S. [Abstract]

Han SS, Ten Haaf K, Hazelton WD, Jeon J, Meza R, Kong CY, Feuer EJ, de Koning HJ, Plevritis SK. Re: Think before you leap. Int J Cancer 2018 Apr 1;142(7):1507-1509. Epub 2017 Dec 28. [Abstract]

Inoue LYT, Lin DW, Newcomb LF, Leonardson AS, Ankerst D, Gulati R, Carter HB, Trock BJ, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Mamedov A, Penson DF, Etzioni R. Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. Ann Intern Med 2018 Jan 2;168(1):1-9. Epub 2017 Nov 28. [Abstract]

Jayasekera J, Li Y, Schechter CB, Jagsi R, Song J, White J, Luta G, Chapman JW, Feuer EJ, Zellars RC, Stout N, Julian TB, Whelan T, Huang X, Shelley Hwang E, Hopkins JO, Sparano JA, Anderson SJ, Fyles AW, Gray R, Sauerbrei W, Mandelblatt J, Berry DA, CISNET-BOLD Collaborative Group. Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer. J Natl Cancer Inst 2018 Dec 1;110(12):1360-1369. [Abstract]

Jayasekera J, Schechter CB, Sparano JA, Jagsi R, White J, Chapman JW, Whelan T, Anderson SJ, Fyles AW, Sauerbrei W, Zellars RC, Li Y, Song J, Huang X, Julian TB, Luta G, Berry DA, Feuer EJ, Mandelblatt J, CISNET-BOLD Collaborative Group. Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer. J Natl Cancer Inst 2018 Dec 1;110(12):1370-1379. [Abstract]

Kaur D, Ulloa-Pérez E, Gulati R, Etzioni R. Racial disparities in prostate cancer survival in a screened population: Reality versus artifact. Cancer 2018 Apr 15;124(8):1752-1759. Epub 2018 Jan 25. [Abstract]

Kim JJ, Burger EA, Regan C, Sy S. Screening for Cervical Cancer in Primary Care: A Decision Analysis for the US Preventive Services Task Force. JAMA 2018 Aug 21;320(7):706-714. [Abstract]

Levy DT, Borland R, Lindblom EN, Goniewicz ML, Meza R, Holford TR, Yuan Z, Luo Y, O'Connor RJ, Niaura R, Abrams DB. Potential deaths averted in USA by replacing cigarettes with e-cigarettes. Tob Control 2018 Jan;27(1):18-25. Epub 2017 Oct 2. [Abstract]

Levy DT, Tam J, Kuo C, Fong GT, Chaloupka F. The Impact of Implementing Tobacco Control Policies: The 2017 Tobacco Control Policy Scorecard. J Public Health Manag Pract 2018 Sep-Oct;24(5):448-457. [Abstract]

Levy DT, Yuan Z, Li Y. The US SimSmoke tobacco control policy model of smokeless tobacco and cigarette use. BMC Public Health 2018 Jun 5;18(1):696. [Abstract]

Liu G, Sharma M, Tan N, Barnabas RV. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS 2018 Mar 27;32(6):795-808. [Abstract]

Meester RGS, Peterse EFP, Knudsen AB, de Weerdt AC, Chen JC, Lietz AP, Dwyer A, Ahnen DJ, Siegel RL, Smith RA, Zauber AG, Lansdorp-Vogelaar I. Optimizing colorectal cancer screening by race and sex: Microsimulation analysis II to inform the American Cancer Society colorectal cancer screening guideline. Cancer 2018 Jul 15;124(14):2974-2985. Epub 2018 May 30. [Abstract]

Munoz DF, Plevritis SK. Estimating Breast Cancer Survival by Molecular Subtype in the Absence of Screening and Adjuvant Treatment. Med Decis Making 2018 Apr;38(1_suppl):32S-43S. [Abstract]

Munoz DF, Xu C, Plevritis SK. A Molecular Subtype-Specific Stochastic Simulation Model of US Breast Cancer Incidence, Survival, and Mortality Trends from 1975 to 2010. Med Decis Making 2018 Apr;38(1_suppl):89S-98S. [Abstract]

Peterse EFP, Meester RGS, Siegel RL, Chen JC, Dwyer A, Ahnen DJ, Smith RA, Zauber AG, Lansdorp-Vogelaar I. The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: Microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline. Cancer 2018 Jul 15;124(14):2964-2973. Epub 2018 May 30. [Abstract]

Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, Lee SJ, van den Broek JJ, Huang X, Schechter CB, Sprague BL, Song J, de Koning HJ, Trentham-Dietz A, van Ravesteyn NT, Gangnon R, Chandler Y, Li Y, Xu C, Ergun MA, Huang H, Berry DA, Mandelblatt JS. Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012. JAMA 2018 Jan 9;319(2):154-164. [Abstract]

Richter JE, Rubenstein JH. Presentation and Epidemiology of Gastroesophageal Reflux Disease. Gastroenterology 2018 Jan;154(2):267-276. Epub 2017 Aug 3. [Abstract]

Rubenstein JH, Waljee AK, Dwamena B, Bergman J, Vieth M, Wani S. Yield of Higher-Grade Neoplasia in Barrett's Esophagus With Low-Grade Dysplasia Is Double in the First Year Following Diagnosis. Clin Gastroenterol Hepatol 2018 Sep;16(9):1529-1530. Epub 2018 Jan 4. [Abstract]

Tam J, Levy DT, Jeon J, Clarke J, Gilkeson S, Hall T, Feuer EJ, Holford TR, Meza R. Projecting the effects of tobacco control policies in the USA through microsimulation: a study protocol. BMJ Open 2018 Mar 23;8(3):e019169. [Abstract]

Tan N, Sharma M, Winer R, Galloway D, Rees H, Barnabas RV. Model-estimated effectiveness of single dose 9-valent HPV vaccination for HIV-positive and HIV-negative females in South Africa. Vaccine 2018 Aug 6;36(32 Pt A):4830-4836. Epub 2018 Jun 8. [Abstract]

Tramontano AC, Nipp R, Kong CY, Yerramilli D, Gainor JF, Hur C. Hospice use and end-of-life care among older patients with esophageal cancer. Health Sci Rep 2018 Jul 19;1(9):e76. doi: 10.1002/hsr2.76. eCollection 2018 Sep. [Abstract]

van den Broek JJ, van Ravesteyn NT, Heijnsdijk EA, de Koning HJ. Simulating the Impact of Risk-Based Screening and Treatment on Breast Cancer Outcomes with MISCAN-Fadia. Med Decis Making 2018 Apr;38(1_suppl):54S-65S. [Abstract]

2017

Burnside ES, Lee SJ, Bennette C, Near AM, Alagoz O, Huang H, van den Broek JJ, Kim JY, Ergun MA, van Ravesteyn NT, Stout NK, de Koning HJ, Mandelblatt JS. Using Collaborative Simulation Modeling to Develop a Web-Based Tool to Support Policy-Level Decision Making About Breast Cancer Screening Initiation Age. MDM Policy Pract 2017 Jul;2. (2). Epub 2017 Jul 8. [Abstract]

Cherng ST, Tam J, Christine PJ, Meza R. The Authors Respond. Epidemiology 2017 Jan;28(1):e1-e2. [Abstract]

de Carvalho TM, Heijnsdijk EA, de Koning HJ. Estimating the risks and benefits of active surveillance protocols for prostate cancer: a microsimulation study. BJU Int 2017 Apr;119(4):560-566. Epub 2016 Jun 26. [Abstract]

de Carvalho TM, Heijnsdijk EAM, de Koning HJ. When should active surveillance for prostate cancer stop if no progression is detected? Prostate 2017 Jun;77(9):962-969. Epub 2017 Apr 17. [Abstract]

Fleischer NL, Thrasher JF, Reynales-Shigematsu LM, Cummings KM, Meza R, Zhang Y, Levy DT. Mexico SimSmoke: how changes in tobacco control policies would impact smoking prevalence and smoking attributable deaths in Mexico. Glob Public Health 2017 Jul;12(7):830-845. Epub 2016 Feb 2. [Abstract]

Gulati R, Albertsen PC. Insights from the PLCO trial about prostate cancer screening. Cancer 2017 Feb 15;123(4):546-548. Epub 2016 Dec 1. [Abstract]

Han SS, Erdogan SA, Toumazis I, Leung A, Plevritis SK. Evaluating the impact of varied compliance to lung cancer screening recommendations using a microsimulation model. Cancer Causes Control 2017 Sep;28(9):947-958. Epub 2017 Jul 12. [Abstract]

Han SS, Rivera GA, Tammemägi MC, Plevritis SK, Gomez SL, Cheng I, Wakelee HA. Risk Stratification for Second Primary Lung Cancer. J Clin Oncol 2017 Sep 1;35(25):2893-2899. Epub 2017 Jun 23. [Abstract]

Lange JM, Trock BJ, Gulati R, Etzioni R. A Framework for Treatment Decision Making at Prostate Cancer Recurrence. Med Decis Making 2017 Nov;37(8):905-913. Epub 2017 May 31. [Abstract]

Levy DT, Borland R, Villanti AC, Niaura R, Yuan Z, Zhang Y, Meza R, Holford TR, Fong GT, Cummings KM, Abrams DB. The Application of a Decision-Theoretic Model to Estimate the Public Health Impact of Vaporized Nicotine Product Initiation in the United States. Nicotine Tob Res 2017 Feb;19(2):149-159. Epub 2016 Jul 14. [Abstract]

Levy DT, Mays D, Yuan Z, Hammond D, Thrasher JF. Public health benefits from pictorial health warnings on US cigarette packs: a SimSmoke simulation. Tob Control 2017 Nov;26(6):649-655. Epub 2016 Nov 2. [Abstract]

Lieu TA, Ray GT, Prausnitz SR, Habel LA, Alexeeff S, Li Y, Ramsey SD, Phelps CE, Chawla N, C O'Neill S, Mandelblatt JS. Oncologist and organizational factors associated with variation in breast cancer multigene testing. Breast Cancer Res Treat 2017 May;163(1):167-176. Epub 2017 Feb 21. [Abstract]

Meester RGS, Doubeni CA, Zauber AG, van Ballegooijen M, Corley DA, Lansdorp-Vogelaar I. Impact of adenoma detection on the benefit of faecal testing vs. colonoscopy for colorectal cancer. Int J Cancer 2017 Dec 1;141(11):2359-2367. Epub 2017 Aug 31. [Abstract]

Reddy KP, Kong CY, Hyle EP, Baggett TP, Huang M, Parker RA, Paltiel AD, Losina E, Weinstein MC, Freedberg KA, Walensky RP. Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States. JAMA Intern Med 2017 Nov 1;177(11):1613-1621. [Abstract]

Shen J, Wang L, Taylor JMG. Estimation of the optimal regime in treatment of prostate cancer recurrence from observational data using flexible weighting models. Biometrics 2017 Jun;73(2):635-645. Epub 2016 Nov 28. [Abstract]

2016

Cherng ST, Tam J, Christine PJ, Meza R. Modeling the Effects of E-cigarettes on Smoking Behavior: Implications for Future Adult Smoking Prevalence. Epidemiology 2016 Nov;27(6):819-26. [Abstract]

Levy D, Mohlman MK, Zhang Y. Estimating the Potential Impact of Tobacco Control Policies on Adverse Maternal and Child Health Outcomes in the United States Using the SimSmoke Tobacco Control Policy Simulation Model. Nicotine Tob Res 2016 May;18(5):1240-9. Epub 2015 Sep 18. [Abstract]

Levy DT, Meza R, Zhang Y, Holford TR. Gauging the Effect of U.S. Tobacco Control Policies From 1965 Through 2014 Using SimSmoke. Am J Prev Med 2016 Apr;50(4):535-542. Epub 2015 Dec 7. [Abstract]

Miglioretti DL, Lange J, van den Broek JJ, Lee CI, van Ravesteyn NT, Ritley D, Kerlikowske K, Fenton JJ, Melnikow J, de Koning HJ, Hubbard RA. Radiation-Induced Breast Cancer Incidence and Mortality From Digital Mammography Screening: A Modeling Study. Ann Intern Med 2016 Feb 16;164(4):205-14. Epub 2016 Jan 12. [Abstract]

Ray GT, Mandelblatt J, Habel LA, Ramsey S, Kushi LH, Li Y, Lieu TA. Breast cancer multigene testing trends and impact on chemotherapy use. Am J Manag Care 2016 May 1;22(5):e153-60. [Abstract]

Roth JA, Gulati R, Gore JL, Cooperberg MR, Etzioni R. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies. JAMA Oncol 2016 Jul 1;2(7):890-8. [Abstract]

Tavakkoli A, Prabhu A, Rubenstein JH. Predicting Lymph Node Metastases in Superficial Esophageal Adenocarcinoma. Gastroenterology 2016 Jun;150(7):1680-1682. Epub 2016 Apr 29. [Abstract]

Tramontano AC, Sheehan DF, McMahon PM, Dowling EC, Holford TR, Ryczak K, Lesko SM, Levy DT, Kong CY. Evaluating the impacts of screening and smoking cessation programmes on lung cancer in a high-burden region of the USA: a simulation modelling study. BMJ Open 2016 Feb 29;6(2):e010227. [Abstract]

2015

Birnbaum JK, Feng Z, Gulati R, Fan J, Lotan Y, Wei JT, Etzioni R. Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer. Cancer Epidemiol Biomarkers Prev 2015 Apr;24(4):677-82. Epub 2015 Jan 22. [Abstract]

de Carvalho TM, Heijnsdijk EA, de Koning HJ. Screening for prostate cancer in the US? Reduce the harms and keep the benefit. Int J Cancer 2015 Apr 1;136(7):1600-7. Epub 2014 Sep 1. [Abstract]

Haug U, Knudsen AB, Lansdorp-Vogelaar I, Kuntz KM. Development of new non-invasive tests for colorectal cancer screening: the relevance of information on adenoma detection. Int J Cancer 2015 Jun 15;136(12):2864-74. Epub 2014 Dec 3. [Abstract]

Henrikson NB, Webber EM, Goddard KA, Scrol A, Piper M, Williams MS, Zallen DT, Calonge N, Ganiats TG, Janssens AC, Zauber A, Lansdorp-Vogelaar I, van Ballegooijen M, Whitlock EP. Family history and the natural history of colorectal cancer: systematic review. Genet Med 2015 Sep;17(9):702-12. Epub 2015 Jan 15. [Abstract]

Inadomi JM. Cost considerations in implementing a screening and surveillance strategy for Barrett's oesophagus. Best Pract Res Clin Gastroenterol 2015 Feb;29(1):51-63. Epub 2014 Dec 18. [Abstract]

Levy DT, Lindblom EN, Fleischer NL, Thrasher J, Mohlman MK, Zhang Y, Monshouwer K, Nagelhout GE. Public Health Effects of Restricting Retail Tobacco Product Displays and Ads. Tob Regul Sci 2015 Apr;1(1):61-75. [Abstract]

Scheel JR, Lee JM, Sprague BL, Lee CI, Lehman CD. Screening ultrasound as an adjunct to mammography in women with mammographically dense breasts. Am J Obstet Gynecol 2015 Jan;212(1):9-17. Epub 2014 Jun 21. [Abstract]

Sprague BL, Gangnon RE, Hampton JM, Egan KM, Titus LJ, Kerlikowske K, Remington PL, Newcomb PA, Trentham-Dietz A. Variation in Breast Cancer-Risk Factor Associations by Method of Detection: Results From a Series of Case-Control Studies. Am J Epidemiol 2015 Jun 15;181(12):956-69. Epub 2015 May 5. [Abstract]

Sprague BL, Stout NK, Schechter C, van Ravesteyn NT, Cevik M, Alagoz O, Lee CI, van den Broek JJ, Miglioretti DL, Mandelblatt JS, de Koning HJ, Kerlikowske K, Lehman CD, Tosteson AN. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. Ann Intern Med 2015 Feb 3;162(3):157-66. [Abstract]

2014

Etzioni R, Xia J, Hubbard R, Weiss NS, Gulati R. A reality check for overdiagnosis estimates associated with breast cancer screening. J Natl Cancer Inst 2014 Oct 31;106. (12). Print 2014 Dec. [Abstract]

Levy D, Rodríguez-Buño RL, Hu TW, Moran AE. The potential effects of tobacco control in China: projections from the China SimSmoke simulation model. BMJ 2014 Feb 18;348:g1134. [Abstract]

Schwartz MD, Valdimarsdottir HB, Peshkin BN, Mandelblatt J, Nusbaum R, Huang AT, Chang Y, Graves K, Isaacs C, Wood M, McKinnon W, Garber J, McCormick S, Kinney AY, Luta G, Kelleher S, Leventhal KG, Vegella P, Tong A, King L. Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. J Clin Oncol 2014 Mar 1;32(7):618-26. Epub 2014 Jan 21. [Abstract]

Stout NK, Lee SJ, Schechter CB, Kerlikowske K, Alagoz O, Berry D, Buist DS, Cevik M, Chisholm G, de Koning HJ, Huang H, Hubbard RA, Miglioretti DL, Munsell MF, Trentham-Dietz A, van Ravesteyn NT, Tosteson AN, Mandelblatt JS. Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography. J Natl Cancer Inst 2014 May 28;106(6):dju092. Print 2014 Jun. [Abstract]

Xia J, Trock BJ, Gulati R, Mallinger L, Cooperberg MR, Carroll PR, Carter HB, Etzioni R. Overdetection of recurrence after radical prostatectomy: estimates based on patient and tumor characteristics. Clin Cancer Res 2014 Oct 15;20(20):5302-10. [Abstract]

Yasuda K, Choi SE, Nishioka NS, Rattner DW, Puricelli WP, Tramontano AC, Kitano S, Hur C. Incidence and predictors of adenocarcinoma following endoscopic ablation of Barrett's esophagus. Dig Dis Sci 2014 Jul;59(7):1560-6. Epub 2014 Jan 7. [Abstract]

2013

Berry DA. Breast cancer screening: controversy of impact. Breast 2013 Aug;22 Suppl 2(0 2):S73-6. [Abstract]

Braithwaite D, Zhu W, Hubbard RA, O'Meara ES, Miglioretti DL, Geller B, Dittus K, Moore D, Wernli KJ, Mandelblatt J, Kerlikowske K, Breast Cancer Surveillance Consortium. Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age, or comorbidity score affect tumor characteristics or false positive rates? J Natl Cancer Inst 2013 Mar 6;105(5):334-41. Epub 2013 Feb 5. [Abstract]

Etzioni R, Durand-Zaleski I, Lansdorp-Vogelaar I. Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality. J Natl Cancer Inst Monogr 2013;2013(46):117-23. [Abstract]

Hubbard RA, Johnson E, Hsia R, Rutter CM. The cumulative risk of false-positive fecal occult blood test after 10 years of colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 2013 Sep;22(9):1612-9. Epub 2013 Jul 18. [Abstract]

Mandelblatt J, van Ravesteyn N, Schechter C, Chang Y, Huang AT, Near AM, de Koning H, Jemal A. Which strategies reduce breast cancer mortality most? Collaborative modeling of optimal screening, treatment, and obesity prevention. Cancer 2013 Jul 15;119(14):2541-8. Epub 2013 Apr 26. [Abstract]

Mandelblatt JS, Tosteson AN, van Ravesteyn NT. Costs, evidence, and value in the Medicare program: the challenges of technology innovation in breast cancer prevention and control. JAMA Intern Med 2013 Feb 11;173(3):227-8. [Abstract]

Munshi V, McMahon P. Importance of Smoking Cessation in a Lung Cancer Screening Program. Curr Surg Rep 2013 Dec;1. (4). [Abstract]

Tramontano AC, Cipriano LE, Kong CY, Shepard JA, Lanuti M, Gazelle GS, McMahon PM. Microsimulation model predicts survival benefit of radiofrequency ablation and stereotactic body radiotherapy versus radiotherapy for treating inoperable stage I non-small cell lung cancer. AJR Am J Roentgenol 2013 May;200(5):1020-7. [Abstract]

Wernli KJ, Rutter CM, Dachman AH, Zafar HM. Suspected extracolonic neoplasms detected on CT colonography: literature review and possible outcomes. Acad Radiol 2013 Jun;20(6):667-74. Epub 2013 Mar 1. [Abstract]

Wever EM, Heijnsdijk EA, Draisma G, Bangma CH, Roobol MJ, Schröder FH, de Koning HJ. Treatment of local-regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors. Br J Cancer 2013 May 28;108(10):1971-7. Epub 2013 May 14. [Abstract]

2012

Haug U, Knudsen AB, Kuntz KM. How should individuals with a false-positive fecal occult blood test for colorectal cancer be managed? A decision analysis. Int J Cancer 2012 Nov 1;131(9):2094-102. Epub 2012 Mar 29. [Abstract]

Hazelton WD, Jeon J, Meza R, Moolgavkar SH. Chapter 8: The FHCRC lung cancer model. Risk Anal 2012 Jul;32 Suppl 1(Suppl 1):S99-S116. [Abstract]

Hur C, Choi SE, Rubenstein JH, Kong CY, Nishioka NS, Provenzale DT, Inadomi JM. The cost effectiveness of radiofrequency ablation for Barrett's esophagus. Gastroenterology 2012 Sep;143(3):567-575. Epub 2012 May 21. [Abstract]

Omer ZB, Ananthakrishnan AN, Nattinger KJ, Cole EB, Lin JJ, Kong CY, Hur C. Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol 2012 Jul;10(7):722-7. Epub 2012 Mar 15. [Abstract]

Xia J, Trock BJ, Cooperberg MR, Gulati R, Zeliadt SB, Gore JL, Lin DW, Carroll PR, Carter HB, Etzioni R. Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res 2012 Oct 1;18(19):5471-8. Epub 2012 Sep 24. [Abstract]

Zauber AG, Winawer SJ, O'Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, Shi W, Bond JH, Schapiro M, Panish JF, Stewart ET, Waye JD. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012 Feb 23;366(8):687-96. [Abstract]

Zeliadt SB, Buist DS, Reid RJ, Grossman DC, Ma J, Etzioni R. Biopsy follow-up of prostate-specific antigen tests. Am J Prev Med 2012 Jan;42(1):37-43. [Abstract]

Zheng W, Rutter CM. Estimated mean sojourn time associated with hemoccult SENSA for detection of proximal and distal colorectal cancer. Cancer Epidemiol Biomarkers Prev 2012 Oct;21(10):1722-30. Epub 2012 Aug 21. [Abstract]

2011

Berrington de González A, Kim KP, Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Smith-Bindman R, Yee J, Kuntz KM, van Ballegooijen M, Zauber AG, Berg CD. Radiation-related cancer risks from CT colonography screening: a risk-benefit analysis. AJR Am J Roentgenol 2011 Apr;196(4):816-23. [Abstract]

Haug U, Knudsen AB, Brenner H, Kuntz KM. Is fecal occult blood testing more sensitive for left- versus right-sided colorectal neoplasia? A systematic literature review. Expert Rev Mol Diagn 2011 Jul;11(6):605-16. [Abstract]

Haug U, Kuntz KM, Knudsen AB, Hundt S, Brenner H. Sensitivity of immunochemical faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia. Br J Cancer 2011 May 24;104(11):1779-85. Epub 2011 May 10. [Abstract]

Hazelton WD, Luebeck EG. Biomarker-based early cancer detection: is it achievable? Sci Transl Med 2011 Nov 16;3(109):109fs9. [Abstract]

2010

Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Savarino JE, van Ballegooijen M, Kuntz KM, Zauber AG. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. J Natl Cancer Inst 2010 Aug 18;102(16):1238-52. Epub 2010 Jul 27. [Abstract]

Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, Wilschut JA, Zauber AG, van Ballegooijen M. Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. Ann Intern Med 2010 Sep 21;153(6):368-77. [Abstract]

Zauber AG. Cost-effectiveness of colonoscopy. Gastrointest Endosc Clin N Am 2010 Oct;20(4):751-70. [Abstract]

2009

Lansdorp-Vogelaar I, van Ballegooijen M, Boer R, Zauber A, Habbema JD. A novel hypothesis on the sensitivity of the fecal occult blood test: Results of a joint analysis of 3 randomized controlled trials. Cancer 2009 Jun 1;115(11):2410-9. [Abstract]

Rue M, Vilaprinyo E, Lee S, Martinez-Alonso M, Carles MD, Marcos-Gragera R, Pla R, Espinas JA. Effectiveness of early detection on breast cancer mortality reduction in Catalonia (Spain). BMC Cancer 2009 Sep 15;9:326. [Abstract]

2008

McMahon PM, Kong CY, Weinstein MC, Tramontano AC, Cipriano LE, Johnson BE, Weeks JC, Gazelle GS. Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period. Cancer 2008 Dec 15;113(12):3440-9. [Abstract]

2007

Zauber AG, Lansdorp-Vogelaar I, Wilschut J, Knudsen AB, van Ballegooijen M, Kuntz KM. Cost-Effectiveness of DNA Stool Testing to Screen for Colorectal Cancer: Report to AHRQ and CMS from the Cancer Intervention and Surveillance Modeling Network (CISNET) for MISCAN and SimCRC Models. 2007 Dec 20. Available at https://www.cms.gov/medicare-coverage-database/details/technology-assessments-details.aspx?TAId=52. [Link]

2006

Levy DT, Mumford EA, Cummings KM, Gilpin EA, Giovino GA, Hyland A, Sweanor D, Warner KE, Compton C. The potential impact of a low-nitrosamine smokeless tobacco product on cigarette smoking in the United States: estimates of a panel of experts. Addict Behav 2006 Jul;31(7):1190-200. Epub 2005 Oct 26. [Abstract]

2004

Levy DT, Mumford EA, Cummings KM, Gilpin EA, Giovino G, Hyland A, Sweanor D, Warner KE. The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts. Cancer Epidemiol Biomarkers Prev 2004 Dec;13(12):2035-42. [Abstract]

2003

van Ballegooijen M, Habbema JDF, Boer R, Zauber AG, Brown ML. Report to the Agency for Healthcare Research and Quality: a comparison of the cost-effectiveness of fecal occult blood tests with different test characteristics in the context of annual screening in the Medicare population. 2003 Aug. Available at https://www.cms.gov/medicare-coverage-database/details/technology-assessments-details.aspx?TAId=20. [Link]

Health Disparities

2023

Cao P, Jeon J, Tam J, Fleischer NL, Levy DT, Holford TR, Meza R. Smoking Disparities by Level of Educational Attainment and Birth Cohort in the U.S. Am J Prev Med 2023 Apr;64(4 Suppl 1):S22-S31. Epub 2023 Jan 16. [Abstract]

Holford TR, McKay L, Jeon J, Tam J, Cao P, Fleischer NL, Levy DT, Meza R. Smoking Histories by State in the U.S. Am J Prev Med 2023 Apr;64(4 Suppl 1):S42-S52. Epub 2023 Jan 16. [Abstract]

Levy DT, Tam J, Jeon J, Holford TR, Fleischer NL, Meza R. Summary and Concluding Remarks: Patterns of Birth Cohort‒Specific Smoking Histories. Am J Prev Med 2023 Apr;64(4 Suppl 1):S72-S79. [Abstract]

Tam J, Levy DT, Feuer EJ, Jeon J, Holford TR, Meza R. Using the Past to Understand the Future of U.S. and Global Smoking Disparities: A Birth Cohort Perspective. Am J Prev Med 2023 Apr;64(4 Suppl 1):S1-S10. Epub 2023 Feb 11. [Abstract]

2022

Brouwer AF, Engle JM, Jeon J, Meza R. Sociodemographic Survival Disparities for Lung Cancer in the United States, 2000-2016. J Natl Cancer Inst 2022 Nov 14;114(11):1492-1500. [Abstract]

Jansen JP, Trikalinos TA, Phillips KA. Assessments of the Value of New Interventions Should Include Health Equity Impact. Pharmacoeconomics 2022 May;40(5):489-495. Epub 2022 Mar 3. [Abstract]

2021

Luebeck GE, Vaughan TL, Curtius K, Hazelton WD. Modeling historic incidence trends implies early field cancerization in esophageal squamous cell carcinoma. PLoS Comput Biol 2021 May 3;17(5):e1008961. doi: 10.1371/journal.pcbi.1008961. eCollection 2021 May. [Abstract]

Rutter CM, Knudsen AB, Lin JS, Bouskill KE. Black and White Differences in Colorectal Cancer Screening and Screening Outcomes: A Narrative Review. Cancer Epidemiol Biomarkers Prev 2021 Jan;30(1):3-12. Epub 2020 Nov 3. [Abstract]

Trentham-Dietz A, Chapman CH, Bird J, Gangnon RE. Recent Changes in the Patterns of Breast Cancer as a Proportion of All Deaths According to Race and Ethnicity. Epidemiology 2021 Nov 1;32(6):904-913. [Abstract]

2020

Blom EF, Ten Haaf K, Arenberg DA, de Koning HJ. Disparities in Receiving Guideline-Concordant Treatment for Lung Cancer in the United States. Ann Am Thorac Soc 2020 Feb;17(2):186-194. [Abstract]

Han SS, Chow E, Ten Haaf K, Toumazis I, Cao P, Bastani M, Tammemagi M, Jeon J, Feuer EJ, Meza R, Plevritis SK. Disparities of National Lung Cancer Screening Guidelines in the US Population. J Natl Cancer Inst 2020 Nov 1;112(11):1136-1142. [Abstract]

Tam J, Taylor GMJ, Zivin K, Warner KE, Meza R. Modeling smoking-attributable mortality among adults with major depression in the United States. Prev Med 2020 Nov;140:106241. Epub 2020 Aug 27. [Abstract]

2019

Palazzo LL, Sheehan DF, Tramontano AC, Kong CY. Disparities and Trends in Genetic Testing and Erlotinib Treatment among Metastatic Non-Small Cell Lung Cancer Patients. Cancer Epidemiol Biomarkers Prev 2019 May;28(5):926-934. Epub 2019 Feb 20. [Abstract]

2018

Tramontano AC, Nipp R, Mercaldo ND, Kong CY, Schrag D, Hur C. Survival Disparities by Race and Ethnicity in Early Esophageal Cancer. Dig Dis Sci 2018 Nov;63(11):2880-2888. Epub 2018 Aug 14. [Abstract]

2017

2016

Holford TR, Levy DT, Meza R. Comparison of Smoking History Patterns Among African American and White Cohorts in the United States Born 1890 to 1990. Nicotine Tob Res 2016 Apr;18 Suppl 1(Suppl 1):S16-29. [Abstract]

Prabhu A, Obi K, Lieberman D, Rubenstein JH. The Race-Specific Incidence of Esophageal Squamous Cell Carcinoma in Individuals With Exposure to Tobacco and Alcohol. Am J Gastroenterol 2016 Dec;111(12):1718-1725. Epub 2016 Aug 30. [Abstract]

2015

Lansdorp-Vogelaar I, Goede SL, Ma J, Xiau-Cheng W, Pawlish K, van Ballegooijen M, Jemal A. State disparities in colorectal cancer rates: Contributions of risk factors, screening, and survival differences. Cancer 2015 Oct 15;121(20):3676-83. Epub 2015 Jul 6. [Abstract]

2013

Batina NG, Trentham-Dietz A, Gangnon RE, Sprague BL, Rosenberg MA, Stout NK, Fryback DG, Alagoz O. Variation in tumor natural history contributes to racial disparities in breast cancer stage at diagnosis. Breast Cancer Res Treat 2013 Apr;138(2):519-28. Epub 2013 Feb 16. [Abstract]

2012

Chang Y, Schechter CB, van Ravesteyn NT, Near AM, Heijnsdijk EA, Adams-Campbell L, Levy D, de Koning HJ, Mandelblatt JS. Collaborative modeling of the impact of obesity on race-specific breast cancer incidence and mortality. Breast Cancer Res Treat 2012 Dec;136(3):823-35. Epub 2012 Oct 27. [Abstract]

Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, van Ballegooijen M, Zauber AG, Jemal A. Contribution of screening and survival differences to racial disparities in colorectal cancer rates. Cancer Epidemiol Biomarkers Prev 2012 May;21(5):728-36. Epub 2012 Apr 18. [Abstract]

2011

Edwards-Bennett SM. Racial disparities in breast cancer mortality--letter. Cancer Epidemiol Biomarkers Prev 2011 May;20(5):1046; author reply 1047. [Abstract]

Naishadham D, Lansdorp-Vogelaar I, Siegel R, Cokkinides V, Jemal A. State disparities in colorectal cancer mortality patterns in the United States. Cancer Epidemiol Biomarkers Prev 2011 Jul;20(7):1296-302. [Abstract]

van Ravesteyn NT, Schechter CB, Near AM, Heijnsdijk EA, Stoto MA, Draisma G, de Koning HJ, Mandelblatt JS. Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United States. Cancer Epidemiol Biomarkers Prev 2011 Jan;20(1):112-22. Epub 2010 Nov 30. [Abstract]

2006

Levy DT, Mumford EA, Compton C. Tobacco control policies and smoking in a population of low education women, 1992-2002. J Epidemiol Community Health 2006 Sep;60 Suppl 2(Suppl 2):20-6. [Abstract]

2005

Rosenberg J, Chia YL, Plevritis S. The effect of age, race, tumor size, tumor grade, and disease stage on invasive ductal breast cancer survival in the U.S. SEER database. Breast Cancer Res Treat 2005 Jan;89(1):47-54. [Abstract]

2004

Mandelblatt JS, Schechter CB, Yabroff KR, Lawrence W, Dignam J, Muennig P, Chavez Y, Cullen J, Fahs M. Benefits and costs of interventions to improve breast cancer outcomes in African American women. J Clin Oncol 2004 Jul 1;22(13):2554-66. Epub 2004 Jun 1. [Abstract]

Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology 2004 Dec;64(6):1171-6. [Abstract]

2003

Zeliadt SB, Penson DF, Albertsen PC, Concato J, Etzioni RD. Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. Cancer 2003 Aug 1;98(3):496-503. [Abstract]

2002

Etzioni R, Berry KM, Legler JM, Shaw P. Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998. Urology 2002 Feb;59(2):251-5. [Abstract]

Individualized Prevention, Screening and Treatment Strategies

2023

2022

Cao P, Jeon J, Meza R. Evaluation of benefits and harms of adaptive screening schedules for lung cancer: A microsimulation study. J Med Screen 2022 Dec;29(4):260-267. Epub 2022 Aug 22. [Abstract]

Yeh JM, Lowry KP, Schechter CB, Diller LR, O'Brien G, Alagoz O, Armstrong GT, Hampton JM, Hudson MM, Leisenring W, Liu Q, Mandelblatt JS, Miglioretti DL, Moskowitz CS, Nathan PC, Neglia JP, Oeffinger KC, Trentham-Dietz A, Stout NK. Breast Cancer Screening Among Childhood Cancer Survivors Treated Without Chest Radiation: Clinical Benefits and Cost-Effectiveness. J Natl Cancer Inst 2022 Feb 7;114(2):235-244. [Abstract]

2021

Carlsson SV, Vickers AJ, Gonsky JP, Hay JL, Hu JC. Problems with Numbers in Decision Aids for Prostate-specific Antigen Screening: A Critical Review. Eur Urol 2021 Mar;79(3):330-333. Epub 2020 Dec 9. [Abstract]

Jayasekera J, Sparano JA, O'Neill S, Chandler Y, Isaacs C, Kurian AW, Kushi L, Schechter CB, Mandelblatt J. Development and Validation of a Simulation Model-Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions. J Clin Oncol 2021 Sep 10;39(26):2893-2902. Epub 2021 Jul 12. [Abstract]

Naslazi E, Hontelez JAC, Naber SK, van Ballegooijen M, de Kok IMCM. The Differential Risk of Cervical Cancer in HPV-Vaccinated and -Unvaccinated Women: A Mathematical Modeling Study. Cancer Epidemiol Biomarkers Prev 2021 May;30(5):912-919. Epub 2021 Apr 9. [Abstract]

Shill DK, Roobol MJ, Ehdaie B, Vickers AJ, Carlsson SV. Active surveillance for prostate cancer. Transl Androl Urol 2021 Jun;10(6):2809-2819. [Abstract]

Tang M, Wang L, Gorin MA, Taylor JMG. Step-adjusted tree-based reinforcement learning for evaluating nested dynamic treatment regimes using test-and-treat observational data. Stat Med 2021 Nov 30;40(27):6164-6177. Epub 2021 Sep 7. [Abstract]

Toumazis I, Alagoz O, Leung A, Plevritis SK. A risk-based framework for assessing real-time lung cancer screening eligibility that incorporates life expectancy and past screening findings. Cancer 2021 Dec 1;127(23):4432-4446. Epub 2021 Aug 12. [Abstract]

2020

Carlsson SV, Eastham JA, Crawford ED, Harris RG. "PSA Surveillance in the Septuagenarian": A Proposed New Terminology for Clinical Follow-up to Assess Risk of Prostate Cancer in Men Aged 70 Years and Older. Eur Urol 2020 Aug;78(2):136-137. Epub 2020 Apr 6. [Abstract]

Carlsson SV, Vickers AJ. Screening for Prostate Cancer. Med Clin North Am 2020 Nov;104(6):1051-1062. Epub 2020 Sep 16. [Abstract]

Chandler Y, Jayasekera JC, Schechter CB, Isaacs C, Cadham CJ, Mandelblatt JS. Simulation of Chemotherapy Effects in Older Breast Cancer Patients With High Recurrence Scores. J Natl Cancer Inst 2020 Jun 1;112(6):574-581. [Abstract]

Rubenstein JH, Tavakkoli A, Koeppe E, Ulintz P, Inadomi JM, Morgenstern H, Appelman H, Scheiman JM, Schoenfeld P, Metko V, Stoffel EM. Family History of Colorectal or Esophageal Cancer in Barrett's Esophagus and Potentially Explanatory Genetic Variants. Clin Transl Gastroenterol 2020 Apr;11(4):e00151. [Abstract]

Ten Haaf K, Bastani M, Cao P, Jeon J, Toumazis I, Han SS, Plevritis SK, Blom EF, Kong CY, Tammemägi MC, Feuer EJ, Meza R, de Koning HJ. A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies. J Natl Cancer Inst 2020 May 1;112(5):466-479. [Abstract]

Toumazis I, Bastani M, Han SS, Plevritis SK. Risk-Based lung cancer screening: A systematic review. Lung Cancer 2020 Sep;147:154-186. Epub 2020 Jul 12. [Abstract]

2019

Alagoz O, Hajjar A, Chootipongchaivat S, van Ravesteyn NT, Yeh JM, Ergun MA, de Koning HJ, Chicoine B, Martin B. Benefits and Harms of Mammography Screening for Women With Down Syndrome: a Collaborative Modeling Study. J Gen Intern Med 2019 Nov;34(11):2374-2381. Epub 2019 Aug 5. [Abstract]

Beesley LJ, Morgan TM, Spratt DE, Singhal U, Feng FY, Furgal AC, Jackson WC, Daignault S, Taylor JMG. Individual and Population Comparisons of Surgery and Radiotherapy Outcomes in Prostate Cancer Using Bayesian Multistate Models. JAMA Netw Open 2019 Feb 1;2(2):e187765. [Abstract]

Carlsson SV, Lilja H. Perspective on Prostate Cancer Screening. Clin Chem 2019 Jan;65(1):24-27. Epub 2018 Nov 20. [Abstract]

Caverly TJ, Meza R. Using Risk Models to Make Lung Cancer Screening Decisions: Evidence-Based and Getting Better. Ann Intern Med 2019 Nov 5;171(9):669-670. Epub 2019 Oct 22. [Abstract]

Dierks T, Heijnsdijk EAM, Korfage IJ, Roobol MJ, de Koning HJ. Informed decision-making based on a leaflet in the context of prostate cancer screening. Patient Educ Couns 2019 Aug;102(8):1483-1489. Epub 2019 Apr 13. [Abstract]

Gulati R, Psutka SP, Etzioni R. Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication. J Urol 2019 Nov;202(5):936-943. Epub 2019 Oct 9. [Abstract]

Petrick JL, Li N, Anderson LA, Bernstein L, Corley DA, El Serag HB, Hardikar S, Liao LM, Liu G, Murray LJ, Rubenstein JH, Schneider JL, Shaheen NJ, Thrift AP, van den Brandt PA, Vaughan TL, Whiteman DC, Wu AH, Zhao WK, Gammon MD, Cook MB. Diabetes in relation to Barrett's esophagus and adenocarcinomas of the esophagus: A pooled study from the International Barrett's and Esophageal Adenocarcinoma Consortium. Cancer 2019 Dec 1;125(23):4210-4223. Epub 2019 Sep 6. [Abstract]

Tammemägi MC, Ten Haaf K, Toumazis I, Kong CY, Han SS, Jeon J, Commins J, Riley T, Meza R. Development and Validation of a Multivariable Lung Cancer Risk Prediction Model That Includes Low-Dose Computed Tomography Screening Results: A Secondary Analysis of Data From the National Lung Screening Trial. JAMA Netw Open 2019 Mar 1;2(3):e190204. [Abstract]

Vaughan TL, Onstad L, Dai JY. Interactive decision support for esophageal adenocarcinoma screening and surveillance. BMC Gastroenterol 2019 Jun 27;19(1):109. [Abstract]

2018

Kinsella N, Stattin P, Cahill D, Brown C, Bill-Axelson A, Bratt O, Carlsson S, Van Hemelrijck M. Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review. Eur Urol 2018 Sep;74(3):261-280. Epub 2018 Mar 26. [Abstract]

Kohestani K, Chilov M, Carlsson SV. Prostate cancer screening-when to start and how to screen? Transl Androl Urol 2018 Feb;7(1):34-45. [Abstract]

2017

de Carvalho TM, Heijnsdijk EAM, de Koning HJ. When should active surveillance for prostate cancer stop if no progression is detected? Prostate 2017 Jun;77(9):962-969. Epub 2017 Apr 17. [Abstract]

Lange JM, Trock BJ, Gulati R, Etzioni R. A Framework for Treatment Decision Making at Prostate Cancer Recurrence. Med Decis Making 2017 Nov;37(8):905-913. Epub 2017 May 31. [Abstract]

Lockwood R, Ozanne E, Hur C, Yachimski P. Patient decision-making and clinical outcomes following endoscopic therapy or esophagectomy for Barrett's neoplasia. Endosc Int Open 2017 Nov;5(11):E1128-E1135. Epub 2017 Nov 8. [Abstract]

Ten Haaf K, Jeon J, Tammemägi MC, Han SS, Kong CY, Plevritis SK, Feuer EJ, de Koning HJ, Steyerberg EW, Meza R. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study. PLoS Med 2017 Apr 4;14(4):e1002277. doi: 10.1371/journal.pmed.1002277. eCollection 2017 Apr. [Abstract]

2016

de Carvalho TM, Heijnsdijk EA, de Koning HJ. Estimating the individual benefit of immediate treatment or active surveillance for prostate cancer after screen-detection in older (65+) men. Int J Cancer 2016 May 15;138(10):2522-8. Epub 2016 Feb 1. [Abstract]

2015

Lowry KP, Gazelle GS, Gilmore ME, Johanson C, Munshi V, Choi SE, Tramontano AC, Kong CY, McMahon PM. Personalizing annual lung cancer screening for patients with chronic obstructive pulmonary disease: A decision analysis. Cancer 2015 May 15;121(10):1556-62. Epub 2015 Feb 3. [Abstract]

Yachimski P, Wani S, Givens T, Howard E, Higginbotham T, Price A, Berman K, Hosford L, Katcher PM, Ozanne E, Perzan K, Hur C. Preference of endoscopic ablation over medical prevention of esophageal adenocarcinoma by patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2015 Jan;13(1):84-90. Epub 2014 Mar 26. [Abstract]

2014

Etzioni R, Gulati R. RE: A model too far. J Natl Cancer Inst 2014 Apr;106(4):dju058. Epub 2014 Mar 21. [Abstract]

Gulati R, Inoue LY, Gore JL, Katcher J, Etzioni R. Individualized estimates of overdiagnosis in screen-detected prostate cancer. J Natl Cancer Inst 2014 Feb;106(2):djt367. Epub 2014 Jan 7. [Abstract]

Lansdorp-Vogelaar I, Gulati R, Mariotto AB, Schechter CB, de Carvalho TM, Knudsen AB, van Ravesteyn NT, Heijnsdijk EA, Pabiniak C, van Ballegooijen M, Rutter CM, Kuntz KM, Feuer EJ, Etzioni R, de Koning HJ, Zauber AG, Mandelblatt JS. Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Ann Intern Med 2014 Jul 15;161(2):104-12. [Abstract]

Saini SD, van Hees F, Vijan S. Smarter screening for cancer: possibilities and challenges of personalization. JAMA 2014 Dec 3;312(21):2211-2. [Abstract]

Salinas CA, Tsodikov A, Ishak-Howard M, Cooney KA. Prostate cancer in young men: an important clinical entity. Nat Rev Urol 2014 Jun;11(6):317-23. Epub 2014 May 13. [Abstract]

Trentham-Dietz A, Sprague BL, Hampton JM, Miglioretti DL, Nelson HD, Titus LJ, Egan KM, Remington PL, Newcomb PA. Modification of breast cancer risk according to age and menopausal status: a combined analysis of five population-based case-control studies. Breast Cancer Res Treat 2014 May;145(1):165-75. Epub 2014 Mar 20. [Abstract]

Vickers AJ, Sjoberg DD, Ulmert D, Vertosick E, Roobol MJ, Thompson I, Heijnsdijk EA, De Koning H, Atoria-Swartz C, Scardino PT, Lilja H. Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. BMC Med 2014 Feb 11;12:26. [Abstract]

2013

Braithwaite D, Mandelblatt JS, Kerlikowske K. To screen or not to screen older women for breast cancer: a conundrum. Future Oncol 2013 Jun;9(6):763-6. [Abstract]

Cho H, Klabunde CN, Yabroff KR, Wang Z, Meekins A, Lansdorp-Vogelaar I, Mariotto AB. Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies. Ann Intern Med 2013 Nov 19;159(10):667-76. [Abstract]

Schackmann EA, Munoz DF, Mills MA, Plevritis SK, Kurian AW. Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers. Fam Cancer 2013 Mar;12(1):65-73. [Abstract]

2012

Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke L, Mills MA, Plevritis SK. Online tool to guide decisions for BRCA1/2 mutation carriers. J Clin Oncol 2012 Feb 10;30(5):497-506. Epub 2012 Jan 9. [Abstract] Decision Tool for Women with BRCA Mutations

Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O'Meara ES, Buist DS, Kerlikowske K, van Ravesteyn NT, Trentham-Dietz A, Mandelblatt JS, Miglioretti DL. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med 2012 May 1;156(9):635-48. [Abstract]

Sigal BM, Munoz DF, Kurian AW, Plevritis SK. A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2012 Jul;21(7):1066-77. Epub 2012 May 3. [Abstract]

van Ravesteyn NT, Miglioretti DL, Stout NK, Lee SJ, Schechter CB, Buist DS, Huang H, Heijnsdijk EA, Trentham-Dietz A, Alagoz O, Near AM, Kerlikowske K, Nelson HD, Mandelblatt JS, de Koning HJ. Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk. Ann Intern Med 2012 May 1;156(9):609-17. [Abstract]

2011

Mandelblatt JS, Stout N, Trentham-Dietz A. To screen or not to screen women in their 40s for breast cancer: is personalized risk-based screening the answer? Ann Intern Med 2011 Jul 5;155(1):58-60. [Abstract]

2010

Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 2010 Jan 10;28(2):222-31. Epub 2009 Dec 7. [Abstract] Decision Tool for Women with BRCA Mutations

2009

Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Boer R, Wilschut J, Winawer SJ, Habbema JD. Individualizing colonoscopy screening by sex and race. Gastrointest Endosc 2009 Jul;70(1):96-108, 108.e1-24. Epub 2009 May 24. [Abstract]

Mandelblatt JS, Silliman R. Hanging in the balance: making decisions about the benefits and harms of breast cancer screening among the oldest old without a safety net of scientific evidence. J Clin Oncol 2009 Feb 1;27(4):487-90. Epub 2008 Dec 15. [Abstract]

2006

Liang W, Kasman D, Wang JH, Yuan EH, Mandelblatt JS. Communication between older women and physicians: preliminary implications for satisfaction and intention to have mammography. Patient Educ Couns 2006 Dec;64(1-3):387-92. Epub 2006 Jul 26. [Abstract]

Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, Garber AM. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 2006 May 24;295(20):2374-84. [Abstract] Decision Tool for Women with BRCA Mutations

2005

Mandelblatt JS, Schechter CB, Yabroff KR, Lawrence W, Dignam J, Extermann M, Fox S, Orosz G, Silliman R, Cullen J, Balducci L, Breast Cancer in Older Women Research Consortium. Toward optimal screening strategies for older women. Costs, benefits, and harms of breast cancer screening by age, biology, and health status. J Gen Intern Med 2005 Jun;20(6):487-96. [Abstract]

2003

Gorlova OY, Amos C, Henschke C, Lei L, Spitz M, Wei Q, Wu X, Kimmel M. Genetic susceptibility for lung cancer: interactions with gender and smoking history and impact on early detection policies. Hum Hered 2003;56(1-3):139-45. [Abstract]

International Cancer Control Planning

2023

2022

Cenin D, Li P, Wang J, de Jonge L, Yan B, Tao S, Lansdorp-Vogelaar I. Optimising colorectal cancer screening in Shanghai, China: a modelling study. BMJ Open 2022 May 16;12(5):e048156. [Abstract]

2021

Castanon A, Rebolj M, Burger EA, de Kok IMCM, Smith MA, Hanley SJB, Carozzi FM, Peacock S, O'Mahony JF. Cervical screening during the COVID-19 pandemic: optimising recovery strategies. Lancet Public Health 2021 Jul;6(7):e522-e527. Epub 2021 Apr 30. [Abstract]

Shin MB, Liu G, Mugo N, Garcia PJ, Rao DW, Bayer CJ, Eckert LO, Pinder LF, Wasserheit JN, Barnabas RV. A Framework for Cervical Cancer Elimination in Low-and-Middle-Income Countries: A Scoping Review and Roadmap for Interventions and Research Priorities. Front Public Health 2021 Jul 1;9:670032. doi: 10.3389/fpubh.2021.670032. eCollection 2021. [Abstract]

Smith MA, Burger EA, Castanon A, de Kok IMCM, Hanley SJB, Rebolj M, Hall MT, Jansen EEL, Killen J, O'Farrell X, Kim JJ, Canfell K. Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an example: A modelled analysis. Prev Med 2021 Oct;151:106623. Epub 2021 May 23. [Abstract]

Sánchez-Romero LM, Zavala-Arciniega L, Reynales-Shigematsu LM, de Miera-Juárez BS, Yuan Z, Li Y, Lau YK, Fleischer NL, Meza R, Thrasher JF, Levy DT. The Mexico SimSmoke tobacco control policy model: Development of a simulation model of daily and nondaily cigarette smoking. PLoS One 2021 Jun 21;16(6):e0248215. doi: 10.1371/journal.pone.0248215. eCollection 2021. [Abstract]

2020

Van Ourti T, O'Donnell O, Koç H, Fracheboud J, de Koning HJ. Effect of screening mammography on breast cancer mortality: Quasi-experimental evidence from rollout of the Dutch population-based program with 17-year follow-up of a cohort. Int J Cancer 2020 Apr 15;146(8):2201-2208. Epub 2019 Aug 7. [Abstract]

Zavala-Arciniega L, Reynales-Shigematsu LM, Levy DT, Lau YK, Meza R, Gutiérrez-Torres DS, Arillo-Santillán E, Fleischer NL, Thrasher J. Smoking trends in Mexico, 2002-2016: before and after the ratification of the WHO's Framework Convention on Tobacco Control. Tob Control 2020 Nov;29(6):687-691. Epub 2020 Feb 4. [Abstract]

2019

Karlsson A, Jauhiainen A, Gulati R, Eklund M, Grönberg H, Etzioni R, Clements M. A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data. PLoS One 2019 Feb 14;14(2):e0211918. doi: 10.1371/journal.pone.0211918. eCollection 2019. [Abstract]

Rojas-Martínez R, Escamilla-Núñez C, Meza R, Vázquez-Salas RA, Zárate-Rojas E, Lazcano-Ponce E. Lung cancer mortality in Mexico, 1990-2016: age-period-cohort effect. Salud Publica Mex 2019 May-Jun;61(3):230-239. [Abstract]

Young GP, Rabeneck L, Winawer SJ. The Global Paradigm Shift in Screening for Colorectal Cancer. Gastroenterology 2019 Mar;156(4):843-851.e2. Epub 2019 Feb 16. [Abstract]

2018

Heijnsdijk EAM, Bangma CH, Borràs JM, de Carvalho TM, Castells X, Eklund M, Espinàs JA, Graefen M, Grönberg H, Lansdorp-Vogelaar I, Leeuwen PJV, Nelen V, Recker F, Roobol MJ, Vandenbulcke P, de Koning HJ. Summary statement on screening for prostate cancer in Europe. Int J Cancer 2018 Feb 15;142(4):741-746. Epub 2017 Oct 25. [Abstract]

Levy DT, Yuan Z, Luo Y, Mays D. Seven years of progress in tobacco control: an evaluation of the effect of nations meeting the highest level MPOWER measures between 2007 and 2014. Tob Control 2018 Jan;27(1):50-57. Epub 2016 Dec 12. [Abstract]

2017

2015

Goede SL, Rabeneck L, Lansdorp-Vogelaar I, Zauber AG, Paszat LF, Hoch JS, Yong JH, van Hees F, Tinmouth J, van Ballegooijen M. The impact of stratifying by family history in colorectal cancer screening programs. Int J Cancer 2015 Sep 1;137(5):1119-27. Epub 2015 Feb 20. [Abstract]

Rabeneck L, Horton S, Zauber AG, Earle C. Colorectal Cancer. In: Gelband H, Jha P, Sankaranarayanan R, Horton S, editors. Disease Control Priorities. Third Edition. Washington, DC: The World Bank; 2015. p. 101-120. [Link]

van Hees F, Zauber AG, van Veldhuizen H, Heijnen ML, Penning C, de Koning HJ, van Ballegooijen M, Lansdorp-Vogelaar I. The value of models in informing resource allocation in colorectal cancer screening: the case of The Netherlands. Gut 2015 Dec;64(12):1985-97. Epub 2015 Jun 10. [Abstract]

Yaffe MJ, Mittmann N, Lee P, Tosteson AN, Trentham-Dietz A, Alagoz O, Stout NK. Modelling mammography screening for breast cancer in the Canadian context: Modification and testing of a microsimulation model. Health Rep 2015 Dec;26(12):3-8. [Abstract]

2014

Cenin DR, St John DJ, Ledger MJ, Slevin T, Lansdorp-Vogelaar I. Optimising the expansion of the National Bowel Cancer Screening Program. Med J Aust 2014 Oct 20;201(8):456-61. [Abstract]

Near AM, Blackman K, Currie LM, Levy DT. Sweden SimSmoke: the effect of tobacco control policies on smoking and snus prevalence and attributable deaths. Eur J Public Health 2014 Jun;24(3):451-8. Epub 2013 Nov 27. [Abstract]

Pataky R, Gulati R, Etzioni R, Black P, Chi KN, Coldman AJ, Pickles T, Tyldesley S, Peacock S. Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. Int J Cancer 2014 Aug 15;135(4):939-47. Epub 2014 Feb 4. [Abstract]

2012

Etzioni R, Mucci L, Chen S, Johansson JE, Fall K, Adami HO. Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden. Clin Cancer Res 2012 Dec 15;18(24):6742-7. Epub 2012 Aug 27. [Abstract]

Weedon-Fekjær H, Bakken K, Vatten LJ, Tretli S. Understanding recent trends in incidence of invasive breast cancer in Norway: age-period-cohort analysis based on registry data on mammography screening and hormone treatment use. BMJ 2012 Jan 30;344:e299. [Abstract]

2011

van Ravesteyn NT, Heijnsdijk EA, Draisma G, de Koning HJ. Prediction of higher mortality reduction for the UK Breast Screening Frequency Trial: a model-based approach on screening intervals. Br J Cancer 2011 Sep 27;105(7):1082-8. Epub 2011 Aug 23. [Abstract]

2010

Kalager M, Zelen M, Langmark F, Adami HO. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med 2010 Sep 23;363(13):1203-10. [Abstract]

Model Descriptions

2021

2020

DeYoreo M, Lansdorp-Vogelaar I, Knudsen AB, Kuntz KM, Zauber AG, Rutter CM. Validation of Colorectal Cancer Models on Long-term Outcomes from a Randomized Controlled Trial. Med Decis Making 2020 Nov;40(8):1034-1040. Epub 2020 Oct 20. [Abstract]

2018

Alagoz O, Berry DA, de Koning HJ, Feuer EJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, Trentham-Dietz A, Mandelblatt JS, CISNET Breast Cancer Working Group members. Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models. Med Decis Making 2018 Apr;38(1_suppl):3S-8S. [Abstract]

Alagoz O, Ergun MA, Cevik M, Sprague BL, Fryback DG, Gangnon RE, Hampton JM, Stout NK, Trentham-Dietz A. The University of Wisconsin Breast Cancer Epidemiology Simulation Model: An Update. Med Decis Making 2018 Apr;38(1_suppl):99S-111S. [Abstract]

Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Collaborators. Breast Cancer Simulation Modeling. Med Decis Making 2018 Apr;38(1 Suppl):3S-150S.

Huang X, Li Y, Song J, Berry DA. A Bayesian Simulation Model for Breast Cancer Screening, Incidence, Treatment, and Mortality. Med Decis Making 2018 Apr;38(1_suppl):78S-88S. Epub 2017 Jun 19. [Abstract]

Lee SJ, Li X, Huang H, Zelen M. The Dana-Farber CISNET Model for Breast Cancer Screening Strategies: An Update. Med Decis Making 2018 Apr;38(1_suppl):44S-53S. [Abstract]

Mandelblatt JS, Near AM, Miglioretti DL, Munoz D, Sprague BL, Trentham-Dietz A, Gangnon R, Kurian AW, Weedon-Fekjaer H, Cronin KA, Plevritis SK. Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling. Med Decis Making 2018 Apr;38(1_suppl):9S-23S. [Abstract]

Schechter CB, Near AM, Jayasekera J, Chandler Y, Mandelblatt JS. Structure, Function, and Applications of the Georgetown-Einstein (GE) Breast Cancer Simulation Model. Med Decis Making 2018 Apr;38(1_suppl):66S-77S. [Abstract]

Tran Q, Kidwell KM, Tsodikov A. A joint model of cancer incidence, metastasis, and mortality. Lifetime Data Anal 2018 Jul;24(3):385-406. Epub 2017 Sep 4. [Abstract]

2014

Inoue LY, Trock BJ, Partin AW, Carter HB, Etzioni R. Modeling grade progression in an active surveillance study. Stat Med 2014 Mar 15;33(6):930-9. Epub 2013 Oct 9. [Abstract]

2012

Foy M, Deng L, Spitz M, Gorlova O, Kimmel M. Chapter 11: Rice-MD Anderson lung cancer model. Risk Anal 2012 Jul;32 Suppl 1:S142-50. [Abstract]

Hazelton WD, Goodman G, Rom WN, Tockman M, Thornquist M, Moolgavkar S, Weissfeld JL, Feng Z. Longitudinal multistage model for lung cancer incidence, mortality, and CT detected indolent and aggressive cancers. Math Biosci 2012 Nov;240(1):20-34. Epub 2012 Jun 15. [Abstract]

Hazelton WD, Jeon J, Meza R, Moolgavkar SH. Chapter 8: The FHCRC lung cancer model. Risk Anal 2012 Jul;32 Suppl 1(Suppl 1):S99-S116. [Abstract]

Holford TR, Ebisu K, McKay L, Oh C, Zheng T. Chapter 12: Yale lung cancer model. Risk Anal 2012 Jul;32 Suppl 1(0 1):S151-65. [Abstract]

Levy DT, Blackman K, Zaloshnja E. Chapter 10: A macro-model of smoking and lung cancer: examining aggregate trends in lung cancer rates using the CPS-I and CPS-II and two-stage clonal expansion models. Risk Anal 2012 Jul;32 Suppl 1(Suppl 1):S125-41. [Abstract]

Lin RS, Plevritis SK. Comparing the benefits of screening for breast cancer and lung cancer using a novel natural history model. Cancer Causes Control 2012 Jan;23(1):175-85. Epub 2011 Nov 25. [Abstract]

Mandelblatt J, Schechter C, Levy D, Zauber A, Chang Y, Etzioni R. Building better models: if we build them, will policy makers use them? Toward integrating modeling into health care decisions. Med Decis Making 2012 Sep-Oct;32(5):656-9. [Abstract]

McMahon PM, Kong CY, Johnson BE, Weinstein MC, Weeks JC, Tramontano AC, Cipriano LE, Bouzan C, Gazelle GS. Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening. Risk Anal 2012 Jul;32 Suppl 1(Suppl 1):S117-24. [Abstract]

Schultz FW, Boer R, de Koning HJ. Chapter 7: Description of MISCAN-lung, the Erasmus MC Lung Cancer microsimulation model for evaluating cancer control interventions. Risk Anal 2012 Jul;32 Suppl 1(Suppl 1):S85-98. [Abstract]

2011

Foy M, Spitz MR, Kimmel M, Gorlova OY. A smoking-based carcinogenesis model for lung cancer risk prediction. Int J Cancer 2011 Oct 15;129(8):1907-13. Epub 2011 Mar 29. [Abstract]

Rutter CM, Miglioretti DL, Savarino JE. Evaluating risk factor assumptions: a simulation-based approach. BMC Med Inform Decis Mak 2011 Sep 7;11:55. [Abstract]

2010

Bailey SL, Sigal BM, Plevritis SK. A simulation model investigating the impact of tumor volume doubling time and mammographic tumor detectability on screening outcomes in women aged 40-49 years. J Natl Cancer Inst 2010 Aug 18;102(16):1263-71. Epub 2010 Jul 27. [Abstract]

Rutter CM, Savarino JE. An evidence-based microsimulation model for colorectal cancer: validation and application. Cancer Epidemiol Biomarkers Prev 2010 Aug;19(8):1992-2002. Epub 2010 Jul 20. [Abstract]

2008

Mandelblatt JS, Potosky AL. On the road to improving the quality of breast cancer care: a distance still to travel. Med Care 2008 Aug;46(8):759-61. [Abstract]

Meza R, Hazelton WD, Colditz GA, Moolgavkar SH. Analysis of lung cancer incidence in the Nurses' Health and the Health Professionals' Follow-Up Studies using a multistage carcinogenesis model. Cancer Causes Control 2008 Apr;19(3):317-28. Epub 2007 Dec 6. [Abstract]

2007

Plevritis SK, Salzman P, Sigal BM, Glynn PW. A natural history model of stage progression applied to breast cancer. Stat Med 2007 Feb 10;26(3):581-95. [Abstract]

2006

Berry DA, Inoue L, Shen Y, Venier J, Cohen D, Bondy M, Theriault R, Munsell MF. Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr 2006;(36):30-6. [Abstract]

Draisma G, Postma R, Schröder FH, van der Kwast TH, de Koning HJ. Gleason score, age and screening: modeling dedifferentiation in prostate cancer. Int J Cancer 2006 Nov 15;119(10):2366-71. [Abstract]

Fryback DG, Stout NK, Rosenberg MA, Trentham-Dietz A, Kuruchittham V, Remington PL. The Wisconsin Breast Cancer Epidemiology Simulation Model. J Natl Cancer Inst Monogr 2006;(36):37-47. [Abstract]

Hanin LG, Miller A, Zorin AV, Yakovlev AY. The University of Rochester model of breast cancer detection and survival. J Natl Cancer Inst Monogr 2006;(36):66-78. [Abstract]

Lee S, Zelen M. A stochastic model for predicting the mortality of breast cancer. J Natl Cancer Inst Monogr 2006;(36):79-86. [Abstract]

Mandelblatt J, Schechter CB, Lawrence W, Yi B, Cullen J. The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000: principles and practice of the model methods. J Natl Cancer Inst Monogr 2006;(36):47-55. [Abstract]

Plevritis SK, Sigal BM, Salzman P, Rosenberg J, Glynn P. A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000. J Natl Cancer Inst Monogr 2006;(36):86-95. [Abstract]

Tan SY, van Oortmarssen GJ, de Koning HJ, Boer R, Habbema JD. The MISCAN-Fadia continuous tumor growth model for breast cancer. J Natl Cancer Inst Monogr 2006;(36):56-65. [Abstract]

Tsodikov A, Szabo A, Wegelin J. A population model of prostate cancer incidence. Stat Med 2006 Aug 30;25(16):2846-66. [Abstract]

Zorin AV, Edler L, Hanin LG, Yakovlev AY. Chapter 19. Estimating the Natural History of Breast Cancer from Bivariate Data on Age and Tumor Size at Diagnosis. In: Edler L, Kitsos CP, editors. Recent Advances in Quantitative Methods for Cancer and Human Health Risk Assessment. New York: John Wiley & Sons, Ltd; 2006 Mar 17. p. 317-27. (Wiley Series in Probability and Statistics) [Link]

2005

Hazelton WD, Clements MS, Moolgavkar SH. Multistage carcinogenesis and lung cancer mortality in three cohorts. Cancer Epidemiol Biomarkers Prev 2005 May;14(5):1171-81. [Abstract]

2004

Chia YL, Salzman P, Plevritis SK, Glynn PW. Simulation-based parameter estimation for complex models: a breast cancer natural history modelling illustration. Stat Methods Med Res 2004 Dec;13(6):507-24. [Abstract]

Modeling Methods

2023

Chesnut GT, Tin AL, Fleshner KA, Benfante NE, Vickers AJ, Eastham JA, Sjoberg DD, Carlsson SV. Estimating patient health in prostate cancer treatment counseling. Prostate Cancer Prostatic Dis 2023 Jun;26(2):271-275. Epub 2021 Nov 3. [Abstract]

Jansen JP, Incerti D, Trikalinos TA. Multi-state network meta-analysis of progression and survival data. Stat Med 2023 Aug 30;42(19):3371-3391. Epub 2023 Jun 10. [Abstract]

2022

Chao YC, Tran Q, Tsodikov A, Kidwell KM. Joint modeling and multiple comparisons with the best of data from a SMART with survival outcomes. Biostatistics 2022 Jan 13;23(1):294-313. [Abstract]

DeYoreo M, Rutter CM, Ozik J, Collier N. Sequentially calibrating a Bayesian microsimulation model to incorporate new information and assumptions. BMC Med Inform Decis Mak 2022 Jan 12;22(1):12. [Abstract]

Wu W, Taylor JMG, Brouwer AF, Luo L, Kang J, Jiang H, He K. Scalable proximal methods for cause-specific hazard modeling with time-varying coefficients. Lifetime Data Anal 2022 Apr;28(2):194-218. Epub 2022 Jan 29. [Abstract]

Xie C, Huang X, Li R, Pisters PWT. A flexible-hazards cure model with application to patients with soft tissue sarcoma. Stat Med 2022 Dec 20;41(29):5698-5714. Epub 2022 Sep 27. [Abstract]

2021

Jalal H, Trikalinos TA, Alarid-Escudero F. BayCANN: Streamlining Bayesian Calibration With Artificial Neural Network Metamodeling. Front Physiol 2021 May 25;12:662314. doi: 10.3389/fphys.2021.662314. eCollection 2021. [Abstract]

Rao DW, Wheatley MM, Goodreau SM, Enns EA. Partnership dynamics in mathematical models and implications for representation of sexually transmitted infections: a review. Ann Epidemiol 2021 Jul;59:72-80. Epub 2021 Apr 28. [Abstract]

Suresh K, Taylor JMG, Tsodikov A. A Gaussian copula approach for dynamic prediction of survival with a longitudinal biomarker. Biostatistics 2021 Jul 17;22(3):504-521. [Abstract]

Suresh K, Taylor JMG, Tsodikov A. A copula-based approach for dynamic prediction of survival with a binary time-dependent covariate. Stat Med 2021 Oct 15;40(23):4931-4946. Epub 2021 Jun 14. [Abstract]

2020

Heath A, Kunst N, Jackson C, Strong M, Alarid-Escudero F, Goldhaber-Fiebert JD, Baio G, Menzies NA, Jalal H. Calculating the Expected Value of Sample Information in Practice: Considerations from 3 Case Studies. Med Decis Making 2020 Apr;40(3):314-326. Epub 2020 Apr 16. [Abstract]

Krijkamp EM, Alarid-Escudero F, Enns EA, Pechlivanoglou P, Hunink MGM, Yang A, Jalal HJ. A Multidimensional Array Representation of State-Transition Model Dynamics. Med Decis Making 2020 Feb;40(2):242-248. Epub 2020 Jan 28. [Abstract]

Kunst N, Wilson ECF, Glynn D, Alarid-Escudero F, Baio G, Brennan A, Fairley M, Goldhaber-Fiebert JD, Jackson C, Jalal H, Menzies NA, Strong M, Thom H, Heath A, Collaborative Network for Value of Information. Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods. Value Health 2020 Jun;23(6):734-742. Epub 2020 May 27. [Abstract]

2019

de Carvalho TM, Heijnsdijk EAM, Coffeng L, de Koning HJ. Evaluating Parameter Uncertainty in a Simulation Model of Cancer Using Emulators. Med Decis Making 2019 May;39(4):405-413. Epub 2019 Jun 10. [Abstract]

Jutkowitz E, Alarid-Escudero F, Kuntz KM, Jalal H. The Curve of Optimal Sample Size (COSS): A Graphical Representation of the Optimal Sample Size from a Value of Information Analysis. Pharmacoeconomics 2019 Jul;37(7):871-877. [Abstract]

2018

Alarid-Escudero F, MacLehose RF, Peralta Y, Kuntz KM, Enns EA. Nonidentifiability in Model Calibration and Implications for Medical Decision Making. Med Decis Making 2018 Oct;38(7):810-821. [Abstract]

Brouwer AF, Eisenberg MC, Meza R. Case Studies of Gastric, Lung, and Oral Cancer Connect Etiologic Agent Prevalence to Cancer Incidence. Cancer Res 2018 Jun 15;78(12):3386-3396. [Abstract]

Buskermolen M, Gini A, Naber SK, Toes-Zoutendijk E, de Koning HJ, Lansdorp-Vogelaar I. Modeling in Colorectal Cancer Screening: Assessing External and Predictive Validity of MISCAN-Colon Microsimulation Model Using NORCCAP Trial Results. Med Decis Making 2018 Nov;38(8):917-929. Epub 2018 Oct 20. [Abstract]

Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Collaborators. Breast Cancer Simulation Modeling. Med Decis Making 2018 Apr;38(1 Suppl):3S-150S.

Fleshner K, Tin A, Benfante N, Carlsson S, Vickers AJ. Comparison of Physician-Documented Versus Patient-Reported Collection of Comorbidities Among Patients With Prostate Cancer Upon First Visit to the Urology Clinic. JCO Clin Cancer Inform 2018 Dec;2:1-10. [Abstract]

Lange JM, Gulati R, Leonardson AS, Lin DW, Newcomb LF, Trock BJ, Carter HB, Cooperberg MR, Cowan JE, Klotz LH, Etzioni R. ESTIMATING AND COMPARING CANCER PROGRESSION RISKS UNDER VARYING SURVEILLANCE PROTOCOLS. Ann Appl Stat 2018 Sep;12(3):1773-1795. Epub 2018 Sep 11. [Abstract]

Lee SJ, Li X, Huang H, Zelen M. The Dana-Farber CISNET Model for Breast Cancer Screening Strategies: An Update. Med Decis Making 2018 Apr;38(1_suppl):44S-53S. [Abstract]

Nautiyal N, Holford TR. A spatiotemporal back-calculation approach to estimate cancer incidence measures. Stat Med 2018 Dec 20;37(29):4472-4489. Epub 2018 Aug 28. [Abstract]

Tran Q, Kidwell KM, Tsodikov A. A joint model of cancer incidence, metastasis, and mortality. Lifetime Data Anal 2018 Jul;24(3):385-406. Epub 2017 Sep 4. [Abstract]

2017

Rice JD, Tsodikov A. Semiparametric time-to-event modeling in the presence of a latent progression event. Biometrics 2017 Jun;73(2):463-472. Epub 2016 Aug 24. [Abstract]

Rice JD, Tsodikov A. Semiparametric profile likelihood estimation for continuous outcomes with excess zeros in a random-threshold damage-resistance model. Stat Med 2017 May 30;36(12):1924-1935. Epub 2017 Feb 13. [Abstract]

Suresh K, Taylor JMG, Spratt DE, Daignault S, Tsodikov A. Comparison of joint modeling and landmarking for dynamic prediction under an illness-death model. Biom J 2017 Nov;59(6):1277-1300. Epub 2017 May 16. [Abstract]

2016

Cevik M, Ergun MA, Stout NK, Trentham-Dietz A, Craven M, Alagoz O. Using Active Learning for Speeding up Calibration in Simulation Models. Med Decis Making 2016 Jul;36(5):581-93. Epub 2015 Oct 15. [Abstract]

Curtius K, Wong CJ, Hazelton WD, Kaz AM, Chak A, Willis JE, Grady WM, Luebeck EG. A Molecular Clock Infers Heterogeneous Tissue Age Among Patients with Barrett's Esophagus. PLoS Comput Biol 2016 May 11;12(5):e1004919. doi: 10.1371/journal.pcbi.1004919. eCollection 2016 May. [Abstract]

Rutter CM, Knudsen AB, Marsh TL, Doria-Rose VP, Johnson E, Pabiniak C, Kuntz KM, van Ballegooijen M, Zauber AG, Lansdorp-Vogelaar I. Validation of Models Used to Inform Colorectal Cancer Screening Guidelines: Accuracy and Implications. Med Decis Making 2016 Jul;36(5):604-14. Epub 2016 Jan 8. [Abstract]

van der Steen A, van Rosmalen J, Kroep S, van Hees F, Steyerberg EW, de Koning HJ, van Ballegooijen M, Lansdorp-Vogelaar I. Calibrating Parameters for Microsimulation Disease Models: A Review and Comparison of Different Goodness-of-Fit Criteria. Med Decis Making 2016 Jul;36(5):652-65. Epub 2016 Mar 8. [Abstract]

Yankeelov TE, An G, Saut O, Luebeck EG, Popel AS, Ribba B, Vicini P, Zhou X, Weis JA, Ye K, Genin GM. Multi-scale Modeling in Clinical Oncology: Opportunities and Barriers to Success. Ann Biomed Eng 2016 Sep;44(9):2626-41. Epub 2016 Jul 6. [Abstract]

2015

Curtius K, Hazelton WD, Jeon J, Luebeck EG. A Multiscale Model Evaluates Screening for Neoplasia in Barrett's Esophagus. PLoS Comput Biol 2015 May 22;11(5):e1004272. doi: 10.1371/journal.pcbi.1004272. eCollection 2015 May. [Abstract]

Etzioni R, Gulati R. Recognizing the Limitations of Cancer Overdiagnosis Studies: A First Step Towards Overcoming Them. J Natl Cancer Inst 2015 Nov 18;108. (3). Print 2016 Mar. [Abstract]

Ha J, Tsodikov A. Semiparametric estimation in the proportional hazard model accounting for a misclassified cause of failure. Biometrics 2015 Dec;71(4):941-9. Epub 2015 Jun 23. [Abstract]

Jalal H, Goldhaber-Fiebert JD, Kuntz KM. Computing Expected Value of Partial Sample Information from Probabilistic Sensitivity Analysis Using Linear Regression Metamodeling. Med Decis Making 2015 Jul;35(5):584-95. Epub 2015 Apr 3. [Abstract]

Oh C, Holford TR. Age-Period-Cohort approaches to back-calculation of cancer incidence rate. Stat Med 2015 May 20;34(11):1953-64. Epub 2015 Feb 26. [Abstract]

2014

Etzioni R, Gulati R. Oversimplifying overdiagnosis. J Gen Intern Med 2014 Sep;29(9):1218-20. [Abstract]

Gallaher J, Babu A, Plevritis S, Anderson ARA. Bridging population and tissue scale tumor dynamics: a new paradigm for understanding differences in tumor growth and metastatic disease. Cancer Res 2014 Jan 15;74(2):426-435. Epub 2014 Jan 9. [Abstract]

Hu C, Tsodikov A. Joint modeling approach for semicompeting risks data with missing nonterminal event status. Lifetime Data Anal 2014 Oct;20(4):563-83. Epub 2014 Jan 16. [Abstract]

Hu C, Tsodikov A. Semiparametric regression analysis for time-to-event marked endpoints in cancer studies. Biostatistics 2014 Jul;15(3):513-25. Epub 2013 Dec 29. [Abstract]

Jia N, Lee SJ. An Exact Formula for Estimation of Age-Specific Sensitivity for Screening Tests. Appl Math 2014 Oct;5(17):2771-2778.

2013

Goldwasser DL, Kimmel M. Small median tumor diameter at cure threshold (<20 mm) among aggressive non-small cell lung cancers in male smokers predicts both chest X-ray and CT screening outcomes in a novel simulation framework. Int J Cancer 2013 Jan 1;132(1):189-97. Epub 2012 May 21. [Abstract]

Inoue LY, Gulati R, Yu C, Kattan MW, Etzioni R. Deriving benefit of early detection from biomarker-based prognostic models. Biostatistics 2013 Jan;14(1):15-27. Epub 2012 Jun 22. [Abstract]

Lee SY, Tsodikov A. Correcting the Results of the Wrong Model: Treatment Effects under Early Detection of Cancer. J Stat Theory Pract 2013 Apr 5;7(2):421-441. [Abstract]

Luo S, Yi M, Huang X, Hunt KK. A Bayesian model for misclassified binary outcomes and correlated survival data with applications to breast cancer. Stat Med 2013 Jun 15;32(13):2320-34. Epub 2012 Sep 21. [Abstract]

O'Mahony JF, van Rosmalen J, Zauber AG, van Ballegooijen M. Multicohort models in cost-effectiveness analysis: why aggregating estimates over multiple cohorts can hide useful information. Med Decis Making 2013 Apr;33(3):407-14. Epub 2012 Aug 27. [Abstract]

2012

Bekele BN, Nieto-Barajas LE, Munsell MF. Analysis of Partially Incomplete Tables of Breast Cancer Characteristics with an Ordinal Variable. J Stat Theory Pract 2012 Dec;6(4):725-744. [Abstract]

Ha J, Tsodikov A. Isotonic estimation of survival under a misattribution of cause of death. Lifetime Data Anal 2012 Jan;18(1):58-79. Epub 2011 Nov 18. [Abstract]

Hazelton WD, Jeon J, Meza R, Moolgavkar SH. Chapter 8: The FHCRC lung cancer model. Risk Anal 2012 Jul;32 Suppl 1(Suppl 1):S99-S116. [Abstract]

Kong CY, Lee JM, McMahon PM, Lowry KP, Omer ZB, Eisenberg JD, Pandharipande PV, Gazelle GS. Using radiation risk models in cancer screening simulations: important assumptions and effects on outcome projections. Radiology 2012 Mar;262(3):977-84. [Abstract]

Morrissey JP, Lich KH, Price RA, Mandelblatt J. Computational modeling and multilevel cancer control interventions. J Natl Cancer Inst Monogr 2012 May;2012(44):56-66. [Abstract]

2010

Gulati R, Inoue L, Katcher J, Hazelton W, Etzioni R. Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. Biostatistics 2010 Oct;11(4):707-19. Epub 2010 Jun 7. [Abstract]

Hur C, Hayeck TJ, Yeh JM, Richards EM, Spechler SJ, Gazelle GS, Kong CY. Development, calibration, and validation of a U.S. white male population-based simulation model of esophageal adenocarcinoma. PLoS One 2010 Mar 1;5(3):e9483. [Abstract]

Weedon-Fekjaer H, Tretli S, Aalen OO. Estimating screening test sensitivity and tumour progression using tumour size and time since previous screening. Stat Methods Med Res 2010 Oct;19(5):507-27. Epub 2010 Mar 31. [Abstract]

2009

Bentley TG, Weinstein MC, Kuntz KM. Effects of categorizing continuous variables in decision-analytic models. Med Decis Making 2009 Sep-Oct;29(5):549-56. Epub 2009 Jul 13. [Abstract]

Chefo S, Tsodikov A. Stage-specific cancer incidence: an artificially mixed multinomial logit model. Stat Med 2009 Jul 10;28(15):2054-76. [Abstract]

Deng L, Kimmel M, Foy M, Spitz M, Wei Q, Gorlova O. Estimation of the effects of smoking and DNA repair capacity on coefficients of a carcinogenesis model for lung cancer. Int J Cancer 2009 May 1;124(9):2152-8. [Abstract]

Rutter CM, Miglioretti DL, Savarino JE. Bayesian Calibration of Microsimulation Models. J Am Stat Assoc 2009 Dec 1;104(488):1338-1350. [Abstract]

2008

Hubbard RA, Inoue LYT, Fann JR. Modeling nonhomogeneous Markov processes via time transformation. Biometrics 2008 Sep;64(3):843-850. Epub 2007 Nov 19. [Abstract]

Inoue LY, Etzioni R, Morrell C, Müller P. Modeling Disease Progression with Longitudinal Markers. J Am Stat Assoc 2008;103(481):259-270. [Abstract]

Lee SJ, Zelen M. Mortality modeling of early detection programs. Biometrics 2008 Jun;64(2):386-95. Epub 2007 Aug 28. [Abstract]

Stout NK, Goldie SJ. Keeping the noise down: common random numbers for disease simulation modeling. Health Care Manag Sci 2008 Dec;11(4):399-406. [Abstract]

Tsodikov A, Chefo S. Generalized Self-Consistency: Multinomial logit model and Poisson likelihood. J Stat Plan Inference 2008;138(8):23802397. [Abstract]

2007

Inoue LY, Neira M, Nelson C, Gleave M, Etzioni R. Cluster-based network model for time-course gene expression data. Biostatistics 2007 Jul;8(3):507-25. Epub 2006 Sep 15. [Abstract]

Marciniak-Czochra A, Kimmel M. Modeling of early lung cancer progression: influence of growth factor production and cooperation between partially transformed cells. Math Models Methods Appl Sci 2007;17(Suppl):1693-1719.

Rutter CM, Yu O, Miglioretti DL. A hierarchical non-homogenous Poisson model for meta-analysis of adenoma counts. Stat Med 2007 Jan 15;26(1):98-109. [Abstract]

Tsodikov A, Garibotti G. Profile information matrix for nonlinear transformation models. Lifetime Data Anal 2007 Mar;13(1):139-59. [Abstract]

2006

Holford TR. Approaches to fitting age-period-cohort models with unequal intervals. Stat Med 2006 Mar 30;25(6):977-93. [Abstract]

Kimmel M, Gorlova OY, Henschke CI. Chapter 10. Modeling Lung Cancer Screening. In: Edler L, Kitsos CP, editors. Recent Advances in Quantitative Methods in Cancer and Human Health Risk Assessment. 2006 Mar 17. p. 161-76. (Wiley Series in Probability and Statistics) [Link]

2005

Clements MS, Armstrong BK, Moolgavkar SH. Lung cancer rate predictions using generalized additive models. Biostatistics 2005 Oct;6(4):576-89. Epub 2005 Apr 28. [Abstract]

Gorlova O, Peng B, Yankelevitz D, Henschke C, Kimmel M. Estimating the growth rates of primary lung tumours from samples with missing measurements. Stat Med 2005 Apr 15;24(7):1117-34. [Abstract]

Shen Y, Zelen M. Robust modeling in screening studies: estimation of sensitivity and preclinical sojourn time distribution. Biostatistics 2005 Oct;6(4):604-14. Epub 2005 Apr 28. [Abstract]

Zelen M. Risks of cancer and families. J Natl Cancer Inst 2005 Nov 2;97(21):1556-7. [Abstract]

2004

Boucher KM, Asselain B, Tsodikov AD, Yakovlev AY. Semiparametric Versus Parametric Regression Analysis Based on the Bounded Cumulative Hazard Model: An Application to Breast Cancer Recurrence. In: Nikulin MS, Balakrishnan N, Mesban M, Limnios N, editors. Parametric and Semiparametric Models with Applications to Reliability, Survival Analysis, and Quality of Life. Boston, MA: Birhauser; 2004. p. 399-415. (Statistics for Industry and Technology)

Broët P, Tsodikov A, De Rycke Y, Moreau T. Two-sample statistics for testing the equality of survival functions against improper semi-parametric accelerated failure time alternatives: an application to the analysis of a breast cancer clinical trial. Lifetime Data Anal 2004 Jun;10(2):103-20. [Abstract]

Davidov O, Zelen M. Overdiagnosis in early detection programs. Biostatistics 2004 Oct;5(4):603-13. [Abstract]

Feuer EJ, Boer R, Holford TR. Developing and comparing population models for the early detection of cancer. Stat Meth Med Res Dec 2004;13(6):419-20.

Hanin LG, Yakovlev AY. Multivariate distributions of clinical covariates at the time of cancer detection. Stat Methods Med Res 2004 Dec;13(6):457-89. [Abstract]

Inoue LY, Etzioni R, Slate EH, Morrell C, Penson DF. Combining longitudinal studies of PSA. Biostatistics 2004 Jul;5(3):483-500. [Abstract]

Lee S, Huang H, Zelen M. Early detection of disease and scheduling of screening examinations. Stat Methods Med Res 2004 Dec;13(6):443-56. [Abstract]

Zelen M. Forward and backward recurrence times and length biased sampling: age specific models. Lifetime Data Anal 2004 Dec;10(4):325-34. [Abstract]

2003

Davidov O, Zelen M. The theory of case-control studies for early detection programs. Biostatistics 2003 Jul;4(3):411-21. [Abstract]

Lee SJ, Zelen M. Modelling the early detection of breast cancer. Ann Oncol 2003 Aug;14(8):1199-202. [Abstract]

Tan SYGL, van Oortmarssen GJ, Piersma N. Estimating Parameters of a Microsimulation Model for Breast Cancer Screening Using the Score Function Method. Ann Oper Res 2003 Mar;119(43):43-61. [Link]

Tsodikov A. Semiparametric models: a generalized self-consistency approach. J R Stat Soc Series B Stat Methodol 2003 Aug 1;65(3):759-774. [Abstract]

Tsodikov AD, Ibrahim JG, Yakovlev AY. Estimating Cure Rates From Survival Data: An Alternative to Two-Component Mixture Models. J Am Stat Assoc 2003 Dec 1;98(464):1063-1078. [Abstract]

2002

Gregori G, Hanin L, Luebeck G, Moolgavkar S, Yakovlev A. Testing goodness of fit for stochastic models of carcinogenesis. Math Biosci 2002 Jan;175(1):13-29. [Abstract]

Hanin LG. Identification problem for stochastic models with application to carcinogenesis, cancer detection and radiation biology. Discrete Dyn Nat Soc 2002 Jan;7(3):177-89. [Link]

Lee SJ, Zelen M. Statistical models for screening: planning public health programs. Cancer Treat Res 2002;113:19-36. [Abstract]

Parmigiani G, Skates S, Zelen M. Modeling and optimization in early detection programs with a single exam. Biometrics 2002 Mar;58(1):30-6. [Abstract]

Zelen M, Lee SJ. Models and the early detection of disease: methodological considerations. Cancer Treat Res 2002;113:1-18. [Abstract]

2001

Bartoszyński R, Edler L, Hanin L, Kopp-Schneider A, Pavlova L, Tsodikov A, Zorin A, Yakovlev AY. Modeling cancer detection: tumor size as a source of information on unobservable stages of carcinogenesis. Math Biosci 2001 Jun;171(2):113-42. [Abstract]

Shen Y, Wu D, Zelen M. Testing the independence of two diagnostic tests. Biometrics 2001 Dec;57(4):1009-17. [Abstract]

National Cancer Control Planning

2023

2019

Blom EF, Ten Haaf K, Arenberg DA, de Koning HJ. Treatment capacity required for full-scale implementation of lung cancer screening in the United States. Cancer 2019 Jun 15;125(12):2039-2048. Epub 2019 Feb 27. [Abstract]

2018

Jeon J, Holford TR, Levy DT, Feuer EJ, Cao P, Tam J, Clarke L, Clarke J, Kong CY, Meza R. Smoking and Lung Cancer Mortality in the United States From 2015 to 2065: A Comparative Modeling Approach. Ann Intern Med 2018 Nov 20;169(10):684-693. Epub 2018 Oct 9. [Abstract]

Levy DT, Yuan Z, Li Y. The US SimSmoke tobacco control policy model of smokeless tobacco and cigarette use. BMC Public Health 2018 Jun 5;18(1):696. [Abstract]

2017

2015

Meester RG, Doubeni CA, Lansdorp-Vogelaar I, Goede SL, Levin TR, Quinn VP, Ballegooijen Mv, Corley DA, Zauber AG. Colorectal cancer deaths attributable to nonuse of screening in the United States. Ann Epidemiol 2015 Mar;25(3):208-213.e1. Epub 2014 Dec 5. [Abstract]

Meester RG, Doubeni CA, Zauber AG, Goede SL, Levin TR, Corley DA, Jemal A, Lansdorp-Vogelaar I. Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018. Cancer 2015 Jul 1;121(13):2281-5. Epub 2015 Mar 12. [Abstract]

2012

Choi SE, Hur C. Screening and surveillance for Barrett's esophagus: current issues and future directions. Curr Opin Gastroenterol 2012 Jul;28(4):377-81. [Abstract]

2011

Levy DT, Pearson JL, Villanti AC, Blackman K, Vallone DM, Niaura RS, Abrams DB. Modeling the future effects of a menthol ban on smoking prevalence and smoking-attributable deaths in the United States. Am J Public Health 2011 Jul;101(7):1236-40. Epub 2011 May 12. [Abstract]

Stock C, Knudsen AB, Lansdorp-Vogelaar I, Haug U, Brenner H. Colorectal cancer mortality prevented by use and attributable to nonuse of colonoscopy. Gastrointest Endosc 2011 Mar;73(3):435-443.e5. [Abstract]

2010

Abrams DB, Graham AL, Levy DT, Mabry PL, Orleans CT. Boosting population quits through evidence-based cessation treatment and policy. Am J Prev Med 2010 Mar;38(3 Suppl):S351-63. [Abstract]

Levy DT, Graham AL, Mabry PL, Abrams DB, Orleans CT. Modeling the impact of smoking-cessation treatment policies on quit rates. Am J Prev Med 2010 Mar;38(3 Suppl):S364-72. [Abstract]

Levy DT, Mabry PL, Graham AL, Orleans CT, Abrams DB. Reaching Healthy People 2010 by 2013: A SimSmoke simulation. Am J Prev Med 2010 Mar;38(3 Suppl):S373-81. [Abstract]

Levy DT, Mabry PL, Graham AL, Orleans CT, Abrams DB. Exploring scenarios to dramatically reduce smoking prevalence: a simulation model of the three-part cessation process. Am J Public Health 2010 Jul;100(7):1253-9. Epub 2010 May 13. [Abstract]

2007

Levy DT. The role of public policies in reducing smoking prevalence: results from the SimSmoke tobacco policy simulation model. In: Bonnie RJ, Stratton K, Wallace RB, editors. Committee on Reducing Tobacco Use: Strategies, Barriers, and Consequences, Ending the Tobacco Problem: A Blueprint for the Nation. Washington, DC: Institute of Medicine; 2007. p. 578-98.

Wang YC, Colditz GA, Kuntz KM. Forecasting the obesity epidemic in the aging U.S. population. Obesity (Silver Spring) 2007 Nov;15(11):2855-65. [Abstract]

2006

Levy DT, Bauer JE, Lee HR. Simulation modeling and tobacco control: creating more robust public health policies. Am J Public Health 2006 Mar;96(3):494-8. Epub 2006 Jan 31. [Abstract]

2005

Levy DT, Nikolayev L, Mumford E, Compton C. The Healthy People 2010 smoking prevalence and tobacco control objectives: results from the SimSmoke tobacco control policy simulation model (United States). Cancer Causes Control 2005 May;16(4):359-71. [Abstract]

Screening Guidelines

2021

Etzioni R, Nyame YA. Prostate Cancer Screening Guidelines for Black Men: Spotlight on an Empty Stage. J Natl Cancer Inst 2021 Jun 1;113(6):650-651. [Abstract]

Knudsen AB, Rutter CM, Peterse EFP, Lietz AP, Seguin CL, Meester RGS, Perdue LA, Lin JS, Siegel RL, Doria-Rose VP, Feuer EJ, Zauber AG, Kuntz KM, Lansdorp-Vogelaar I. Colorectal Cancer Screening: An Updated Modeling Study for the US Preventive Services Task Force. JAMA 2021 May 18;325(19):1998-2011. [Abstract]

2018

Hadjiliadis D, Khoruts A, Zauber AG, Hempstead SE, Maisonneuve P, Lowenfels AB, Cystic Fibrosis Colorectal Cancer Screening Task Force. Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations. Gastroenterology 2018 Feb;154(3):736-745.e14. Epub 2017 Dec 29. [Abstract]

Han SS, Ten Haaf K, Hazelton WD, Jeon J, Meza R, Kong CY, Feuer EJ, de Koning HJ, Plevritis SK. Re: Think before you leap. Int J Cancer 2018 Apr 1;142(7):1507-1509. Epub 2017 Dec 28. [Abstract]

Kim JJ, Burger EA, Regan C, Sy S. Screening for Cervical Cancer in Primary Care: A Decision Analysis for the US Preventive Services Task Force. JAMA 2018 Aug 21;320(7):706-714. [Abstract]

2017

Gulati R, Cheng HH, Lange PH, Nelson PS, Etzioni R. Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms. Cancer Epidemiol Biomarkers Prev 2017 Feb;26(2):222-227. Epub 2016 Oct 14. [Abstract]

2016

Carlsson SV, de Carvalho TM, Roobol MJ, Hugosson J, Auvinen A, Kwiatkowski M, Villers A, Zappa M, Nelen V, Páez A, Eastham JA, Lilja H, de Koning HJ, Vickers AJ, Heijnsdijk EA. Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis. Cancer 2016 Nov 15;122(21):3386-3393. Epub 2016 Jul 26. [Abstract]

2015

Mandelblatt J, Cronin K, de Koning H, Miglioretti DL, Schechter C, Stout N. Collaborative Modeling of U.S. Breast Cancer Screening Strategies. Writing Committee of the Breast Cancer Working Group; 2015 Apr. AHRQ Publication No. 14-05201-EF-4. [Resources]

Ten Haaf K, de Koning HJ. Should Never-Smokers at Increased Risk for Lung Cancer Be Screened? J Thorac Oncol 2015 Sep;10(9):1285-1291. [Abstract]

Ten Haaf K, de Koning HJ. Overdiagnosis in lung cancer screening: why modelling is essential. J Epidemiol Community Health 2015 Nov;69(11):1035-9. Epub 2015 Jun 12. [Abstract]

van Ravesteyn NT, Stout NK, Schechter CB, Heijnsdijk EA, Alagoz O, Trentham-Dietz A, Mandelblatt JS, de Koning HJ. Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosis. J Natl Cancer Inst 2015 May 6;107. (7). Print 2015 Jul. [Abstract]

2014

de Koning HJ, Meza R, Plevritis SK, ten Haaf K, Munshi VN, Jeon J, Erdogan SA, Kong CY, Han SS, van Rosmalen J, Choi SE, Pinsky PF, Berrington de Gonzalez A, Berg CD, Black WC, Tammemägi MC, Hazelton WD, Feuer EJ, McMahon PM. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med 2014 Mar 4;160(5):311-20. [Abstract]

Habbema JD, Wilt TJ, Etzioni R, Nelson HD, Schechter CB, Lawrence WF, Melnikow J, Kuntz KM, Owens DK, Feuer EJ. Models in the development of clinical practice guidelines. Ann Intern Med 2014 Dec 2;161(11):812-8. [Abstract]

2013

Etzioni R, Gulati R, Cooperberg MR, Penson DM, Weiss NS, Thompson IM. Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. Med Care 2013 Apr;51(4):295-300. [Abstract]

Etzioni RD. Review of evidence concerning PSA screening for prostate cancer has limitations as basis for policy development. Evid Based Med 2013 Apr;18(2):75-6. Epub 2012 Jul 7. [Abstract]

Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med 2013 Feb 5;158(3):145-53. [Abstract]

2012

Knudsen AB, Hur C, Gazelle GS, Schrag D, McFarland EG, Kuntz KM. Rescreening of persons with a negative colonoscopy result: results from a microsimulation model. Ann Intern Med 2012 Nov 6;157(9):611-20. [Abstract]

2011

Mandelblatt J, Cronin K. Response to Hendrick and Helvie by the Cancer Intervention Surveillance Modeling Network (CISNET) Breast Working Group. AJR Am J Roentgenol 2011 Oct;197(4):W792; author reply 794. [Abstract]

van Ravesteyn NT, Heijnsdijk EA, de Koning HJ. More on screening mammography. N Engl J Med 2011 Jan 20;364(3):282-3; author reply 285-6. [Abstract]

2010

Zauber AG, van Ballegooijen M, Petitti D, Lansdorp-Vogelaar I. United States Preventive Services Task Force recommendations: age to end screening misunderstood. Dis Colon Rectum 2010 Oct;53(10):1453; author reply 1453. [Abstract]

2009

Lansdorp-Vogelaar I. Effects of Colorectal Cancer Screening on Population Health - a modeling assessment. PhD thesis for Department of Public Health, Erasmus University, Rotterdam, the Netherlands. Ipskamp Drukkers; 2009 Apr. p. 1-192.

Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, Huang H, Lee SJ, Munsell M, Plevritis SK, Ravdin P, Schechter CB, Sigal B, Stoto MA, Stout NK, van Ravesteyn NT, Venier J, Zelen M, Feuer EJ, Breast Cancer Working Group of the Cancer Intervention and Surveillance Modeling Network. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med 2009 Nov 17;151(10):738-47. [Abstract]

2008

Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2008 Nov 4;149(9):659-69. Epub 2008 Oct 6. [Abstract]

2003

Mandelblatt J, Saha S, Teutsch S, Hoerger T, Siu AL, Atkins D, Klein J, Helfand M, Cost Work Group of the U.S. Preventive Services Task Force. The cost-effectiveness of screening mammography beyond age 65 years: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2003 Nov 18;139(10):835-42. [Abstract]

2001

Saha S, Hoerger TJ, Pignone MP, Teutsch SM, Helfand M, Mandelblatt JS, Cost Work Group Third US Preventive Services Task Force. The art and science of incorporating cost effectiveness into evidence-based recommendations for clinical preventive services. Am J Prev Med 2001 Apr;20(3 Suppl):36-43. [Abstract]

State and Local Cancer Control Planning

2023

Holford TR, McKay L, Jeon J, Tam J, Cao P, Fleischer NL, Levy DT, Meza R. Smoking Histories by State in the U.S. Am J Prev Med 2023 Apr;64(4 Suppl 1):S42-S52. Epub 2023 Jan 16. [Abstract]

2019

Rubenstein JH, Morgenstern H, Longstreth K. Clustering of esophageal cancer among white men in the United States. Dis Esophagus 2019 Jan 1;32. (1). [Abstract]

2018

Donahoe JT, Titus AR, Fleischer NL. Key Factors Inhibiting Legislative Progress Toward Smoke-Free Coverage in Appalachia. Am J Public Health 2018 Mar;108(3):372-378. Epub 2018 Jan 18. [Abstract]

2017

2016

Levy D, Fergus C, Rudov L, McCormick-Ricket I, Carton T. Tobacco Policies in Louisiana: Recommendations for Future Tobacco Control Investment from SimSmoke, a Policy Simulation Model. Prev Sci 2016 Feb;17(2):199-207. [Abstract]

Levy DT, Huang AT, Havumaki JS, Meza R. The role of public policies in reducing smoking prevalence: results from the Michigan SimSmoke tobacco policy simulation model. Cancer Causes Control 2016 May;27(5):615-25. Epub 2016 Mar 17. [Abstract]

2015

2012

Near AM, Mandelblatt JS, Schechter CB, Stoto MA. Using Simulation Modeling to Inform Strategies to Reduce Breast Cancer Mortality in Black Women in the District of Columbia. Epidemiol Res Int 2012 Apr 26;2012. (2012). [Abstract]

2011

2008

Levy DT, Tworek C, Hahn EJ, Davis RE. The Kentucky SimSmoke tobacco policy simulation model: reaching Healthy People 2010 goals through policy change. South Med J 2008 May;101(5):503-7. [Abstract]

2007

Levy DT, Hyland A, Higbee C, Remer L, Compton C. The role of public policies in reducing smoking prevalence in California: results from the California tobacco policy simulation model. Health Policy 2007 Jul;82(2):167-85. Epub 2006 Oct 19. [Abstract]

Levy DT, Ross H, Powell L, Bauer JE, Lee HR. The role of public policies in reducing smoking prevalence and deaths caused by smoking in Arizona: results from the Arizona tobacco policy simulation model. J Public Health Manag Pract 2007 Jan-Feb;13(1):59-67. [Abstract]

2004

Andersen LD, Remington PL, Trentham-Dietz A, Robert S. Community trends in the early detection of breast cancer in Wisconsin, 1980-1998. Am J Prev Med 2004 Jan;26(1):51-5. [Abstract]

Trial Design and Interpretation of Trial Results

2023

2021

Winawer SJ, Zauber AG, O'Brien MJ, Geenen J, Waye JD. The National Polyp Study at 40: challenges then and now. Gastrointest Endosc 2021 Mar;93(3):720-726. Epub 2020 Sep 30. [Abstract]

2020

2019

Heijnsdijk EAM, Adolfsson J, Auvinen A, Roobol MJ, Hugosson J, de Koning HJ. The Impact of Design and Performance in Prostate-Specific Antigen Screening: Differences Between ERSPC Centers. Eur Urol 2019 Sep;76(3):276-279. Epub 2019 Apr 26. [Abstract]

Lansdorp-Vogelaar I, Jagsi R, Jayasekera J, Stout NK, Mitchell SA, Feuer EJ. Evidence-based sizing of non-inferiority trials using decision models. BMC Med Res Methodol 2019 Jan 7;19(1):3. [Abstract]

Ryser MD, Gulati R, Eisenberg MC, Shen Y, Hwang ES, Etzioni RB. Identification of the Fraction of Indolent Tumors and Associated Overdiagnosis in Breast Cancer Screening Trials. Am J Epidemiol 2019 Jan 1;188(1):197-205. [Abstract]

2018

Etzioni R, Gulati R. When Clinical Trials Disagree. J Urol 2018 Sep;200(3):506-507. Epub 2018 Mar 1. [Abstract]

Tsodikov A, Gulati R, Etzioni R. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Ann Intern Med 2018 Apr 17;168(8):608-609. [Abstract]

2017

Gulati R, Etzioni R. A Matched Cohort Analysis of Prostate Cancer Screening in Younger Men in Sweden. Eur Urol 2017 Jan;71(1):53-54. Epub 2016 Apr 16. [Abstract]

2016

Gulati R, Feuer EJ, Etzioni R. Conditions for Valid Empirical Estimates of Cancer Overdiagnosis in Randomized Trials and Population Studies. Am J Epidemiol 2016 Jul 15;184(2):140-7. Epub 2016 Jun 29. [Abstract]

2015

Ten Haaf K, de Koning HJ. Overdiagnosis in lung cancer screening: why modelling is essential. J Epidemiol Community Health 2015 Nov;69(11):1035-9. Epub 2015 Jun 12. [Abstract]

2014

Berry DA. Failure of researchers, reviewers, editors, and the media to understand flaws in cancer screening studies: application to an article in Cancer. Cancer 2014 Sep 15;120(18):2784-91. Epub 2014 Jun 12. [Abstract]

Etzioni RD, Thompson IM. What do the screening trials really tell us and where do we go from here? Urol Clin North Am 2014 May;41(2):223-8. Epub 2014 Feb 19. [Abstract]

2013

Etzioni R, Gulati R. Response: Reading between the lines of cancer screening trials: using modeling to understand the evidence. Med Care 2013 Apr;51(4):304-6. [Abstract]

Etzioni R, Gulati R, Mallinger L, Mandelblatt J. Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Ann Intern Med 2013 Jun 4;158(11):831-8. [Abstract]

Xia J, Gulati R, Au M, Gore JL, Lin DW, Etzioni R. Effects of screening on radical prostatectomy efficacy: the prostate cancer intervention versus observation trial. J Natl Cancer Inst 2013 Apr 17;105(8):546-50. Epub 2013 Feb 14. [Abstract]

2012

Gulati R, Tsodikov A, Wever EM, Mariotto AB, Heijnsdijk EA, Katcher J, de Koning HJ, Etzioni R. The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes Control 2012 Jun;23(6):827-35. Epub 2012 Apr 10. [Abstract]

2011

Gulati R, Mariotto AB, Chen S, Gore JL, Etzioni R. Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. J Clin Epidemiol 2011 Dec;64(12):1412-7. [Abstract]

Shi L, Tian H, McCarthy WJ, Berman B, Wu S, Boer R. Exploring the uncertainties of early detection results: model-based interpretation of mayo lung project. BMC Cancer 2011 Mar 7;11:92. [Abstract]

Wever EM, Draisma G, Heijnsdijk EA, de Koning HJ. How does early detection by screening affect disease progression? Modeling estimated benefits in prostate cancer screening. Med Decis Making 2011 Jul-Aug;31(4):550-8. Epub 2011 Mar 15. [Abstract]

2010

Goldwasser DL, Kimmel M. Modeling excess lung cancer risk among screened arm participants in the Mayo Lung Project. Cancer 2010 Jan 1;116(1):122-31. [Abstract]

Wever EM, Draisma G, Heijnsdijk EA, Roobol MJ, Boer R, Otto SJ, de Koning HJ. Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam. J Natl Cancer Inst 2010 Mar 3;102(5):352-5. Epub 2010 Feb 8. [Abstract]

2008

McMahon PM, Kong CY, Johnson BE, Weinstein MC, Weeks JC, Kuntz KM, Shepard JA, Swensen SJ, Gazelle GS. Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology 2008 Jul;248(1):278-87. Epub 2008 May 5. [Abstract]

2006

Zeliadt SB, Potosky AL, Penson DF, Etzioni R. Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys 2006 Oct 1;66(2):395-402. Epub 2006 Aug 14. [Abstract]

2005

Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 2005 Aug 17;97(16):1195-203. [Abstract]

2004

Hu P, Zelen M. Planning of randomized early detection trials. Stat Methods Med Res 2004 Dec;13(6):491-506. [Abstract]

2002

Hu P, Zelen M. Experimental design issues for the early detection of disease: novel designs. Biostatistics 2002 Sep;3(3):299-313. [Abstract]

2001

Shen Y, Zelen M. Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations. J Clin Oncol 2001 Aug 1;19(15):3490-9. [Abstract]

Understanding National Trends in Cancer Incidence and Mortality

2023

DeYoreo M, Rutter CM, Lee SD. Use of 2-Stage Modeling to Identify How Colorectal Cancer Risk Changes With Period and Cohort. Am J Epidemiol 2023 Feb 1;192(2):230-236. [Abstract]

2021

2019

Meester RGS, Mannalithara A, Lansdorp-Vogelaar I, Ladabaum U. Trends in Incidence and Stage at Diagnosis of Colorectal Cancer in Adults Aged 40 Through 49 Years, 1975-2015. JAMA 2019 May 21;321(19):1933-1934. [Abstract]

Ryser MD, Hendrix LH, Worni M, Liu Y, Hyslop T, Hwang ES. Incidence of Ductal Carcinoma In Situ in the United States, 2000-2014. Cancer Epidemiol Biomarkers Prev 2019 Aug;28(8):1316-1323. Epub 2019 Jun 11. [Abstract]

2018

Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Collaborators. Breast Cancer Simulation Modeling. Med Decis Making 2018 Apr;38(1 Suppl):3S-150S.

Caswell-Jin JL, Plevritis SK, Tian L, Cadham CJ, Xu C, Stout NK, Sledge GW, Mandelblatt JS, Kurian AW. Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review. JNCI Cancer Spectr 2018 Nov;2(4):pky062. Epub 2018 Dec 24. [Abstract]

Munoz DF, Plevritis SK. Estimating Breast Cancer Survival by Molecular Subtype in the Absence of Screening and Adjuvant Treatment. Med Decis Making 2018 Apr;38(1_suppl):32S-43S. [Abstract]

2016

Etzioni R, Gulati R. Recent Trends in PSA Testing and Prostate Cancer Incidence: A Look at Context. JAMA Oncol 2016 Jul 1;2(7):955-6. [Abstract]

2015

Gangnon RE, Sprague BL, Stout NK, Alagoz O, Weedon-Fekjær H, Holford TR, Trentham-Dietz A. The contribution of mammography screening to breast cancer incidence trends in the United States: an updated age-period-cohort model. Cancer Epidemiol Biomarkers Prev 2015 Jun;24(6):905-12. Epub 2015 Mar 18. [Abstract]

Hazelton WD, Curtius K, Inadomi JM, Vaughan TL, Meza R, Rubenstein JH, Hur C, Luebeck EG. The Role of Gastroesophageal Reflux and Other Factors during Progression to Esophageal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2015 Jul;24(7):1012-23. Epub 2015 Apr 30. [Abstract]

Kroep S, Lansdorp-Vogelaar I, Rubenstein JH, de Koning HJ, Meester R, Inadomi JM, van Ballegooijen M. An Accurate Cancer Incidence in Barrett's Esophagus: A Best Estimate Using Published Data and Modeling. Gastroenterology 2015 Sep;149(3):577-85.e4; quiz e14-5. Epub 2015 Apr 29. [Abstract]

Meza R, Meernik C, Jeon J, Cote ML. Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010. PLoS One 2015 Mar 30;10(3):e0121323. doi: 10.1371/journal.pone.0121323. eCollection 2015. [Abstract]

Zauber AG. The impact of screening on colorectal cancer mortality and incidence: has it really made a difference? Dig Dis Sci 2015 Mar;60(3):681-91. Epub 2015 Mar 5. [Abstract]

2014

Gulati R, Tsodikov A, Etzioni R, Hunter-Merrill RA, Gore JL, Mariotto AB, Cooperberg MR. Expected population impacts of discontinued prostate-specific antigen screening. Cancer 2014 Nov 15;120(22):3519-26. Epub 2014 Jul 25. [Abstract]

Holford TR, Levy DT, McKay LA, Clarke L, Racine B, Meza R, Land S, Jeon J, Feuer EJ. Patterns of birth cohort-specific smoking histories, 1965-2009. Am J Prev Med 2014 Feb;46(2):e31-7. [Abstract] [Resources]

Holford TR, Meza R, Warner KE, Meernik C, Jeon J, Moolgavkar SH, Levy DT. Tobacco control and the reduction in smoking-related premature deaths in the United States, 1964-2012. JAMA 2014 Jan 8;311(2):164-71. [Abstract] [Resources]

Jewett PI, Gangnon RE, Trentham-Dietz A, Sprague BL. Trends of postmenopausal estrogen plus progestin prevalence in the United States between 1970 and 2010. Obstet Gynecol 2014 Oct;124(4):727-733. [Abstract]

Kroep S, Lansdorp-Vogelaar I, Rubenstein JH, Lemmens VE, van Heijningen EB, Aragonés N, van Ballegooijen M, Inadomi JM. Comparing trends in esophageal adenocarcinoma incidence and lifestyle factors between the United States, Spain, and the Netherlands. Am J Gastroenterol 2014 Mar;109(3):336-43; quiz 335, 344. Epub 2013 Dec 17. [Abstract]

Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, Berry DA, Burnside ES, Chang Y, Chisholm G, de Koning HJ, Ali Ergun M, Heijnsdijk EA, Huang H, Stout NK, Sprague BL, Trentham-Dietz A, Mandelblatt JS, Plevritis SK. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst 2014 Sep 24;106. (11). Print 2014 Nov. [Abstract]

Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiol Rev 2014;36(1):114-36. [Abstract]

Sprague BL, Gangnon RE, Burt V, Trentham-Dietz A, Hampton JM, Wellman RD, Kerlikowske K, Miglioretti DL. Prevalence of mammographically dense breasts in the United States. J Natl Cancer Inst 2014 Sep 12;106. (10). Print 2014 Oct. [Abstract]

2013

Hur C, Miller M, Kong CY, Dowling EC, Nattinger KJ, Dunn M, Feuer EJ. Trends in esophageal adenocarcinoma incidence and mortality. Cancer 2013 Mar 15;119(6):1149-58. Epub 2012 Dec 11. [Abstract]

Rutter CM, Johnson EA, Feuer EJ, Knudsen AB, Kuntz KM, Schrag D. Secular trends in colon and rectal cancer relative survival. J Natl Cancer Inst 2013 Dec 4;105(23):1806-13. Epub 2013 Oct 30. [Abstract]

2012

Anderson CM, Burns DM, Dodd KW, Feuer EJ. Chapter 2: Birth-cohort-specific estimates of smoking behaviors for the U.S. population. Risk Anal 2012 Jul;32 Suppl 1(0 1):S14-24. [Abstract] [Resources]

Bloch M, Backinger CL, Compton WM, Conway K. Standing on the threshold of change. Risk Anal 2012 Jul;32 Suppl 1:S1-5. [Abstract]

Boer R, Moolgavkar SH, Levy DT. Chapter 15: Impact of tobacco control on lung cancer mortality in the United States over the period 1975-2000--summary and limitations. Risk Anal 2012 Jul;32 Suppl 1(Suppl 1):S190-201. [Abstract]

Etzioni R, Gulati R, Tsodikov A, Wever EM, Penson DF, Heijnsdijk EA, Katcher J, Draisma G, Feuer EJ, de Koning HJ, Mariotto AB. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer 2012 Dec 1;118(23):5955-63. Epub 2012 May 17. [Abstract]

Feuer EJ, Levy DT, McCarthy WJ. Chapter 1:The impact of the reduction in tobacco smoking on U.S. lung cancer mortality, 1975-2000: an introduction to the problem. Risk Anal 2012 Jul;32 Suppl 1(0 1):S6-S13. [Abstract]

Feuer EJ, Moolgavkar SH, Levy DT, Kimmel M, Clarke LD. The Impact of the Reduction in Tobacco Smoking on U.S. Lung Cancer Mortality (1975-2000): Collective Results from the Cancer Intervention and Surveillance Modeling Network (CISNET). Risk Anal 2012 Aug 7;32(S1):S1-S201.

Gangnon RE, Sprague B, Stout N, Alagoz O, Trentham-Dietz A. Age-period-cohort analysis of invasive breast cancer incidence in the United States, 1935-2008. Proceedings of 45th Annual SEER Meeting; June 27-30, 2012; 2012. p. S6. [Link]

Holford TR, Clark L. Chapter 4: Development of the counterfactual smoking histories used to assess the effects of tobacco control. Risk Anal 2012 Jul;32 Suppl 1(Suppl 1):S39-50. [Abstract]

Jeon J, Meza R, Krapcho M, Clarke LD, Byrne J, Levy DT. Chapter 5: Actual and counterfactual smoking prevalence rates in the U.S. population via microsimulation. Risk Anal 2012 Jul;32 Suppl 1(Suppl 1):S51-68. [Abstract]

McCarthy WJ, Meza R, Jeon J, Moolgavkar SH. Chapter 6: Lung cancer in never smokers: epidemiology and risk prediction models. Risk Anal 2012 Jul;32 Suppl 1(Suppl 1):S69-84. [Abstract]

Moolgavkar SH, Holford TR, Levy DT, Kong CY, Foy M, Clarke L, Jeon J, Hazelton WD, Meza R, Schultz F, McCarthy W, Boer R, Gorlova O, Gazelle GS, Kimmel M, McMahon PM, de Koning HJ, Feuer EJ. Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975-2000. J Natl Cancer Inst 2012 Apr 4;104(7):541-8. Epub 2012 Mar 14. [Abstract] [Resources]

Rosenberg MA, Feuer EJ, Yu B, Sun J, Henley SJ, Shanks TG, Anderson CM, McMahon PM, Thun MJ, Burns DM. Chapter 3: Cohort life tables by smoking status, removing lung cancer as a cause of death. Risk Anal 2012 Jul;32 Suppl 1(Suppl 1):S25-38. [Abstract] [Resources]

Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol 2012 Sep;120(3):595-603. [Abstract]

2011

Kong CY, Nattinger KJ, Hayeck TJ, Omer ZB, Wang YC, Spechler SJ, McMahon PM, Gazelle GS, Hur C. The impact of obesity on the rise in esophageal adenocarcinoma incidence: estimates from a disease simulation model. Cancer Epidemiol Biomarkers Prev 2011 Nov;20(11):2450-6. Epub 2011 Sep 19. [Abstract]

Mandelblatt JS, Cronin KA, Berry DA, Chang Y, de Koning HJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, van Ravesteyn NT, Zelen M, Feuer EJ. Modeling the impact of population screening on breast cancer mortality in the United States. Breast 2011 Oct;20 Suppl 3(Suppl 3):S75-81. [Abstract]

2010

Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, van Ballegooijen M, Goede SL, Ries LA. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010 Feb 1;116(3):544-73. [Abstract]

Hayeck TJ, Kong CY, Spechler SJ, Gazelle GS, Hur C. The prevalence of Barrett's esophagus in the US: estimates from a simulation model confirmed by SEER data. Dis Esophagus 2010 Aug;23(6):451-7. Epub 2010 Mar 26. [Abstract]

2009

Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009 Mar 18;101(6):374-83. Epub 2009 Mar 10. [Abstract]

Etzioni R, Gulati R, Mariotto AB. Overview of US Prostate Cancer Trends in the Era of PSA Screening. In: Ankerst DP, Tangen CM, Thompson IM Jr, editors. Prostate Cancer Screening. 2nd. Humana Press; 2009. p. 3-14. (Current Clinical Urology)

Fesinmeyer MD, Gulati R, Zeliadt S, Weiss N, Kristal AR, Etzioni R. Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States. Cancer Epidemiol Biomarkers Prev 2009 Mar;18(3):808-15. Epub 2009 Mar 3. [Abstract]

2008

Etzioni R, Feuer E. Studies of prostate-cancer mortality: caution advised. Lancet Oncol 2008 May;9(5):407-9. [Abstract]

Etzioni R, Gulati R, Falcon S, Penson DF. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making 2008 May-Jun;28(3):323-31. Epub 2008 Mar 4. [Abstract]

Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, DiTommaso D, Karnofski K, Gulati R, Penson DF, Feuer E. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control 2008 Mar;19(2):175-81. Epub 2007 Nov 20. [Abstract]

Telesca D, Etzioni R, Gulati R. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics 2008 Mar;64(1):10-9. Epub 2007 May 14. [Abstract]

2007

Levy DT, Mumford EA, Gerlowski DA. Examining trends in quantity smoked. Nicotine Tob Res 2007 Dec;9(12):1287-96. [Abstract]

Mariotto AB, Etzioni R, Krapcho M, Feuer EJ. Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer 2007 May 1;109(9):1877-86. [Abstract]

Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007 Apr 19;356(16):1670-4. [Abstract]

2006

Bentley TG, Willett WC, Weinstein MC, Kuntz KM. Population-level changes in folate intake by age, gender, and race/ethnicity after folic acid fortification. Am J Public Health 2006 Nov;96(11):2040-7. Epub 2006 Oct 3. [Abstract]

Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Collaborators. The Impact of Mammography and Adjuvant Therapy on U.S. Breast Cancer Mortality (1975–2000): Collective Results from the Cancer Intervention and Surveillance Modeling Network. JNCI Monographs 2006;2006(36):1-126.

Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Collaborators. Executive Summary. JNCI Monographs 2006 Oct 1;2006(36):1-2. [Link]

Cronin KA, Feuer EJ, Clarke LD, Plevritis SK. Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000: comparison of mortality results from the cisnet breast cancer base case analysis. J Natl Cancer Inst Monogr 2006;(36):112-21. [Abstract]

Cronin KA, Mariotto AB, Clarke LD, Feuer EJ. Additional common inputs for analyzing impact of adjuvant therapy and mammography on U.S. mortality. J Natl Cancer Inst Monogr 2006;(36):26-9. [Abstract]

Feuer EJ. Modeling the impact of adjuvant therapy and screening mammography on U.S. breast cancer mortality between 1975 and 2000: introduction to the problem. J Natl Cancer Inst Monogr 2006;(36):2-6. [Abstract]

Habbema JD, Schechter CB, Cronin KA, Clarke LD, Feuer EJ. Modeling cancer natural history, epidemiology, and control: reflections on the CISNET breast group experience. J Natl Cancer Inst Monogr 2006;(36):122-6. [Abstract]

Habbema JD, Tan SY, Cronin KA. Impact of mammography on U.S. breast cancer mortality, 1975-2000: are intermediate outcome measures informative? J Natl Cancer Inst Monogr 2006;(36):105-11. [Abstract]

Holford TR, Cronin KA, Mariotto AB, Feuer EJ. Changing patterns in breast cancer incidence trends. J Natl Cancer Inst Monogr 2006;(36):19-25. [Abstract]

Mariotto AB, Feuer EJ, Harlan LC, Abrams J. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. J Natl Cancer Inst Monogr 2006;(36):7-15. [Abstract]

Rosenberg MA. Competing risks to breast cancer mortality. J Natl Cancer Inst Monogr 2006;(36):15-9. [Abstract]

Vogelaar I, van Ballegooijen M, Schrag D, Boer R, Winawer SJ, Habbema JD, Zauber AG. How much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modification, screening, and treatment. Cancer 2006 Oct 1;107(7):1624-33. [Abstract]

2005

Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ, Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005 Oct 27;353(17):1784-92. [Abstract]

Cronin KA, Yu B, Krapcho M, Miglioretti DL, Fay MP, Izmirlian G, Ballard-Barbash R, Geller BM, Feuer EJ. Modeling the dissemination of mammography in the United States. Cancer Causes Control 2005 Aug;16(6):701-12. [Abstract]

Knudsen AB. Explaining secular trends in colorectal cancer incidence and mortality with an empirically-calibrated microsimulation model [Ph.D. dissertation]. Cambridge, MA: Harvard University; 2005.

Levy DT, Nikolayev L, Mumford E. Recent trends in smoking and the role of public policies: results from the SimSmoke tobacco control policy simulation model. Addiction 2005 Oct;100(10):1526-36. [Abstract]

2004

Feuer EJ, Etzioni R, Cronin KA, Mariotto A. The use of modeling to understand the impact of screening on U.S. mortality: examples from mammography and PSA testing. Stat Methods Med Res 2004 Dec;13(6):421-42. [Abstract]

Shaw PA, Etzioni R, Zeliadt SB, Mariotto A, Karnofski K, Penson DF, Weiss NS, Feuer EJ. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. Am J Epidemiol 2004 Dec 1;160(11):1059-69. [Abstract]

2002

Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002 Jul 3;94(13):981-90. [Abstract]

Mariotto A, Feuer EJ, Harlan LC, Wun LM, Johnson KA, Abrams J. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst 2002 Nov 6;94(21):1626-34. [Abstract]